Radiology Review Manual
6th Edition

Liver, Bile Ducts, Pancreas, and Spleen
Differential Diagnosis of Hepatic, Biliary, Pancreatic, and Splenic Disorders
Right Upper Quadrant Pain
  • BILE DUCTS
    • Biliary colic/bile duct obstruction
    • Acute cholecystitis/cholangitis
  • LIVER
    • Acute hepatitis: alcoholic, viral, drug-related, toxic
    • Hepatic abscess
    • Hepatic tumor: metastases, hepatocellular carcinoma, hemangioma, focal nodular hyperplasia, hepatic adenoma
    • Hemorrhagic cyst
    • Hepatic congestion: acute hepatic congestion, Budd-Chiari syndrome
    • Perihepatitis from gonococcal/chlamydial infection (Fitz-Hugh-Curtis syndrome)
  • PANCREAS
    • Acute pancreatitis
  • INTESTINES
    • Acute appendicitis
    • Peripyloric ulcer
    • Small bowel obstruction
    • Irritable bowel
    • Colitis/ileitis
    • Intestinal tumor
  • LUNG
    • Pneumonia
    • Pulmonary infarction
  • KIDNEY
    • Acute pyelonephritis
    • Ureteral calculus
    • Renal/perirenal abscess
    • Renal infarction
    • Renal tumor
  • OTHERS
    • Costochondritis
    • Herpes zoster
Liver
Diffuse Liver Disease
  • Fatty liver
  • Cirrhosis
  • Hepatitis
  • Hemochromatosis
  • Glycogen storage disease
  • Budd-Chiari syndrome
Diffuse Hepatic Enlargement = Hepatomegaly
  • METABOLIC
    • Fatty infiltration
    • Amyloid
    • Wilson disease
    • Gaucher disease
    • Von Gierke disease
    • Niemann-Pick disease
    • Weber-Christian disease
    • Galactosemia
  • MALIGNANCY
    • Lymphoma
    • Diffuse metastases
    • Diffuse HCC
    • Angiosarcoma
  • INFLAMMATION/INFECTION
    • Hepatitis
    • Mononucleosis
    • Miliary TB, histoplasmosis, sarcoid
    • Malaria
    • Syphilis
    • Leptospirosis
    • Chronic granulomatous disease of childhood
    • Sarcoidosis
  • VASCULAR
    • Passive congestion
  • OTHERS
    • Early cirrhosis
    • Polycystic liver disease
Hepatosplenomegaly
  • Disorders associated with extramedullary hematopoiesis + hemolytic anemia
  • Metabolic storage disease
  • Viral infection
  • Sarcoidosis
  • Leukemia, lymphoma, myeloproliferative disease
Increased Liver Attenuation
  • = abnormal deposits of substances with high atomic numbers
  • IRON
    • diffuse iron accumulation
      • Genetic/primary hemochromatosis
      • Erythropoietic hemochromatosis
      • Bantu siderosis
      • Transfusional iron overload
    • focal iron accumulation
      • Hemorrhagic metastases: choriocarcinoma, melanoma
      • Hepatic adenoma
      • Siderotic regenerative nodules of cirrhosis
        • An iron-poor focus within a siderotic nodule on T2WI suggests HCC!
      • Focal hemochromatosis
  • COPPER
    • Wilson disease = hepatolenticular degeneration
    • = increased copper deposits in liver + basal ganglia
  • IODINE
    • Amiodarone (= antiarrhythmic drug with 37% iodine by weight)
    • 95–145 HU (range of normal for liver 30–70 HU)
  • GOLD
    • Colloidal form of gold for therapy of rheumatoid arthritis
  • P.668

  • THOROTRAST
    • Alpha-emitter with atomic number of 90
  • THALLIUM
    • Accidental/suicidal ingestion of rodenticides (lethal dose is 0.2–1.0 gram)
  • ACUTE MASSIVE PROTEIN DEPOSITS
  • GLYCOGEN STORAGE DISEASE
mnemonic: GG CHAT
  • Gold therapy
  • Glycogen storage disease
  • Cyclophosphamide
  • Hemochromatosis/hemosiderosis
  • Amiodarone
  • Thorotrast
Generalized Increase In Liver Echogenicity
  • Fatty liver
  • Steatohepatitis
  • Cirrhosis (fibrosis + fatty liver)
  • Chronic hepatitis
  • Vacuolar degeneration
Marked Decrease in Hepatic T2 Signal Intensity
  • = paramagnetic effect of intracellular iron deposition (ferritin, hemosiderin)
  • signal intensity of pancreas does not help distinguish between primary + secondary hemochromatosis
  • Primary/hereditary hemochromatosis (dietary iron)
  • Secondary hemochromatosis
    • bone marrow of low signal intensity (DDx: myelofibrosis)
  • Transfusional siderosis (RES)
    • bone marrow of low signal intensity
    • decreased T2 signal in spleen
  • Intravenous administration of ultrasmall superparamagnetic iron oxide
Liver Mass
  • Hepatic masses account only for 5–6% of all intraabdominal masses in children!
Primary Benign Liver Tumor
  • EPITHELIAL TUMORS
    • hepatocellular
      • Regenerative nodules
      • Adenomatous hyperplastic nodules
      • Focal nodular hyperplasia
      • Hepatic adenoma
    • cholangiocellular
      • Bile duct hamartoma/adenoma
      • Biliary cystadenoma
      • Papillary adenoma
  • MESENCHYMAL TUMORS
    • tumor of adipose tissue
      • Hepatic lipoma
      • Hepatic myelolipoma
      • Hepatic angiomyolipoma
    • tumor of muscle tissue
      • Leiomyoma
    • tumor of blood vessels
      • Infantile hemangioendothelioma
      • Hemangioma
      • Peliosis hepatis
    • mesothelial tumor
      • Benign mesothelioma
  • MIXED TISSUE TUMOR
    • Mesenchymal hamartoma
    • Hepatoblastoma
    • Benign teratoma
  • MISCELLANEOUS
    • Adrenal rest tumor
    • Pancreatic rest
Primary Malignant Liver Tumor
  • Hepatic malignancies are the most common GI malignancy in children, but account for <2% of all pediatric malignancies!
  • EPITHELIAL TUMOR
    • hepatocellular
      • Hepatoblastoma (7%)
      • Hepatocellular carcinoma (75%)
    • cholangiocellular (6%)
      • Cholangiocarcinoma
      • Biliary cystadenocarcinoma
  • MESENCHYMAL TUMOR
    • tumor of blood vessels
      • Angiosarcoma
      • Epithelioid hemangioendothelioma
      • Kaposi sarcoma
    • other tumor
      • Embryonal sarcoma
      • Fibrosarcoma
  • TUMOR OF MUSCLE TISSUE
    • Leiomyosarcoma
    • Embryonal rhabdomyosarcoma of the biliary tree
  • MISCELLANEOUS
    • Carcinosarcoma
    • Teratoma
    • Yolk sac tumor
    • Carcinoid
    • Squamous carcinoma
    • Primary lymphoma
Solitary Liver Lesion
  • BENIGN TUMOR
    • Cavernous hemangioma
    • Adenoma
    • Focal nodular hyperplasia
    • Mesenchymal hamartoma
  • INFECTION
    • Pyogenic abscess
    • Echinococcal cyst
    • Inflammatory pseudotumor
  • TRAUMA
    • Hematoma
    • Traumatic cyst
  • MALIGNANT TUMOR
    • Primary tumor
    • Metastasis
  • OTHER
    • Fatty change
    • Simple cyst
P.669

SOLITARY ECHOGENIC LIVER MASS
mnemonic: Hyperechoic Focal Masses Affecting the Liver
  • Hematoma, Hepatoma, Hemangioma, Hemochromatosis, Hepatoblastoma
  • Fatty infiltration, Focal nodular hyperplasia, Fibrosis
  • Metastasis
  • Adenoma
  • Lipoma
LIVER MASS SURROUNDED BY ECHOGENIC RIM
  • Metastasis: esp., cystic islet cell tumor
  • Adenoma
  • Hemangioma
Multiple Liver Lesions
  • BENIGN TUMOR
    • Cavernous hemangioma
    • Adenoma
    • Regenerating hepatic nodules
    • Multiple bile duct hamartoma
  • INFECTION
    • Multiple abscesses
    • Mycobacterial + fungal infection
    • Inflammatory pseudotumors
  • CONGENITAL
    • Polycystic disease
    • Caroli disease
  • MALIGNANCY
    • Metastases (most common malignant liver tumor)
    • Multifocal hepatoma
    • Lymphoma
  • OTHER
    • Sarcoidosis
    • Simple cysts
    • Langerhans cell histiocytosis (echogenic nodules)
BULL’s-EYE LESIONS OF LIVER
  • Candidiasis (in immunocompromised)
  • Metastases
  • Lymphoma, leukemia
  • Sarcoidosis
  • Septic emboli
  • Other opportunistic infections
  • Kaposi sarcoma
MILIARY HEPATOSPLENIC LESIONS
  • Tuberculosis
  • Metastases
  • Fungal infections
  • Sarcoidosis
  • Lymphoma
Cystic Liver Lesion
  • NONNEOPLASTIC
    • Congenital hepatic cyst
    • Hematoma
    • Echinococcal cyst
    • Abscess
    • Fibropolycystic liver disease
  • NEOPLASTIC
    • Mesenchymal hamartoma
    • Undifferentiated sarcoma (embryonal sarcoma)
    • Malignant mesenchymoma
    • Biliary cystadenoma/cystadenocarcinoma
      • <5% of intrahepatic cysts are of biliary origin!
    • Lymphangioma
    • Necrotic neoplasm
    • Cystic metastasis (ovarian/gastric carcinoma
FIBROPOLYCYSTIC LIVER DISEASE
  • = unique group of entities with derangement of embryonic biliary ductal plate development
  • coexistence of hepatic + renal anomalies
  • small interlobular bile ducts
    • Congenital hepatic fibrosis
    • Biliary hamartoma
    Associated with: autosomal recessive (juvenile) polycystic kidney disease
  • medium-sized bile ducts
    • Autosomal dominant polycystic disease
    Associated with: autosomal dominant (adult) polycystic kidney disease
  • large intrahepatic bile ducts
    • Caroli disease
  • large extrahepatic bile ducts
    • Choledochal cyst
Vascular “Scar” Tumor of Liver
  • Focal nodular hyperplasia
  • Giant cavernous hemangioma
  • Fibrolamellar carcinoma of liver
  • Well-differentiated hepatocellular carcinoma
  • Hypervascular metastasis
  • Intrahepatic cholangiocarcinoma
Liver Mass with Capsular Retraction
  • Cholangiocarcinoma
  • Fibrolamellar carcinoma or any hepatic malignancy
Low-density Mass in Porta Hepatis
  • Choledochal cyst
  • Hepatic cyst
  • Pancreatic pseudocyst
  • Enteric duplication
  • Hepatic artery aneurysm
  • Biloma
  • Embryonal rhabdomyosarcoma of biliary tree
Low-density Hepatic Mass with Enhancement
  • Hepatoma
  • Hypervascular metastases (lesions that may be obscured after contrast injection: pheochromocytoma, carcinoid, melanoma)
  • Cavernous hemangioma
  • Focal nodular hyperplasia with central fibrous scar
  • Hepatic adenoma
Fat-containing Liver Mass
  • Lipoma
  • Angiolipoma
  • Angiomyolipoma (eg, tuberous sclerosis)
  • Hepatocellular carcinoma
  • P.670

  • Hepatic adenoma
  • Liposarcoma metastasis
  • Malignant teratoma metastasis (+ calcifications)
  • Focal fatty change
Hyperintense Liver Mass on T1WI
  • Focal fat deposit
  • High protein content
  • Hemorrhage (methemoglobin)
  • Melanoma metastasis
  • Paramagnetic contrast agents + iodized oil
Hypervascular Liver Mass
  • detected during hepatic arterial phase
  • BENIGN
    • Focal nodular hyperplasia
    • Hepatocellular adenoma
    • Hemangioma
  • MALIGNANT
    • Primary malignant liver tumor
      • Hepatocellular carcinoma
      • Hemangioendothelioma
      • Angiosarcoma
    • Hypervascular liver metastases
      • Neuroendocrine tumors: islet cell, carcinoid
      • Renal cell carcinoma
      • Thyroid carcinoma
      • Choriocarcinoma
      • Melanoma
      • Breast carcinoma (some)
Hepatic Calcification
  • INFECTION (most common cause)
    • Granulomatous disease: tuberculosis (48%), histoplasmosis, brucellosis, coccidioidomycosis
      • calcium involves entire lesion
    • Echinococcal cyst (in 10–20%)
      • curvilinear/ring calcification
    • CMV, toxoplasmosis, Pneumocystis carinii
    • Chronic granulomatous disease of childhood
    • Old pyogenic/amebic abscess
    • Schistosomiasis
      • turtleback/tortoise shell calcifications
    • Cysticercosis, filariasis, paragonimiasis, Armillifer infection, dracunculiasis
    • Syphilitic gumma
  • VASCULAR
    • Hepatic artery aneurysm
    • Portal vein thrombosis
    • Hematoma
  • BILIARY
    • Intrahepatic calculi
    • Ascariasis, clonorchiasis
  • BENIGN TUMORS
    • Congenital cyst
    • Cavernous hemangioma
      • large coarse centrally located calcification (in 10–20%)
    • Hepatocellular adenoma
    • Capsule of regenerating nodules
    • Infantile hemangioendothelioma
  • PRIMARY MALIGNANT TUMOR
    • Fibrolamellar carcinoma (calcified in 15–25%)
    • Hepatocellular carcinoma
    • Hepatoblastoma (10–20%)
    • Intrahepatic cholangiocarcinoma (in 18%)
      • calcification accompanied by desmoplastic reaction
    • Epithelioid hemangioendothelioma
    • Cystadenocarcinoma
  • METASTATIC TUMOR
    • Mucin-producing neoplasm: carcinoma of colon, breast, stomach
    • Ovarian carcinoma (psammomatous bodies)
    • Melanoma, thyroid carcinoma, pleural mesothelioma, chondro- and osteosarcoma, carcinoid, leiomyosarcoma, neuroblastoma
mnemonic: 4H TAG MAP
  • Hepatoma
  • Hemochromatosis
  • Hemangioma
  • Hydatid disease
  • Thorotrast
  • Abscess
  • Granulomas (healed)
  • Metastases
  • Absent mnemonic
  • Porcelain gallbladder
Spontaneous Hepatic Hemorrhage
  • Hepatocellular carcinoma
  • Hepatocellular adenoma
  • Focal nodular hyperplasia
  • Hepatic hemangioma
  • Hepatic metastases: lung, RCC, melanoma
  • HELLP syndrome
  • Amyloidosis
  • Peliosis hepatis
  • Angiomyolipoma
Liver Circulation
Transient Hepatic Parenchymal Enhancement
  • = Hyperperfusion Abnormalities Of Liver
  • = areas of early enhancement on arterial-dominant phase due to decreased portal blood flow/formation of intrahepatic arterioportal shunts/increased aberrant drainage through hepatic veins
  • LOBAR/SEGMENTAL
    • Portal vein obstruction:
      • portal vein thrombosis, tumor invasion, surgical ligation
    • Cirrhosis with arterioportal shunt
    • Hypervascular gallbladder disease
  • SUBSEGMENTAL
    • Obstruction of peripheral portal branches
    • Percutaneous needle biopsy + drainage procedure/ethanol ablation
    • Acute cholecystitis + cholangitis
  • SUBCAPSULAR
    • due to peripheral parenchymal compression
      • Rib compression
      • Perihepatic peritoneal implants
      • P.671

      • Pseudomyxoma peritonei
      • Perihepatic fluid collections
    • idiopathic/unexplained
  • PSEUDOLESIONS
    • = systemic venous blood flow draining into hepatic sinusoids
    • Accessory cystic vein of gallbladder fossa
    • Aberrant right gastric vein
    • Capsular veins
  • RETICULAR-MOSAIC PATTERN
    • Cirrhosis
    • Hereditary hemorrhagic telangiectasia
    • Hepatic vein obstruction
Arterioportal Shunt
  • = organic/functional communication between high-pressure hepatic arterial branch + low-pressure portal venous system
Cause:
  • Primary hepatic neoplasm
    • Hepatocellular carcinoma
    • Hemangioma
    • Cholangiocarcinoma
  • Metastatic tumor
  • Hepatic trauma
    • Blunt abdominal trauma
    • Iatrogenic: biopsy, percutaneous abscess drainage, percutaneous biliary drainage, ethanol injection
  • Cirrhosis
  • Rupture of hepatic artery pseudoaneurysm
  • Congenital malformation
Routes:
  • Macroscopic fistula
  • Transsinusoidal = between microscopic interlobular arteriole + portal venule
  • Transvasal = via tumor thrombus
  • Transtumoral = via draining vein from a hypervascular tumor
  • Transplexal/peribiliary = via capillary network surrounding bile ducts
Pathophysiology:
  • shunted contrast material enhances a focal area of liver parenchyma before adjacent parenchyma is enhanced via the usual splanchnic route
CECT (in hepatic arterial phase):
  • pseudolesion = transient peripheral wedge-shaped hepatic parenchymal enhancement:
    • small shunt may resemble nodular lesion
    • lesion disappears in portal venous phase
  • enhancement of portal vein branch ± main portal vein from periphery without enhancement of splenic vein/superior mesenteric vein
Hepatic Artery Enlargement
  • Cirrhosis (compensatory response to decreased portal venous flow)
  • Intrahepatic arteriovenous shunting
    • vascular neoplasm
    • hepatic artery-portal vein fistula
      Cause: biopsy, trauma
      • turbulent high-velocity low-resistance flow
      • soft-tissue bruit (= random assignment of color in perivascular soft tissue due to tissue vibration)
      • arterialized frequently retrograde flow in portal vein
  • Hereditary hemorrhagic telangiectasia
    • large tortuous feeding arteries with high velocity + aliased flow
    • multiple dilated vessels (representing AVMs)
    • large draining veins
    • areas of fatty change + fibrosis
  • Chronic active hepatitis
Dampening of Hepatic Vein Doppler Waveform
  • = dampened oscillations of hepatic veins resembling portal vein flow due to “shielding” of hepatic veins from activity of right atrium
  • = “portalization” of hepatic vein flow pattern
  • Increased liver tissue stiffness
    • Liver cirrhosis
    • Various parenchymal abnormalities of liver
  • Intrinsic/extrinsic venous obstruction
    • Budd-Chiari syndrome
    • Inferior vena cava obstruction
    • Extrinsic compression of hepatic veins
Pulsatile Portal Vein
  • = waveform pulsatility with >2/3 change from peak to minimal velocity
  • Congestive heart failure
  • Hepatic artery-portal vein fistula
  • Arteriovenous shunt in cirrhosis
  • Portal-to-hepatic vein fistula
Portal Venous Gas
  • Should be considered a life-threatening event and sign of bowel infarction + gangrene until proved otherwise!
Etiology:
  • INTESTINAL NECROSIS (in 74% of adults)
    • Bowel infarction secondary to arterial and venous occlusions (vascular accidents, superior mesenteric artery syndrome)
    • Ulcerative colitis
    • Necrotizing enterocolitis associated with mesenteric arterial thrombosis
    • Perforated gastric ulcer
  • GI OBSTRUCTION
    • Small bowel obstruction (duodenal atresia)
    • Imperforate anus
    • Esophageal atresia
  • MISCELLANEOUS
    • Hemorrhagic pancreatitis
    • Sigmoid diverticulitis
    • Intraabdominal abscess
    • Pneumonia
    • Iatrogenic injection of air during endoscopy
    • Dead fetus
    • Diabetes, diarrhea
mnemonic: BE NICE
  • BE (air embolism during double contrast barium enema)
  • Necrotizing enterocolitis
  • Infarction (mesenteric)
  • P.672

  • Catheterization of umbilical vein
  • Erythroblastosis fetalis
Pathogenesis:
  • Intestinal wall alteration permitting passage of intraluminal air into intestinal venules:
    • ulceration of gastric, duodenal, bowel wall
    • sloughing of epithelial lining
    • enhanced mucosal permeability eg, intestinal ischemia with bowel necrosis (most common), perforated gastric carcinoma/ulcer, inflammatory bowel disease (Crohn disease, ulcerative colitis)
    Prognosis: 75–90% mortality rate within 1 week of diagnosis
  • Bowel distension with elevated intraluminal pressure causes minimal mucosal disruption + permits passage of intraluminal air into veins:
    • iatrogenic dilatation of hollow viscus (gastrostomy, sclerotherapy, ERCP, colonoscopy, barium enema)
    • spontaneous paralytic ileus, mechanical obstruction, acute gastric dilatation
    • blunt trauma (<1%) with acute pressure changes
    • barotrauma
    Prognosis: surgery often not indicated
  • Intraabdominal sepsis
    • ? gas from septicemia in branches of mesenteric veins/portal vein (pylephlebitis)
    • ? increased intraluminal fermentation of carbohydrates due to bacterial overgrowth
    • ? mesocolic abscess causing inframesocolic perforation dissecting between peritoneal leaflets eg, diverticulitis, intra- or retroperitoneal abscess/gangrene, TB
  • Idiopathic (15%)
    • eg, organ transplantation (liver [18%], kidney, bone marrow), pulmonary disease (chronic obstructive pulmonary disease, bronchopneumonia, asthma), drugs (steroids, cytostatics), seizure
Composition of colonic gas:
  • methane, carbon dioxide, oxygen, nitrogen, hydrogen
Plain film:
  • Substantial amount necessary for detection
  • branching linear gas densities:
    • in periphery of liver extending to within 2 cm of liver capsule
    • predominantly within more anteriorly located left lobe of liver
  • pneumatosis of intestinal wall
CT:
  • Small amount of gas detectable
  • tubular areas of decreased attenuation in periphery of liver
  • gas in superior/inferior mesenteric veins
  • gas in small mesenteric veins at mesenteric border of bowel
US:
  • Small amount of gas detectable
  • intensely hyperechoic foci within lumen of portal vein + liver parenchyma
Doppler:
  • tall sharp bidirectional spikes (overloading of Doppler receiver from strong reflection of gas bubble in bloodstream) superimposed on normal portal vein spectrum
DDx: pneumobilia (located centrally within bile ducts close to liver hilum + within left lobe of liver)
Gallbladder
Nonvisualization of Gallbladder on OCG
  • Peak opacification of gallbladder: 14–19 hours (13–35% of dose excreted in urine)
  • EXTRABILIARY CAUSES
    • Failure to ingest contrast
    • Fasting
    • Failure to reach absorptive surface of bowel
      • vomiting, nasogastric suction
      • esophageal/gastric obstruction
      • hiatal, umbilical, inguinal hernias
      • Zenker, epiphrenic, gastric, duodenal, jejunal diverticulum
      • gastric ulcer, gastrocolic fistula
      • malabsorption, diarrhea
      • postoperative ileus, severe trauma
      • inflammation: acute pancreatitis, acute peritonitis
    • Deficiency of bile salts
      • Crohn disease, surgical resection of terminal ileum, liver disease, cholestyramine therapy, abnormal communication between biliary system and gastrointestinal tract
  • INTRINSIC GALLBLADDER DISEASE
    • Cholecystectomy
    • Anomalous position
    • Obstruction of cystic duct
    • Chronic cholecystitis
Oral Cholecystogram (OCG)
Dose: 6 × 0.5 g tablets 2 hours after evening meal
  • PATIENT SELECTION
    • • bilirubin <5 mg% (not necessary if due to hemolysis)
    • Contraindicated in serious liver disease!
    • Relative contraindications in peritonitis, postoperative ileus, acute pancreatitis!
  • TOXICITY
    • Nausea + vomiting (also noted in 29% on placebo)
    • Immediate anaphylactic response
    • Delayed hypotensive reaction (increased risk in cirrhosis)
    • Renal failure
    • Precipitation of hyperthyroidism
Nonvisualization of Gallbladder on US
  • Status post cholecystectomy
  • Obscured by costal margin
  • Anomalous position (intrahepatic, subphrenic)
  • Gallbladder carcinoma replacing gallbladder
  • Perforation of gallbladder
  • Congenital absence
  • Contracted gallbladder
    • nonfasting status without stones
    • P.673

    • in fasting status with stones
      • wall-echo-shadow (WES triad) interfaces
Shadowing in Gallbladder Fossa
  • WES (wall-echo-shadow) triad
  • Gas in duodenum/colon obscuring gallbladder
  • Porcelain gallbladder
  • Emphysematous cholecystitis
  • Cholecystoenteric fistula
  • Status post ERCP with retrograde air injection
High-Density Bile
  • Hemorrhagic cholecystitis
  • Hemobilia
  • Prior contrast administration
    • vicarious excretion of urographic agent
    • cholecystopaque
  • Milk of calcium bile
Displaced Gallbladder
  • NORMAL IMPRESSION
    • by duodenum/colon (positional change)
  • HEPATIC MASS
    • hepatoma, hemangioma, regenerating nodule, metastases, intrahepatic cyst, polycystic liver, hydatid disease, hepar lobatum (tertiary syphilis), granuloma, abscess
  • EXTRAHEPATIC MASS
    • Retroperitoneal tumor (renal, adrenal)
    • Polycystic kidney
    • Lymphoma
    • Lymph node metastasis to porta hepatis
    • Pancreatic pseudocyst
Alteration in Gallbladder Size
Enlarged Gallbladder
  • = CHOLECYSTOMEGALY = HYDROPS OF GALLBLADDER
  • Size:
    (a) infants <1 year: >3 cm in length
    (b) children: >7 cm in length
    (c) adults: >4 × 10 cm
  • OBSTRUCTION
    • Cystic duct obstruction (40%)
      • Hydrops: chronic cystic duct obstruction + distension with clear sterile mucus (white bile)
      • Empyema: acute/chronic obstruction with superinfection of bile
    • Cholelithiasis causing obstruction (37%)
    • Cholecystitis with cholelithiasis (11%)
    • Courvoisier phenomenon (10%)
      • secondary to neoplastic process in pancreas / duodenal papilla/ampulla of Vater/common bile duct
    • Pancreatitis
    • Infection: leptospirosis, ascariasis, typhoid fever, scarlet fever, familial Mediterranean fever
  • UNOBSTRUCTED (mostly neuropathic)
    • S/P vagotomy
    • Diabetes mellitus
    • Alcoholism
    • Appendicitis (in children)
    • Narcotic analgesia
    • WDHA syndrome
    • Hyperalimentation
    • Acromegaly
    • Kawasaki syndrome
    • Anticholinergics
    • Bedridden patient with prolonged illness
    • AIDS (in 18%)
    • Dehydration
    • Prolonged fasting
    • Total parenteral nutrition
    • Sepsis
  • NORMAL (2%)
Small Gallbladder
  • Chronic cholecystitis
  • Cystic fibrosis: in 25% of patients
  • Congenital hypoplasia/multiseptated gallbladder
  • Postprandial
  • Intrahepatic cholestasis (viral, drug-related)
Gallbladder Wall Thickening
Diffuse Gallbladder Wall Thickening
  • = anterior wall of gallbladder >3 mm
  • INTRINSIC
    • infection
      • Acute cholecystitis
      • Chronic cholecystitis (10–25%)
      • Xanthogranulomatous cholecystitis
      • Gallbladder perforation
      • Sepsis
      • Brucellosis
    • inflammation
      • AIDS cholangiopathy (average of 9 mm in up to 55%)
      • Sclerosing cholangitis
      • Eosinophilic cholecystitis
    • tumor infiltration
      • Gallbladder carcinoma (in 41% diffuse)
      • Leukemic infiltration (AML)
      • Multiple myeloma
    • others
      • Hyperplastic cholecystosis (in 91% diffuse)
      • Gallbladder varices
  • EXTRINSIC
    • liver disease
      • Hepatitis (in 80%)
      • Cirrhosis
      • Hepatic venous obstruction
    • fluid overload
      • Hypoalbuminemia
      • Renal failure
      • Right heart failure
      • Systemic venous hypertension
      • Ascites
      • Lymphatic obstruction (by portal nodes)
    • others
      • Graft-versus-host disease
      • Pancreatitis
    • P.674

    • drugs
      • Chemoinfusion of hepatic artery (ischemia)
      • Treatment with interleukin
  • PHYSIOLOGIC
    • = contracted gallbladder after eating
Focal Gallbladder Wall Thickening
  • METABOLIC
    • Metachromatic sulfatides
    • Hyperplastic cholecystoses
  • BENIGN TUMOR
    • Adenoma: glandular elements (0.2%)
    • Papilloma: fingerlike projections (0.2%)
    • Villous hyperplasia
    • Fibroadenoma
    • Cystadenoma:? premalignant
    • Neurinoma, hemangioma
    • Carcinoid tumor
  • MALIGNANT TUMOR
    • Carcinoma of gallbladder: adenocarcinoma/squamous cell carcinoma (in 59% focal)
    • Leiomyosarcoma
    • Metastases: from malignant melanoma (15%), lung, kidney, esophagus, breast, carcinoid, Kaposi sarcoma, lymphoma, leukemia
  • INFLAMMATION/INFECTION
    • Inflammatory polyp: in chronic cholecystitis
    • Parasitic granuloma: Ascaris lumbricoides, Paragonimus westermani, Clonorchis, filariasis, Schistosoma, Fasciola
    • Intramural epithelial cyst/mucinous retention cyst
    • Xanthogranulomatous cholecystitis (in 9% focal)
  • WALL-ADHERENT GALLSTONE = embedded stone
  • HETEROTOPIC MUCOSA
    • Ectopic pancreatic tissue
    • Ectopic gastric glands
    • Ectopic intestinal glands
    • Ectopic hepatic tissue
    • Ectopic prostatic tissue
Filling Defects of Gallbladder
Fixed Filling Defects of Gallbladder
mnemonic: PANTS
  • Polyp
  • Adenomyomatosis
  • Neurinoma
  • Tumor, primary/secondary
  • Stone, wall-adherent
GALLBLADDER POLYPS
  • NONNEOPLASTIC (95%)
    • Cholesterol (60%): on average 8 polyps
    • Adenomyoma (25%): in gallbladder fundus
    • Inflammatory polyp (10%):
      • solitary (in 1/2), 2–5 (in 1/2)
    • Others: heterotopic gastric glands
  • NEOPLASTIC (5%)
    • Adenoma: solitary (in 66%); 2–5 (in 33%)
    • Metastasis
    • Fibroma, leiomyoma, lipoma, neurofibroma
Mobile Intraluminal Mass in Gallbladder
  • Tumefactive sludge
  • Blood clot
  • Nonshadowing stone
Comet-tail Artifact in Liver and Gallbladder
  • LIVER
    • Foreign metallic body (eg, surgical clip)
    • Intrahepatic calcification
    • Pneumobilia
    • Multiple bile duct hamartoma = von Meyenburg complex
  • GALLBLADDER
    • Rokitansky-Aschoff sinus
    • Intramural stone
    • Cholesterolosis of gallbladder
Echogenic Fat in Hepatoduodenal Ligament
  • = sign of pericholecystic inflammation
  • Cholecystitis
  • Perforated duodenal ulcer
  • Pancreatitis
  • Diverticulitis
Bile Ducts
Hemobilia
  • Iatrogenic trauma: percutaneous needle biopsy, transhepatic cholangiography/biliary drainage /portography
  • Blunt/penetrating trauma
  • Rupture of aneurysm/pseudoaneurysm
Gas in Biliary Tree = Pneumobilia
mnemonic: I GET UP
  • Incompetent sphincter of Oddi (after sphincterotomy/passage of a gallstone)
  • Gallstone ileus
  • Emphysematous cholecystitis (actually in gallbladder)
  • Trauma
  • Ulcer (duodenal ulcer perforating into CBD)
  • Postoperative (eg, cholecystoenterostomy)
  • gas outlines choledochus ± gallbladder
  • peripheral branches of bile ducts not filled
Obstructive Jaundice in Adult
Etiology:
  • BENIGN DISEASE (76%)
    • Traumatic/postoperative stricture (44%)
    • Calculi (21%)
    • Chronic pancreatitis (8%)
    • Sclerosing cholangitis (1%)
    • Recurrent pyogenic cholangitis
    • Parasitic disease (ascariasis)
    • Liver cysts
    • Aortic aneurysm
    • Papillary stenosis
  • MALIGNANCY (24%)
    • Pancreatic carcinoma (18%)
    • Ampullary/duodenal carcinoma (8%)
    • Cholangiocarcinoma (3%)
    • P.675

    • Metastatic disease (2%)
      • from stomach, pancreas, lung, breast, colon, lymphoma
Level and cause of obstruction:
  • INTRAPANCREATIC
    • Choledocholithiasis
      • Most common cause of biliary obstruction (in 15% of patients with cholelithiasis)!
    • Chronic pancreatitis
    • Pancreatic carcinoma
  • SUPRAPANCREATIC (5%)
    • = between pancreas + porta hepatis
    • Cholangiocarcinoma
    • Metastatic adenopathy
  • PORTA HEPATIS (5%)
    • Klatskin tumor
    • Spread from adjacent tumor (GB, liver)
    • Surgical stricture
  • INTRAHEPATIC
    • Cystadenoma, cystadenocarcinoma
    • Mirizzi syndrome
    • Caroli disease
    • Cholangitis: recurrent pyogenic cholangitis, sclerosing cholangitis, AIDS cholangitis
Incidence of infected bile in bile duct obstruction:
  • incomplete/partial obstruction in 64%
  • complete obstruction in 10%
  • Infection twice as high with biliary calculi than with malignant obstruction!
Organism: E. coli (21%), Klebsiella (21%), enterococci (18%), Proteus (15%)
Test Sensitivity for Common Bile Duct Obstruction:
  • Intravenous cholangiography
    • depends on level of bilirubin: <1 mg/dL in 92%; <2 mg/dL in 82%; <3 mg/dL in 40%; >4 mg/dL in <10%
    False-negative rate: 45%
    Cx: adverse reactions in 4–10%
  • US
    • 88–90% sensitivity for dilatation of CBD
    • In 27–95% correct level of obstruction determined by US
    • In 23–81% correct cause of obstruction determined by US
    • CBD >4–6 mm/10% of patient’s age in years
    • increase in CBD size after fatty meal
    • “Swiss cheese sign” = abundance of fluid-filled structures on liver sections
    • intrahepatic “double channel”/“shotgun” sign= two parallel tubular structures composed of portal vein + dilated intrahepatic bile ducts
    • intrahepatic bile duct >2 mm/>40% of adjacent portal vein branch
    False-negative: not dilated in acute obstruction (in 70%), sclerosing cholangitis, intermittent obstruction from choledocholithiasis
    False-positive: dilated hepatic artery in cirrhosis/portal hypertension/hepatic neoplasm, patients after cholecystectomy
  • CT
    • 100% visualization in tumorous obstruction, 60% in nontumorous obstruction
  • NUC
    • delayed/nonvisualization of biliary system (93% specificity)
    • vicarious excretion of tracer through kidneys
DDx: Hepatocellular dysfunction (delayed clearance of cardiac blood pool)
Hyperbilirubinemia in Infants
  • = UNCONJUGATED HYPERBILIRUBINEMIA
  • PHYSIOLOGIC
    Frequency: in 60% of full-term infants, in 80% of preterm infants
    Course: increase by day 2–3, peak by day 5–7 (up to 12 mg/dL in full-term babies, up to 14 mg/dL in premature infants)
    • Breast-fed babies may have an elevated bilirubin level until the end of 2nd week of life!
  • NONPHYSIOLOGIC
    • onset of jaundice within first 24 hours
    • persistent/new-onset jaundice in infants 2 weeks of age
    • rise of serum bilirubin >5 mg/dL per 24 hours
    • direct bilirubin level >1 mg/dL
Neonatal Obstructive Jaundice
  • = severe persistent jaundice in a child beyond 3–4 weeks of age
  • Cause:
    • INFECTION
      (a) bacterial: E. coli, Listeria monocytogenes
      (b) viral: TORCH, Coxsackie virus, echovirus, Adenovirus
    • METABOLIC
      (a) inherited: alpha-1 antitrypsin deficiency, cystic fibrosis, galactosemia, hereditary tyrosinemia
      (b) acquired: inspissated bile syndrome
      = “bile plug” syndrome
      (= cholestasis due to erythroblastosis); cholestasis due to total parenteral nutrition; choledocholithiasis
    • BILIARY TRACT ABNORMALITIES
      (a) extrahepatic: biliary obstruction/hypoplasia/atresia, choledochal cyst, spontaneous perforation of bile duct
      (b) intrahepatic: ductular hypoplasia/atresia
    • IDIOPATHIC NEONATAL HEPATITIS
    • The 3 most common causes of jaundice in neonates are hepatitis, biliary atresia, and choledochal cyst!
      mnemonic: CAN
      • Choledochal cyst
      • Atresia
      • Neonatal hepatitis
    • P.676

    • NUC–imaging regimen:
      • Premedication with phenobarbital (5 mg/kg/day) over 5 days to induce hepatic microsomal enzymes, which enhance uptake and excretion of certain compounds and increase bile flow
      • IDA scintigraphy (50 μCi/kg; minimum of 1 mCi)
      • Imaging at 5-minute intervals for 1 hour + at 2, 4, 6, 8, 24 hours
Jaundice in Older Children
  • DISEASE OF HEPATOCYTES
    • hepatitis
      • Acute hepatitis: infection, toxic agents, drugs
      • Chronic hepatitis
    • metabolic
      • Wilson disease
      • Cystic fibrosis
      • Glycogen storage disease
      • Tyrosinemia
      • Alpha-1 antitrypsin deficiency
  • OBSTRUCTION
    • malignant neoplasm
      • Hepatoblastoma
      • Hepatocellular carcinoma
      • Sarcomas: angiosarcoma, lymphosarcoma, rhabdomyosarcoma of bile ducts, undifferentiated embryonal sarcoma
      • Metastatic disease: neuroblastoma, Wilms tumor, leukemia/lymphoma
    • benign neoplasm
      • Infantile hemangioendothelioma
      • Mesenchymal hamartoma
    • benign stricture
    • cholelithiasis/choledocholithiasis (uncommon)
Large Nonobstructed CBD
  • Passage of stone (return to normal after days to weeks)
  • Common bile duct surgery (return to normal in 30–50 days)
  • Postcholecystectomy dilatation (in up to 16%)
  • Intestinal hypomotility
  • Normal variant (aging)
  • Fatty-meal sonography (to differentiate from obstruction with 74% sensitivity, 100% specificity)
    Method: peroral Lipomul (1.5 mL/kg) followed by 100 mL of water [cholecystokinin causes contraction of gallbladder, relaxation of sphincter of Oddi, increase in bile secretion], CBD measured before and 45/60 minutes after stimulation
    • little change/decrease in size = normal response
    • increase in size >2 mm = partial obstruction
Filling Defect in Bile Ducts
  • ARTIFACT
    • Pseudocalculus
      • contracted sphincter of Boyden + Oddi with smooth arcuate contour
      • bridge of tissue between cystic duct + CHD
      • underfilling of cystic duct during ERCP
      • admixture defect at cystic duct junction
    • Air bubble: confirmed by positional changes
    • Blood clot: spheroid configuration, spontaneous resolution with time
  • BILIARY CALCULI
  • MIRIZZI SYNDROME
  • NEOPLASM
    • malignant
      • Cholangiocarcinoma: irregular stricture, intraluminal polypoid mass
      • Metastatic tumor (GI tract, pancreas, breast, melanoma, lymphoma)
      • Others: ampullary carcinoma, hepatoma, hamartoma, carcinoid, embryonal rhabdomyosarcoma of biliary tree
    • benign
      • Papilloma (most common benign neoplasm)
        Histo: vascular connective tissue covered by single layer of columnar epithelium
      • Adenoma
        Histo: epithelial glandular tissue surrounded by fibrous tissue
      • Fibroma, lipoma, neuroma
      • Granular cell myoblastoma (= Schwann-cell–derived biliary tumor) in young black woman
  • PARASITES
    • Ascaris lumbricoides: long linear filling defect/discrete mass if coiled
    • Liver fluke (Clonorchis sinensis, Fasciola hepatica): intrahepatic epithelial hyperplasia, periductal fibrosis, cholangitis, liver abscess, hepatic duct stones, common duct obstruction
    • Schistosoma japonicum: portal vein infection
    • Hydatid cyst: after erosion into biliary tree
Echogenic Material in Bile Ducts
  • Calculi
  • Gas
  • Blood
  • Tumor
  • Parasites
Bile Duct Narrowing
  • BENIGN STRICTURE (44%)
    • trauma
      • Postoperative stricture (95–99%)
        • associated with cholecystectomy
      • Blunt/penetrating trauma
      • Hepatic artery embolization
      • Infusion of chemotherapeutic agents
    • inflammation
      • Sclerosing cholangitis
      • Recurrent pyogenic cholangitis
      • Eosinophilic cholangiopathy
      • Acute/chronic pancreatitis
      • Pancreatic pseudocyst
      • Perforated duodenal ulcer
      • Erosion by biliary calculus
      • Gallstones + cholecystitis
      • Abscess
      • Radiation therapy
      • P.677

      • Papillary stenosis
      • Acquired immunodeficiency syndrome
    • congenital
      • Choledochal cyst
  • MALIGNANT STRICTURE
    • Pancreatic carcinoma
    • Ampullary carcinoma
    • Cholangiocarcinoma
    • Compression by enlarged lymph node
    • Metastasis
Multifocal Intrahepatic Bile Duct Strictures
  • Primary sclerosing cholangitis
  • Ascending cholangitis due to stricture/stone/bile duct anomaly
  • Oriental cholangiohepatitis
  • AIDS-related cholangitis
  • Ischemia
    • floxuridine treatment
    • hepatic arterial thrombosis (in liver transplant)
  • Neoplasm
    • cholangiocarcinoma
    • metastases
  • Previous bile surgery
  • Congenital biliary anomalies
Papillary Stenosis
  • Etiology:
    • PRIMARY PAPILLARY STENOSIS (10%)
      • Congenital malformation of papilla
      • Sequelae of acute/chronic inflammation
      • Adenomyosis
    • SECONDARY PAPILLARY STENOSIS (90%)
      • Mechanical trauma of stone passage
        • (choledocholithiasis in 64%; cholecystolithiasis in 26%)
      • Functional stenosis: associated with pancreas divisum, history of pancreatitis
      • Reflex spasm = papillary dyskinesia
      • Scar from previous surgical manipulation
      • Periampullary neoplasm
  • prestenotic dilatation of CBD
  • increase in pancreatic duct diameter (83%)
  • long smooth narrowing/beak (fibrotic stenosis)
  • prolonged bile-to-bowel transit time >45 minutes on Tc-IDA scintigraphy
Periampullary Tumor
  • Pancreatic carcinoma (85%)
  • Cholangiocarcinoma of distal common bile duct (6%)
  • Ampullary tumor (4%)
  • Duodenal wall tumor
    • adenocarcinoma, adenoma, carcinoid, smooth muscle tumor
Double-Duct Sign
  • = dilatation of common bile duct + pancreatic duct
  • Ampullary tumor (most common)
  • Pancreatic ductal adenocarcinoma
  • Stone impacted in ampulla of Vater
  • Papillary stenosis
Congenital Biliary Cysts
  • (Todani classification)
  • Choledochal cyst (77–87%)
    IA cystic dilatation of CBD
    IB focal segmental dilatation of CBD
    IC fusiform dilatation of CBD
  • II. Diverticulum of extrahepatic ducts (1.2–3%)
    • originating from CBD/CHD
    • neck of diverticulum open/closed
  • III. Choledochocele (1.4–6%)
  • IV. Multiple segmental bile duct cysts
    IVA multiple intra- and extrahepatic biliary cysts + saccular dilatation of CBD (19%)
    IVB multiple extrahepatic biliary cysts + normal intrahepatic bile ducts (rare)
  • Caroli disease = intrahepatic biliary cysts
Pancreas
Congenital Pancreatic Anomalies
  • Pancreas divisum
  • Annular pancreas
  • Agenesis of dorsal pancreas
image
Classification of Congenital Biliary Cysts
P.678

May be associated with: abnormal situs, polysplenia, intestinal malrotation
Pancreatic Calcification
  • CHRONIC PANCREATITIS
    • Numerous irregular stippled calcifications of varying size; predominantly intraductal
    • Alcoholic pancreatitis (in 20–50%):
      • calcifications limited to head/tail in 25%
    • Biliary pancreatitis (in 2%)
    • Hereditary pancreatitis (in 35–60%):
      • round calcifications throughout gland
    • Idiopathic pancreatitis
    • Pancreatic pseudocyst
  • NEOPLASM
    • Microcystic adenoma (in 33%):
      • “sunburst” appearance of calcifications
    • Macrocystic cystadenoma In 15%):
      • amorphous peripheral calcifications
    • Adenocarcinoma (in 2%): with “sunburst” pattern
    • Cavernous lymphangioma/hemangioma:
      • multiple phleboliths
    • Metastases from colon cancer
  • INTRAPARENCHYMAL HEMORRHAGE
    • Old hematoma/abscess/infarction
    • Rupture of intrapancreatic aneurysm
  • HYPERPARATHYROIDISM (in 20%):
    • 50% of patients develop chronic pancreatitis + concomitant nephrocalcinosis
    • Indistinguishable from alcoholic pancreatitis
  • CYSTIC FIBROSIS
    • Fine granular calcifications imply advanced pancreatic fibrosis
  • HEMOCHROMATOSIS
  • KWASHIORKOR = juvenile tropical pancreatitis
    • Indistinguishable from alcoholic pancreatitis
Atrophy of Pancreas
  • Main pancreatic duct obstruction
  • Cystic fibrosis
    • Most common cause in childhood!
  • Schwachman-Diamond syndrome
  • Johanson-Blizzard syndrome (= pancreatic insufficiency, nasal alar hypoplasia, absence of permanent teeth, short stature, congenital deafness)
  • Hemochromatosis
  • Viral infection
  • Malnutrition
  • Cushing syndrome, steroid therapy, obesity
Pancreatic Mass
  • NEOPLASTIC
    • Adenocarcinoma
    • Islet cell tumor
    • Cystadenoma/-carcinoma
    • Solid and papillary neoplasm
    • Lymphoma
  • INFLAMMATORY
    • Acute pancreatitis
    • Pseudocyst
    • Pancreatic abscess
Pancreatic Neoplasm
Origin: — in 99% exocrine ductal epithelium
— in 1% acinar portion of pancreatic glands
— in 0.1% malignant ampullary tumor with better prognosis
  • EXOCRINE NEOPLASM
    • Ductal cell origin
      • Ductal adenocarcinoma (90%)
      • Ductectatic mucinous tumor
        • = mucin-hypersecreting carcinoma
      • Cystic neoplasm (10–15%)
        • serous microcystic neoplasm
        • mucinous macrocystic neoplasm
      • Solid and papillary epithelial neoplasm (rare)
      • Cystic changes of von Hippel-Lindau disease
    • Acinar cell origin
      • Acinar cell carcinoma (1%)
      • Adenoma
    • Indeterminate origin
      • Pancreatoblastoma = infantile pancreatic carcinoma
      • Dermoid cyst
      • Giant cell tumor
  • ENDOCRINE NEOPLASM
    • Nonfunctioning islet cell tumor
    • Functioning islet cell tumor
      • Insulinoma (β cells)
      • Glucagonoma
      • Gastrinoma (δ cells)
      • Somatostatinoma
      • VIPoma (WDHA syndrome)
      • “PP-oma” = pancreatic polypeptide
      • Carcinoid
  • NONEPITHELIAL ORIGIN
    • Primary tumor
      • Primary lymphoma
        • <1% of pancreatic neoplasms
      • Primitive neuroectodermal tumor
      • Rhabdomyosarcoma
    • Mesenchymal tumor (1%)
      • Schwannoma
      • Neurofibroma
      • Lymphangioma
      • Teratoma
      • Lipoma
    • Metastases
      • Renal cell carcinoma
      • Lung cancer
      • Breast cancer
      • Colon cancer
      • Melanoma
      • Soft-tissue sarcoma, Kaposi sarcoma
      • Secondary lymphoma:
        • large homogeneous solid mass, infrequently with central cystic area
        • peripancreatic nodal masses
        • peripancreatic vessels displaced + stretched
        • dilatation of pancreatic + bile duct uncommon
      • P.679

      • Ovarian cancer
      • Hepatocellular carcinoma
Hypervascular Pancreatic Tumors
  • PRIMARY
    • Islet cell tumor, microcystic adenoma, solid and papillary epithelial neoplasm
  • METASTASES from
    • angiosarcoma, leiomyosarcoma, melanoma, carcinoid, renal cell carcinoma, adrenal carcinoma, thyroid carcinoma
Pancreatic Cyst
  • INFLAMMATORY/INFECTIOUS
    • pseudocyst (85%): secondary to obstructive tumor/trauma/acute pancreatitis (in 2–4%), chronic pancreatitis (in 10–15%) [develop within 10–20 days, consolidated after 6–8 weeks]
    • acquired cyst:
      • Retention cyst (= exudate within bursa omentalis from acute pancreatitis)
      • Parasitic cyst: Echinococcus multilocularis, amebiasis
      • Pancreatic abscess
  • CONGENITAL (rare)
    • solitary true cyst
    • multiple true cysts (when associated with cystic disease of the liver/other organs):
      • Autosomal dominant polycystic kidney disease (hepatic cysts in 90% at autopsy)
        • nearly always associated with renal cysts
      • Von Hippel-Lindau disease (pancreatic cysts in 72% at autopsy; in only 25% on CT)
      • Cystic fibrosis
  • NEOPLASTIC
    • common cystic pancreatic neoplasms (5–15%):
      • Mucinous cystic neoplasm
        • Most common cystic tumor of pancreas!
        • Potentially malignant
      • Serous cystadenoma = microcystic adenoma
      • Intraductal papillary mucinous tumor (IPMT)
    • rare cystic pancreatic neoplasms:
      • Solid and papillary epithelioid neoplasm
      • Acinar cell cystadenocarcinoma
      • Retroperitoneal lymphangioma/hemangioma
      • Paraganglioma
    • solid pancreatic neoplasms with cystic degeneration:
      • Pancreatic adenocarcinoma
      • Cystic islet cell tumor (rare)
      • Cystic metastasis (3–12% at autopsy):
        • renal cell carcinoma, melanoma, lung tumors, breast carcinoma, hepatocellular carcinoma, ovarian carcinoma
      • Cystic teratoma
      • Pancreatic sarcoma (extremely rare)
Unilocular Pancreatic Cyst
  • A cyst <3 cm is almost always benign + may be followed at 6-month intervals for 3 years!
  • Pseudocyst
    • history of pancreatitis
  • Intraductal papillary mucinous neoplasm (IPMN)
    • narrow neck at cyst-duct junction
  • Unilocular serous cystadenoma
  • Lymphoepithelial cyst
Pancreatic Cyst with Solid Component
  • All tumors are either malignant or have a high malignant potential!
  • — true cystic neoplasm
    • 1. Mucinous cystic neoplasm
    • 2. IPMN
  • — cystically degenerated neoplasm
    • 3. Islet cell tumor
    • 4. Solid pseudopapillary tumor
    • 5. Pancreatic adenocarcinoma
    • 6. Metastasis
Macrocystic Lesion of Pancreas
  • = multilocular cyst, each compartment >2 cm in size
  • Mucinous cystic neoplasm
    • in body + tail of pancreas
    • peripheral eggshell calcification
  • IPMN: side-branch/mixed
    • septated cyst communicating with main duct
  • Nonfunctioning neuroendocrine tumor
  • Congenital lymphangioma
Microcystic Lesion of Pancreas
  • = pancreatic lesion with >6 cysts each <2 cm in size
  • Serous cystadenoma
    • fibrous central scar ± stellate pattern (30%)
    • growth rate of 4 mm/year at follow-up
Hyperamylasemia
  • PANCREATIC
    • Acute/chronic pancreatitis
    • Pancreatic trauma
    • Pancreatic carcinoma
  • GASTROINTESTINAL
    • Perforated peptic ulcer
    • Intestinal obstruction
    • Peritonitis
    • Acute appendicitis
    • Afferent loop syndrome
    • Mesenteric ischemia/infarction
    • Portal vein thrombosis
  • TRAUMA
    • Burns
    • Cerebral trauma
    • Postoperative
  • OBSTETRICAL
    • Pregnancy
    • Ruptured ectopic pregnancy
  • RENAL
    • Transplantation
    • Renal insufficiency
  • METABOLIC
    • Diabetic ketoacidosis
    • Drugs
  • PNEUMONIA
  • SALIVARY GLAND LESION
    P.680

    • Facial trauma
    • Mumps
Spleen
Nonvisualization of Spleen
  • Asplenia syndrome
  • Polysplenia syndrome
  • Traumatic fragmentation of spleen
  • Wandering spleen
Small Spleen
  • Infarction
  • Celiac disease
  • Congenital/hereditary hypoplasia
    • Associated with recurrent bacterial infections!
  • Fanconi anemia
  • Irradiation
  • Partial splenectomy
  • Polysplenia syndrome
  • Atrophy
Splenomegaly
  • inferior tip of spleen extends below tip of right lobe of liver
  • AP diameter of spleen >2/3 of abdominal diameter
  • CONGESTIVE SPLENOMEGALY
    • heart failure, portal hypertension, cirrhosis, cystic fibrosis, portal/splenic vein thrombosis, acute splenic sequestration crisis of sickle cell anemia
  • NEOPLASM
    • leukemia, lymphoma, lymphoproliferative disease, Langerhans cell histiocytosis, metastases, primary neoplasm
  • STORAGE DISEASE
    • Gaucher disease, Niemann-Pick disease, mucopolysaccharidoses, gargoylism, amyloidosis, diabetes mellitus, hemochromatosis
  • INFECTION
    • bacterial: TB, subacute bacterial endocarditis, typhoid fever, syphilis, brucellosis
    • viral: hepatitis, infectious mononucleosis
    • protozoal: echinococcosis, malaria, kala azar, American leishmaniosis
    • fungal: histoplasmosis
  • HEMOLYTIC ANEMIA
    • hemoglobinopathy, hereditary spherocytosis, primary neutropenia, thrombotic thrombocytopenic purpura, extracorporeal membrane oxygenation (due to RBC damage)
  • EXTRAMEDULLARY HEMATOPOIESIS
    • osteopetrosis, myelofibrosis
  • COLLAGEN VASCULAR DISEASE
    • systemic lupus erythematosus, rheumatoid arthritis, Felty syndrome
  • SPLENIC TRAUMA
  • OTHERS
    • Sarcoidosis
      • splenomegaly in up to 60%
      • inhomogeneous enhancement after bolus injection (multiple 2–3-cm hypodense nodular lesions)
      • necrotic mass with focal calcifications
    • Hemodialysis
    • Autoimmune lymphoproliferative syndrome
Solid Splenic Lesion
  • MALIGNANT TUMOR
    • Lymphoma (Hodgkin disease, non-Hodgkin lymphoma, primary splenic lymphoma)
      • Splenomegaly in non-Hodgkin lymphoma indicates involvement in most patients
      • 30% of patients with splenomegaly have no involvement from non-Hodgkin lymphoma
      • 30% of patients with lymphoma of any kind have splenic involvement without splenomegaly
      • homogeneous splenomegaly (from diffuse infiltration)
      • miliary nodules
      • large 2–10-cm nodules (10–25%)
      • nodes in splenic hilum (50%) in NHL; uncommon in Hodgkin disease
    • Metastasis (7%)
      • melanoma (6–34%), breast carcinoma (12–21%), bronchogenic carcinoma (9–18%), colon carcinoma (4%), renal cell carcinoma (3%), ovary (8%), prostate (6%), stomach (7%), pancreas, endometrial cancer
    • Angiosarcoma
    • Malignant fibrous histiocytoma, leiomyosarcoma, fibrosarcoma
    • Langerhans cell histiocytosis
      • splenomegaly
      • multiple hypoechoic nodules (less often)
  • BENIGN TUMOR
    • Hamartoma = splenoma
    • Hemangioma
    • Hematopoietic
    • Sarcoidosis
      • nodular lesions in liver and spleen in 5–c15%
        • (= coalescent granulomata) occurring within 5 years of diagnosis
      • hepatosplenomegaly
      • abdominal adenopathy (mean size of 2.6 cm)
    • Gaucher disease (islands of RES cells laden with glucosylceramide)
    • Inflammatory pseudotumor
    • Lymphangioma
  • SPLENIC INFARCTION
Cystic Splenic Lesion
  • CONGENITAL
    • Epidermoid cyst = true cyst = congenital cyst
  • VASCULAR
    • Splenic laceration/fracture
    • Hematoma
    • false cyst = posttraumatic cyst = nonpancreatic pseudocyst of the spleen
      • 80% of all splenic cysts are pseudocysts
        • (= secondary cysts)
      Cause: cystic end stage of trauma, infection, infarction
      • internal echoes from debris
      • P.681

      • calcifications within cyst wall may resemble eggshell
      • smaller size than true cyst
    • Cystic degeneration of infarct
      • occlusion of splenic a./branches (hemolytic anemia, endocarditis, SLE, arteritides, pancreatic cancer)
      • venous thrombosis of splenic sinusoids (massive splenomegaly)
    • Peliosis
  • INFECTION/INFLAMMATION
    • Pyogenic abscess
      Prevalence: 0.1–0.7%
      Cause: hematogenous spread in sepsis (75%), penetrating trauma (15%), infarction (10%)
      Predisposed: endocarditis, drug abuse, penetrating trauma, neoplasm, sickle cell disease
      • • fever, chills, LUQ pain (in <50%)
      • irregular borders without capsule
      • gas bubbles within abscess
      • rim enhancement
      Rx: 76% success rate for percutaneous drain
    • Microabscesses
      Organism: fungus (especially Candida, Aspergillus, Cryptococcus)
      Prevalence: 26% of splenic abscesses
      Predisposed: immunocompromised patient
      • hepatosplenomegaly
      • multiple round hypoechoic/hypoattenuating “target” lesions of 5–10 mm often associated with hepatic + renal involvement
      • “wheel-in-wheel” appearance when central hyperechoic portion becomes necrotic + hypoechoic
    • Granulomatous infection
      • Mycobacterium tuberculosis: miliary TB
        • mild splenomegaly uncommon
      • M. avium-intracellulare
        • marked splenomegaly in 20%
    • Pneumocystis carinii infection
      • splenomegaly + multiple hypoattenuating foci
    • Parasitic cyst (Echinococcus)
      Prevalence: in <2% of patients with hydatid disease
      Cause: systemic dissemination, intraperitoneal spread of ruptured liver cyst
      • solitary cyst ± subjacent daughter cysts
      • hydatid sand ± infolded membranes
      • ± linear calcification
    • Intrasplenic pancreatic pseudocyst
      Prevalence: in 1–5% of patients with pancreatitis
  • CYSTIC NEOPLASM
    • Cavernous hemangioma
      • Most common primary neoplasm of the spleen!
      • hyperdense lesion
    • Lymphoma (most common malignant neoplasm!)
      • splenomegaly
      • multiple small/large masses
    • Lymphangioma/lymphangiomatosis
      • multiple septated subcapsular cystic lesions
    • Necrotic metastasis:
      • malignant melanoma (in 50%); breast, lung, ovarian, pancreatic, endometrial, colonic, prostatic, carcinoma; chondrosarcoma
      • In 7% of patients with widespread metastasis!
  • TRUE CYST (with epithelial lining)
    • Congenital cyst = epidermoid cyst
    • Parasitic cyst
  • FALSE CYST = PSEUDOCYST (lacking epithelial lining)
    • Traumatic cyst
    • Postinfarct cyst
Solitary Splenic Lesion
mnemonic: L’CHAIM
  • Lymphoma
  • Cyst
  • Hematoma, Hemangioma, Hamartoma
  • Abscess
  • Infarct
  • Metastasis
Multiple Splenic Nodules and Masses
  • Lymphoma, leukemia
  • Metastases
  • Inflammatory lesions
  • Benign tumors
  • Splenic cysts
  • Splenic infarcts
  • Gaucher cells
Increased Splenic Density
  • Sickle cell anemia (in 5% of sicklers)
  • Hemochromatosis
  • Thorotrast exposure
  • Lymphangiography
Splenic Calcification
  • DISSEMINATED
    • Phlebolith: visceral angiomatosis
    • Granuloma (most common): histoplasmosis, TB, brucellosis
  • CAPSULAR & PARENCHYMAL
    • Pyogenic/tuberculous abscess
    • Pneumocystis carinii infection
    • Infarction (multiple)
    • Hematoma
  • VASCULAR
    • Splenic artery calcification
    • Splenic artery aneurysm
    • Splenic infarct
    • Autosplenectomy
  • CALCIFIED CYST WALL
    • Congenital cyst
    • Posttraumatic cyst
    • Echinococcal cyst
    • Cystic dermoid
    • Epidermoid
P.682

mnemonic: HITCH
  • Histoplasmosis (most common)
  • Infarct (sickle cell disease)
  • Tuberculosis
  • Cyst (Echinococcus)
  • Hematoma
Iron Accumulation in Spleen
  • DIFFUSE
    • Multiple blood transfusions
    • Sickle cell anemia
  • FOCAL
    • Gamna Gandy bodies
    • Angiosarcoma
Hyperechoic Splenic Spots
  • Granulomas: miliary tuberculosis, histoplasmosis
  • Phleboliths
  • Lymphoma/leukemia
  • Myelofibrosis
  • Gamna-Gandy nodules (in portal hypertension)
Spontaneous Splenic Rupture
  • Posttraumatic delayed rupture
  • Splenomegaly
  • Hemangioma
  • Epidermoid cyst
  • Peliosis
  • Previous splenic infarction
P.683

Anatomy of Liver, Bile Ducts, Pancreas, and Spleen
image
Extrahepatic Portal Vein Tributaries
image
Variations of Intrahepatic Portal Venous System
image
Intrahepatic Portal Vein Branches
P.684

image
image
Level of Hepatic Vein Junction
image
Level of Left Portal Vein
image
Level of Right Portal Vein
image
Level of Splenic Vein
Functional Segmental Live Anatomy
Goldsmith & Woodburne Couinaud & Bismuth
CAUDATE LOBE Caudate lobe 1
LEFT LOBE Left lateral segment Left lateral superior subsegment 2
Left lateral inferior subsegment 3
Left medial segment Left medial superior subsegment 4a
Left medial inferior subsegment 4b
RIGHT LOBE Right anterior segment Right anterior inferior subsegment 5
Right anterior superior subsegment 8
Right posterior segment Right posterior inferior subsegment 6
Right posterior superior subsegment 7
P.685

image
Michels Classification of Hepatic Arterial Anatomy
Liver
Functional Segmental Liver Anatomy
  • based on distribution of 3 major hepatic veins:
    • middle hepatic vein
      • divides liver into right and left lobe. also separated by main portal vein scissura (Cantlie line) passing through IVC + long axis of gallbladder)
    • left hepatic vein
      • divides left lobe into medial + lateral sectors
    • right hepatic vein
      • divides right lobe into anterior + posterior sectors
  • Each of the four sections is further divided:
    • by an imaginary transverse line drawn through the right + left portal vein into anterior + posterior segments; the segments are numbered counterclockwise from IVC
Hepatic Arterial Anatomy (Michels classification)
Type 1 (55%):
  • celiac trunk trifurcates into L gastric a. + splenic a. + common hepatic a.
  • common hepatic a. divides into gastroduodenal a. + proper hepatic a.
  • RT hepatic a. + LT hepatic a. arise from proper hepatic a.
  • middle hepatic a. (supplying caudate lobe) arises from:
    • L/R hepatic a.
    • proper hepatic a. (in 10%)
Type 2 (10%):
  • common hepatic a. divides into gastroduodenal + R hepatic a.
  • L hepatic a. replaced to L gastric a.
  • middle hepatic a. from R hepatic a.
Type 3 (11%):
  • common hepatic a. divides into gastroduodenal + L hepatic a.
  • R hepatic a. replaced to superior mesenteric a.
  • middle hepatic a. from L hepatic a.
Type 4 (1%):
  • common hepatic a. divides into middle hepatic a. + gastroduodenal a.
  • R hepatic a. + L hepatic a. are both replaced
Type 5 (8%):
  • accessory L hepatic a. arises from L gastric a.
Type 6 (7%):
  • accessory R hepatic a. arises from SMA
Type 7 (1%):
  • accessory R + L hepatic a.
Type 8 (2%):
  • combinations of accessory + replaced hepatic aa.
Type 9 (4.5%):
  • hepatic trunk replaced to superior mesenteric a.
Type 10 (0.5%):
  • hepatic trunk replaced to L gastric a.
Aberrant Hepatic Artery
  • = hepatic artery coursing between IVC + portal vein
P.686

  • Replaced right hepatic artery (50%)
  • Right hepatic artery with early bifurcation of common hepatic artery into right + left hepatic arteries (20%)
  • Accessory right hepatic artery (15%)
  • Replacement of entire hepatic trunk to SMA (15%)
Third Inflow to Liver
  • = aberrant veins supplying small areas of liver tissue + communicating with intrahepatic portal vein branches
Effect: focal decrease of portal vein perfusion resulting in areas of fat-sparing/fat accumulation
  • Cholecystic veins
    • directly entering liver segments 4 + 5
    • veins joining the parabiliary veins via triangle of Calot
  • Parabiliary venous system
    • = venous network within hepatoduodenal ligament anterior to main portal vein
    • Tributaries:
      • cholecystic vein through triangle of Calot
      • pancreaticoduodenal vein
      • right gastric/pyloric vein
    • pseudolesion at dorsal aspect of segment 4
  • Epigastric-paraumbilical venous system
    • = small veins around falciform ligament draining anterior part of abdominal wall directly into liver
    • Subgroups:
      • superior vein of Sappey
        • drains upper portion of falciform ligament + medial part of diaphragm
        • enters peripheral left portal vein branches
        • communicates with superior epigastric + internal thoracic veins
      • inferior vein of Sappey
        • drains lower portion of falciform ligament
        • enters peripheral left portal vein branches
        • communicates with branches of inferior epigastric vein around the umbilicus
      • vein of Burow
        • terminates in middle portion of collapsed umbilical vein
        • communicates with branches of inferior epigastric vein around the umbilicus
      • intercalary veins
        • interconnect vein of Burow + inferior vein of Sappey
Hepatic Fissures
  • Fissure for ligamentum teres = umbilical fissure
    • = invagination of ligamentum teres = embryologic remnant of obliterated umbilical vein connecting placental venous blood with left portal vein
    • — located at dorsal free margin of falciform ligament
    • — runs into liver with visceral peritoneum
    • — divides left hepatic lobe into medial + lateral segments (divides subsegment 3 from 4)
  • Fissure for ligamentum venosum
    • = invagination of obliterated ductus venosus
    • = embryologic connection of left portal vein with left hepatic vein
    • — separates caudate lobe from left lobe of liver
    • — lesser omentum within fissure separates the greater sac anteriorly from lesser sac posteriorly
  • Fissure for gallbladder (GB)
    • = shallow peritoneal invagination containing the GB
    • — divides right from left lobe of liver
  • Transverse fissure
    • = invagination of hepatic pedicle into liver
    • — contains horizontal portion of left + right portal veins
  • Accessory fissures
    • Right inferior accessory fissure = from gallbladder fossa/just inferior to it to lateroinferior margin of liver
    • Others (rare)
Size of Liver
  • YOUNG INFANT
    • right hepatic lobe should not extend >1 cm below right costal margin
  • CHILD
    • right hepatic lobe should not extend below right costal margin
  • ADULT
    • midclavicular line (vertical/craniocaudad axis):
      <13 cm = normal
      13.0–15.5 cm = indeterminate (in 25%)
      >15.5 cm = hepatomegaly (87% accuracy)
    • preaortic line <10 cm
    • prerenal line <14 cm
image
Hepatic Fissures
Liver Echogenicity & Attenuation
US: pancreatic > splenic ≥hepatic > renal echogenicity
CT: 40–70 HU (precontrast)
CECT: early arterial phase (20 sec), late arterial phase (30–40 sec), portal venous phase (60–70 sec); maximal enhancement at 45–60 sec
Maximum Cross-sectional Diameter of Portal Vein
(a) child <10 years of age: 8.5 mm
(b) 10–20 years of age: 10.0 mm
(c) adult: 13.0 mm
P.687

Normal Hemodynamics Parameter of Liver
Portal vein velocity: >11 cm/sec
Congestion index (= cross-sectional area of portal vein divided by average velocity): 0.070 ± 0.09
Hepatic artery resistive index: 0.60–0.64 ± 0.06
Liver Tests
  • Alkaline phosphatase (AP)
    Formation: bone, liver, intestine, placenta
    • High increase:
      • cholestasis with extrahepatic biliary obstruction (confirmed by rise in γGT), drugs, granulomatous disease (sarcoidosis), primary biliary cirrhosis, primary + secondary malignancy of liver
    Mild increase: all forms of liver disease, heart failure
  • Gamma-glutamyl transpeptidase (γGT)
    • very sensitive in almost all forms of liver disease
    Utility: confirms hepatic source of elevated AP, may indicate significant alcohol use
  • Transaminases
    high increase: viral/toxin-induced acute hepatitis
    • aspartate aminotransferase (AST; formerly serum glutamic oxaloacetic transaminase [SGOT])
      Formation: liver, muscle, kidney, pancreas, RBCs
    • alanine aminotransferase (ALT; formerly serum glutamic pyruvic transaminase [SGPT])
      Formation: primarily in liver
    • rather specific elevation in liver disease
  • Bilirubin
    • helps differentiate between various causes of jaundice
    • (a) unconjugated/indirect bilirubin = insoluble in water
      Formation: breakdown of senescent RBCs
      Metabolism: tightly bound to albumin in vessels, actively taken up by liver, cannot be excreted by kidneys
    • (b) conjugated/direct bilirubin = water-soluble
      Formation: conjugation in liver cells
      Metabolism: excretion into bile; not reabsorbed by intestinal mucosa + excreted in feces
      • Elevation:
        • overproduction: hemolytic anemia, resorption of hematoma, multiple transfusions
        • decreased hepatic uptake: drugs, sepsis
        • decreased conjugation: Gilbert syndrome, neonatal jaundice, hepatitis, cirrhosis, sepsis
        • decreased excretion into bile: hepatitis, cirrhosis, drug-induced cholestasis, sepsis, extrahepatic biliary obstruction
  • Lactic dehydrogenase (LDH)
    • nonspecific and therefore not helpful
    high increase: primary or metastatic liver involvement
  • Alpha fetoprotein (AFP)
    >400 ng/mL strongly suggests that focal mass represents a hepatocellular carcinoma
Bile ducts
Normal Size of Bile Ducts
  • @ CBD at point of maximum diameter = free edge of gastrohepatic ligament (point of least constraint):
    • adolescents & adults
      • ≤5 mm = normal; 6–7 mm = equivocal; ≥8 mm = dilated
      • In patient >60 years of age add 1 mm/decade
      • Following cholecystectomy up to 8 mm
    • neonates: <1 mm
    • infants up to 1 year of age: <2 mm
    • older children: <4 mm
  • @ CHD at porta hepatis + CBD in head of pancreas: 5 mm
  • @ right intrahepatic bile duct just proximal to CHD: 2–3 mm/<40% of diameter of accompanying portal vein
  • @ Cystic duct
    • Valves of Heister = normal mucosal folds
    Diameter: 1.8 mm
    Average length: 1–2 cm
    • distal cystic duct posterior to CBD (in 95%), anterior to CBD (in 5%)
Bile Duct Variants
Prevalence: 2.4% of autopsies;
13–18.5% of operative cholangiograms
Significance: aberrant ducts near cystic duct /gallbladder have the greatest risk of iatrogenic injury at cholecystectomy
Cx: (1) postoperative bile leak if severed
(2) segmental biliary obstruction if ligated
  • ABERRANT INTRAHEPATIC DUCT
    • may join CHD, CBD, cystic duct, right hepatic duct, gallbladder
    • — major right segmental bile duct joins extrahepatic bile duct at/near cystic duct insertion (4–5%)
    • — cysticohepatic duct (1–2%) = anomalous right hepatic duct inserts into cystic duct
    • — anomalous left hepatic ducts: not susceptible to injury + therefore of no clinical significance
  • CYSTIC DUCT ENTERING RIGHT HEPATIC DUCT
  • DUCTS OF LUSCHKA
    • = small ducts from hepatic bed draining directly into gallbladder
  • DUPLICATION OF CYSTIC DUCT/CBD
    • ± duplication of gallbladder
  • CONGENITAL tracheobiliary FISTULA
    • = fistulous communication between carina and left hepatic duct
    • • infants with respiratory distress
    • • productive cough with bilious sputum
    • pneumobilia
image
Bile Duct Variants
P.688

Variants of Cystic Duct Insertion
Prevalence: variations occur in 18–23%
  • Craniocaudad direction:
    • — proximal third = common hepatic duct high in porta hepatis
    • — middle third of extrahepatic bile duct in 75%
    • — distal third of extrahepatic bile duct in 10%
      • cystic duct parallels extrahepatic bile duct (implies common fibrous sheath)
      Cx: during cholecystectomy
      (1) common hepatic duct stricture
      (2) inadvertent ligation/transection of extrahepatic bile duct
      (3) long cystic duct remnant
  • Mediolateral direction:
    • right lateral
    • anterior spiral
    • posterior spiral
    • low lateral (with common sheath)
    • low medial (at/near ampulla of Vater)
  • Insertion into intrahepatic bile duct
    • right hepatic duct (0.3%)
    • left hepatic duct (rare)
  • absence of cystic duct
    • gallbladder drains directly into common bile duct
Gallbladder
Size & Capacity & Wall Thickness
Length:
(a) infant < 1 year old: 1.5–3 cm in length
(b) older child: 3–7 cm in length
(c) adult: 7-10 cm in length; 2-3.5 cm in width
Capacity: 30-50 mL
Wall thickness: 2-3 mm
Bile volume: 250-1,000 mL/day secreted by hepatocytes
GB function: concentration of bile through absorption of 90% of water
Congenital Gallbladder Anomalies
Agenesis of Gallbladder
Incidence: 0.04-0.07% (autopsy)
  • Associated with:
    • common: rectovaginal fistula, imperforate anus, hypoplasia of scapula + radius, intracardiac shunt
    • rare: absence of corpus callosum, microcephaly, atresia of external auditory canal, tricuspid atresia, TE fistula, dextroposition of pancreas + esophagus, absent spleen, high position of cecum, polycystic kidney
Hypoplastic Gallbladder
  • congenital
  • associated with cystic fibrosis
Septations of Gallbladder
  • LONGITUDINAL SEPTA
    • Duplication of gallbladder
      • = two separate lumens + two cystic ducts
      Incidence: 1:3,000-1:12,000
    • Bifid gallbladder = double gallbladder
      • = two separate lumens with one cystic duct
    • Triple gallbladder (extremely rare)
  • TRANSVERSE SEPTA
    • Isolated transverse septum
    • phrygian cap (2-6% of population)
      • = kinking/folding of fundus ±septum
    • Multiseptated gallbladder (rare)
      • = multiple cystlike compartments connected by small pores
      Cx: stasis + stone formation
  • GALLBLADDER DIVERTICULUM
    • = persistence of cystohepatic duct
image
Anatomic Variants of Cystic Duct Insertion
Gallbladder Ectopia
  • Most frequent locations:
    • (1) beneath the left lobe of the liver > (2) intrahepatic > (3) retrohepatic
  • Rare locations:
    • (4) within falciform ligament, (5) within interlobar fissure, (6) suprahepatic (lodged between superior surface of right hepatic lobe + anterior chest wall), (7) within anterior abdominal wall, (8) transverse mesocolon, (9) retrorenal, (10) near posterior spine + IVC, (11) intrathoracic GB (inversion of liver)
    Associated with: eventration of diaphragm
    P.689

    “Floating GB”
    • = gallbladder with loose peritoneal reflections, may herniate through foramen of Winslow into lesser sac
    “Torqued GB”
    • = results in hydrops
Pancreas
Size
–pancreatic head: 1.0–2.2 cm
pancreatic body: 0.4–1.0 cm
pancreatic tail: 0.8–1.8 cm
Physiology of Pancreas
  • pancreatic islet cells = endocrine cells (1–2% of mass of pancreas) clustered in islets of Langerhans;
  • receive 10–15% of pancreatic blood flow
Function: secretion of
  • insulin in b-cells; most abundant in center of islet
  • glucagon in a-cells
  • somatostatin in d-cells
  • VIP in d1-cells
  • serotonin in enterochromaffin cells
  • pancreatic polypeptide in PP cells (stimulate secretion of gastric and intestinal enzymes + inhibit intestinal motility)
Pancreatic Development & Anatomy
  • during the 4th week of gestation 2 endodermal diverti-cula form in the foregut near its junction with the yolk sac
  • — dorsal diverticulum forms dorsal pancreas
  • — ventral diverticulum forms liver, gallbladder, bile ducts, ventral pancreas
  • DORSAL ANLAGE (in mesoduodenum)
    Origin: arises from dorsal wall of duodenum + is later displaced to the left
    • Forms cranial portion of head + isthmus + body + tail of pancreas
    • — prone to atrophy (poor in polypeptides)
    • drains to the minor papilla through accessory duct of Santorini
  • VENTRAL ANLAGE (below primordial liver bud)
    Origin: ventral bud arises from ventral wall of duodenum and is composed of right + left lobes (the left ventral bud regresses completely), rotates dorsally and inferiorly + then to the left of the duodenum + fuses with dorsal anlage during 6–7th week GA
    • Forms caudal portion of the pancreatic head + uncinate process + CBD
    • — not prone to atrophy (rich in polypeptides)
    • ventral duct drains with CBD through ampulla of Vater + becomes the major drainage pathway for the entire pancreas after fusion with dorsal duct
  • MAIN PANCREATIC DUCT OF WIRSUNG
    • [Johann Wirsüng (1589–1643), German physician in Padua, Italy]
    • distal portion of dorsal duct connects with ventral duct; proximal portion of dorsal duct may disappear
    • measures 1–2–3 mm in diameter
    • receives 20–35 tributaries/side branches that enter at right angles
    • usually drains through major papilla
    • Major drainage route in 91% of individuals
  • ACCESSORY PANCREATIC DUCT OF SANTORINI
    • [Giovanni Santorini (1681–1737), anatomist in Venice, Italy]
    • = proximal portion of dorsal duct, which has not atrophied
    • Present in 44% of individuals
  • AMPULLA OF VATER
    • = space within medial wall of second portion of duodenum below surface of papilla of Vater
  • MAJOR DUODENAL PAPILLA = papilla of Vater
    • Drainage of common bile duct in 100%
    • Drainage of main pancreatic duct of Wirsung in 90%
  • MINOR DUODENAL PAPILLA (present in 60%)
    • Drainage of accessory pancreatic duct of Santorini
    • Drainage of main pancreatic duct in 10%
    • located a few cm orad to papilla of Vater
image
Pancreatic Duct Diameters
image
Embryologic Development of Pancreas
Pancreaticobiliary Junction Variants
  • Angle between CBD + pancreatic duct:
    • usually acute at 5°–30°
    • occasionally abnormal at up to 90°
  • P.690

  • Sphincter of Oddi = sphincter of hepaticopancreatic ampulla
    • [Ruggero Oddi (1864–1913), physiologist in Genoa, Italy]
    • = muscle fibers encircling the CBD + pancreatic duct at choledochoduodenal junction
    • (a) choledochal sphincter (Boyden) = encircles distal CBD
    • (b) pancreatic duct sphincter (in 33% separate)
    • (c) ampullary sphincter
  • Types of union between CBD + pancreatic duct:
    • Normal junction = union inside duodenal wall
      • 2–10 (mean 5) mm short common channel (55–85%) with a diameter of 3–5 mm
      • separate entrances into duodenum (42%)
      • 8–15 mm long common channel
    • Anomalous junction = union outside duodenal wall beyond the influence of the sphincter of Boyden (1.5–3.2%)
      • pancreatic duct inserting into CBD >15 mm from entrance into duodenum
      • CBD inserting into pancreatic duct
image
Normal Union between CBD & Pancreatic Duct
image
Variations in Pancreatic Duct Anatomy
Spleen
Size of Spleen
in adults: 12 cm length, 7–8 cm anteroposterior diameter, 3–4 cm thick; splenic index (L × W × H) of <480
in children: logarithmic increase in length with increasing age; formula for length = 5.7 + 0.31 × age (in years)
in infants (0–3 months of age): <6.0 cm in length
Weight of Spleen
at birth: 15 g
in adults: 150 (100–265) g
  • estimated weight = splenic index × 0.55
Embryology of Spleen
  • — spleen arises from mesenchymal cells between layers of dorsal mesogastrium during 5th week GA
  • — splenic primordium differentiates to form capsule, connective tissue framework, splenic parenchyma
  • — major site of hematopoiesis until 28 weeks GA; retains capacity for extramedullary hematopoiesis well into adult life
  • spleen recognizable by 12th week GA (as fusion of mesenchymal aggregates occurs)
  • splenic clefts/notches/lobules may persist
  • accessory spleen (in up to 30% by autopsy)
P.691

Histology of Spleen
  • RED PULP = numerous vascular sinuses
  • WHITE PULP = lymphoid follicles + cells of RES
Development: ratio of white to red pulp increases with age + progressive antigenic stimulation
Imaging Characteristics of Spleen
  • CT ATTENUATION
    • without enhancement:
      • 40–60 HU; 5–10 HU less than liver
    • with enhancement:
      • normal heterogeneous enhancement during first minute after bolus injection (due to different blood flow rates through the cords of the red + white pulp)
      • arciform (alternating bands of high + low attenuation)/focal/diffuse heterogeneity
      • heterogeneity resolved in portal venous phase
  • MR SIGNAL INTENSITY
    • directly related to ratio of white to red pulp
    • (a) neonate <8 months of age:
      • T1WI- and T2WI-intensity: spleen < liver (due to predominance of red pulp)
      DDx: hemochromatosis
    • (b) adult + older child:
      • T2WI-intensity: spleen > liver
      • T1WI-intensity: liver > spleen > muscle
Iron metabolism
Total body iron: 5 g
  • functional iron: 1g
    Location: hemoglobin of RBCs, myoglobin of muscle, various enzymes
  • stored iron: 1g
    Location: hepatocytes, reticuloendothelial cells of liver (Kupffer cells) + spleen + bone marrow
Absorption: 1-2 mg/day through gut
Transport: bound to transferrin intravascularly
Deposition:
  • transferrin-transfer to:
    • hepatocytes, RBC precursors in erythron, parenchymal tissues (eg, muscle)
  • phagocytosis by:
    • reticuloendothelial cells phagocytize senescent erythrocytes (= extravascular hemolysis); RBC iron stored as ferritin/released and bound to transferrin
image
Extraperitoneal Spaces
P.692

Disorders of Liver, Biliary Tract, Pancreas, and Spleen
Accessory Spleen
  • = failure of coalescence of several small mesodermal buds in the dorsal mesogastrium that comprise the spleen
Incidence: 10–30% of population; multiple (up to 6) in 10%
  • Undergoes hypertrophy after splenectomy and is responsible for recurrence of hematologic disorders (idiopathic thrombocytopenic purpura, hereditary spherocytosis, acquired autoimmune hemolytic anemia, hypersplenism)
  • Location:
    • near splenic hilum along the course of splenic vessels (most common)
    • within layers of omentum (gastrosplenic ligament, other suspensory ligaments of spleen)
    • anywhere in abdomen (eg, pancreas, pelvis)
    • attached to left ovary/testis = splenogonadal fusion (due to close relationship between developing spleen + mesonephros + left gonadal anlage)
  • NUC (Tc-99m sulfur colloid scan/spleen-specific Tc-99m denatured RBCs):
    • usually <1 cm in diameter
    • <10% identified when normal spleen present
Cx: disease recurrence due to hypertrophy of accessory spleen after splenectomy for hypersplenism
Ampullary Tumor
  • = benign/malignant tumors arising from glandular epithelium of ampulla of Vater
Age: 6th + 7th decade; M:F = 2:1
Path: average diameter of <3 cm
Histo: (a) dysplastic epithelium in glandular/villous structures of tubular/villous adenoma
(b) carcinoma in situ
(c) invasive carcinoma often with desmoplastic reaction
Associated with: familial adenomatous polyposis syndromes (eg, familial polyposis coli, Gardner syndrome) [100–200-fold risk], colon carcinoma
  • malaise, epigastric pain, weight loss
  • intestinal bleeding (tumor ulceration)
  • intermittent jaundice (ductal obstruction)
  • gray “aluminum/silver-colored” stools (3%)
  • chills, fever, RUQ pain (ascending cholangitis) in up to 20%
  • endoscopy: tumor extending through orifice (63%), prominent papilla/submucosal mass (25%), not visualized (9%)
TNM staging:
T1: tumor confined to ampulla
T2: tumor extending into duodenal wall
T3: invasion of pancreas <2 cm deep
T4: invasion of pancreas >2 cm deep
International Union Against Cancer Staging:
I = tumor confined to ampulla
II = tumor extension into duodenal wall/pancreas
III = regional lymph node involvement (Lnn stations around head + body of pancreas, anterior + posterior pancreaticoduodenal, pyloric, common bile duct, proximal mesenteric)
IV = invasion of pancreas >2 cm deep
  • tumor often inapparent due to small size
  • UGI:
    • indentation of duodenal lumen at papilla of Vater with filling defect >1.5 cm
    • surface irregularity + deep barium-filled crevices in villous tumor
  • Biliary imaging:
    • dilatation of most distal segment of common bile duct
    • stenosis (circumferential tumor growth around ampulla/desmoplastic reaction)
    • irregular predominantly polypoid filling defect
    • ± pancreatic dilatation = double-duct sign (may be absent if tumor small/accessory pancreatic duct decompresses pancreatic system/main pancreatic duct drains into minor papilla)
  • Endoscopic US (most sensitive technique):
    • 87% staging accuracy
Rx: Whipple procedure (= pancreaticoduodenectomy)
Prognosis: 28–70% 5-year survival for ampullary carcinomas (depending on stage)
DDx:
  1. 1. Periampullary duodenal adenoma/adenocarcinoma (usually larger lesion with significant intraduodenal extension)
  2. Choledochocele (cystic lesion filling with biliary contrast)
  3. Brunner gland tumor, pancreatic rest (“myoepithelial hamartoma”), leiomyoma, carcinoid (often produce somatostatin)
  4. Duodenitis, pancreatitis
  5. 5. Stone impaction in ampulla
Annular Pancreas
  • = second most common congenital anomaly wherein a ring of normal pancreatic tissue encircles the duodenum secondary to abnormal migration of ventral pancreas (head + uncinate)
Incidence: 1:20,000 autopsies
Age at discovery: childhood (52%); adulthood (48%)
Associated with: other congenital anomalies (in 75%):
esophageal atresia, TE fistula, duodenal atresia/stenosis, duodenal diaphragm, imperforate anus, malrotation, Down syndrome
Location: 2nd portion of duodenum (85%);
1st/3rd portion of duodenum (15%)
  • mostly asymptomatic with incidental discovery
• neonate: persistent vomiting (duodenal obstruction)
• adult: nausea, vomiting (60%), abdominal pain
(70%), hematemesis (10%), jaundice (50%)
  • polyhydramnios (in utero)
  • “double bubble” = dilated duodenal bulb + stomach
  • proximal duodenal dilatation
  • enlargement of pancreatic head
  • UGI:
    • eccentric narrowing with lateral notching + medial retraction of 2nd part of duodenum
    • concentric narrowing of mid-descending duodenum
    • reverse peristalsis, pyloric incompetency
  • P.693

  • CT:
    • pancreatic tissue surrounding descending duodenum
  • ERCP (most specific)/MR pancreatography:
    • normally located main duct in pancreatic body + tail
    • small duct originating on anterior left + passing posteriorly around duodenum communicates with main duct (in 85%)
Cx: increased incidence of
  1. periampullary peptic ulcers
  2. pancreatitis (15–20%) usually confined to pancreatic head and annulus
Rx: gastrojejunostomy/duodenojejunostomy
Ascariasis
  • Most frequent helminthic infection in humans
Organism: Ascaris lumbricoides, 25–35 cm long as adult worm; life span of 1 year
Country: 644 million humans harbor the roundworm; 70–90% in America; in United States endemic in: Appalachian range, southern + Gulf coast states
Prevalence: 25% of world population infected
(a) in United States: 12% in blacks, 1% in whites
(b) in parts of Africa, Asia, South America: 90%
Cycle:
  • ingestion of contaminated water/soil/vegetable; larvae penetrate intestinal wall; migrate into mesenteric lymphatics + veins into liver; reach lung via right heart + pulmonary artery; mature in pulmonary capillary bed to 2–3 mm length; burrow into alveoli; ascend in respiratory tract; are swallowed and again reach small intestine, where they become adult worms whose eggs leave the body by the fecal route
  • • abnormal liver function tests + biliary colic
  • • hypereosinophilia only present during acute stage of larval migration
  • barium study
  • cholangiography (49%)
  • US:
    • tubular echogenic filling defect with 2–4-mm wide central sonolucent line (= worm with digestive tract) within dilated common bile duct
Cx:
  1. Intestinal obstruction
  2. Intermittent biliary obstruction with acute cholangitis, cholecystitis, pancreatitis
  3. Liver abscess (rare)
  4. Granulomatous stricture of extrahepatic bile ducts (rare)
Rx: Mebendazole
Autosomal Dominant Polycystic Disease
  • = POLYCYSTIC LIVER DISEASE
  • = biliary ductal plate malformation at the level of the small intrahepatic bile ducts with progressive dilation of the abnormal noncommunicating bile ducts of biliary hamartomas
  • M:F = 1:2
Associated with: polycystic kidney disease (in 50%)
  • • upper abdominal pain + distension from hepatomegaly
  • enlarged diffusely cystic liver (cysts of 1 mm–12 cm in diameter)
  • calcifications of cyst walls
  • ± diffuse dilatation of intra- and extrahepatic bile ducts
Cx: infection, compression, bleeding, rupture of cysts
Banti Syndrome
  • = NONCIRRHOTIC IDIOPATHIC PORTAL HYPERTENSION= NONCIRRHOTIC PORTAL FIBROSIS = HEPATOPORTAL SCLEROSIS
  • = syndrome characterized by
    • splenomegaly
    • hypersplenism
    • portal hypertension
Etiology: increased portal vascular resistance possibly due to portal fibrosis + obliterative venopathy of intrahepatic portal branches
Histo: slight portal fibrosis, dilatation of sinusoids, intimal thickening with eccentric sclerosis of peripheral portal vein walls
Age: middle-aged women; rare in America + Europe but common in India + Japan
  • • elevated portal vein pressure (without cirrhosis, parasites, venous occlusion)
  • • normal liver function tests
  • • cytopenia (due to hypersplenism)
  • • normal/slightly elevated hepatic venous wedge pressure
  • esophageal varices
  • patent hepatic veins
  • patent extrahepatic portal vein + multiple collaterals
Prognosis: 90% 5-year survival; 55% 30-year survival
Biliary Cystadenocarcinoma
  • = BILE DUCT CYSTADENOCARCINOMA
  • rare malignant multilocular cystic tumor originating from biliary cystadenoma
Histo: (a) with ovarian stroma (good prognosis), in females only
(b) without ovarian stroma (bad prognosis)
  • • hemorrhagic internal fluid
  • nodularity with septations are suggestive of malignancy
  • coarse calcifications
DDx: no image differentiation from biliary cystadenoma
Biliary Cystadenoma
  • = BILE DUCT CYSTADENOMA
  • = rare benign premalignant multilocular cystic tumor originating in bile ducts; probably deriving from ectopic nests of primitive biliary tissue
Incidence: 4.6% of all intrahepatic cysts of bile duct origin
Age: >30 years (82%), peak incidence in 5th decade; M:F = 1:4; predominantly Caucasian
Path: multilocular cystic tumor containing proteinaceous fluid with well-defined thick capsule
Histo: single layer of cuboidal/tall columnar biliary-type epithelium with papillary projections, subepithelial stroma resembling that of the ovary
♢ Similar to mucinous cystic tumors of pancreas + ovary
Location: intrahepatic:extrahepatic bile ducts = 85:15;
right lobe (48%); left lobe (20–35%);
both lobes (15–30%); gallbladder (rare)
  • • chronic abdominal pain
  • • dyspepsia, anorexia, nausea + vomiting
  • • jaundice
  • • abdominal swelling with palpable mass (90%)
  • mass of 1.5–35 cm in size
  • P.694

  • up to 11 liters of clear/cloudy, serous/mucinous/gelatinous, purulent/hemorrhagic/bilious fluid containing hemosiderin/cholesterol/necrosis
  • papillary excrescences + mural nodules
  • septations between cysts
  • US:
    • ovoid multiloculated anechoic mass with highly echogenic septations/papillary growths
    • may contain fluid-fluid levels
  • CT:
    • multiloculated mass of near water density
    • contrast enhancement in wall + internal septa
  • MR:
    • locules with variable signal intensity on T1WI + T2WI depending on their protein content
  • Angio:
    • avascular mass with small clusters of peripheral abnormal vessels
    • stretching + displacement of vessels
    • thin subtle blush of neovascularity in septa + wall
Cx: (1) malignant transformation into cystadenocarcinoma (indicated by invasion of capsule)
(2) rupture into peritoneum/retroperitoneum
Rx: surgical resection (recurrence common)
DDx: liver abscess, echinococcal cyst, cystic mesenchymal hamartoma (children + young adults), undifferentiated sarcoma (children + young adults), necrotic hepatic metastasis, cystic primary hepatocellular carcinoma
Biliary-Enteric Fistula
Incidence: 5% at cholecystectomy; 0.5% at autopsy
Etiology: cholelithiasis (90%), acute/chronic cholecystitis, biliary tract carcinoma, regional invasive neoplasm, diverticulitis, inflammatory bowel disease, peptic ulcer disease, echinococcal cyst, trauma, congenital communication
Communication with:
  • duodenum (70%), colon (26%), stomach (4%), jejunum, ileum, hepatic artery, portal vein (caused death of Ignatius Loyola), bronchial tree, pericardium, renal pelvis, ureter, urinary bladder, vagina, ovary
  • CHOLECYSTODUODENAL FISTULA (51–80%)
    • Perforated gallstone (90%):
      • associated with gallstone ileus in 20%
    • Perforated duodenal ulcer (10%)
    • Surgical anastomosis
    • Gallbladder carcinoma
  • CHOLECYSTOCOLIC FISTULA (13–21%)
  • CHOLEDOCHODUODENAL FISTULA (13–19%)
    • due to perforated duodenal ulcer disease
  • MULTIPLE FISTULAE (7%)
    • pneumobilia = branching tubular radiolucencies, more prominent centrally within the liver
    • barium filling of biliary tree
    • shrunken gallbladder mimicking pseudodiverticulum of duodenal bulb
    • multiple hyperechoic foci with dirty shadowing
DDx: patulous sphincter of Oddi, ascending cholangitis, surgery (choledochoduodenostomy, cholecystojejunostomy, sphincterotomy)
Budd-Chiari Syndrome
  • = syndrome of global/segmental hepatic venous outflow obstruction
Cause:
  • IDIOPATHIC (66%)
  • THROMBOSIS
    • hypercoagulable state:
      • polycythemia rubra vera (1/3), oral contraceptives, pregnancy + postpartum state, paroxysmal nocturnal hemoglobulinuria (12%), sickle cell disease
      mnemonic: 5 P’s
      • Paroxysmal nocturnal hemoglobulinuria
      • Platelets (thrombocytosis)
      • Pill (birth control pills)
      • Pregnancy
      • Polycythemia rubra vera
    • injury to vessel wall:
      • phlebitis, trauma, hepatic radiation injury, chemotherapeutic + immunosuppressive drugs in patients with bone marrow transplants, venoocclusive disease from pyrrolizidine alkaloids (senecio) found in medicinal bush teas in Jamaica
  • NONTHROMBOTIC OBSTRUCTION
    • tumor growth into IVC/hepatic veins (renal cell carcinoma, hepatoma, adrenal carcinoma, metastasis, primary leiomyosarcoma of IVC)
    • membranous obstruction of suprahepatic IVC
      • = IVC diaphragm (believed to be a congenital web or an acquired lesion from long-standing IVC thrombosis); common in oriental + Indian population (South Africa, India, Japan, Korea); very rare in Western countries
    • right atrial tumor
    • constrictive pericarditis
    • right heart failure
Pathophysiology: hepatic venous thrombosis leads to elevation of sinusoidal pressure, which causes delayed/reversed portal venous inflow, ascites, alteration in hepatic morphology
Age: all ages; M < F
  • right upper quadrant pain
  • shortness of breath (due to decreased cardiac return)
  • nonspecific elevated transaminases, jaundice
  • lower-extremity edema
Location:
Type I : occlusion of IVC ± hepatic veins
Type II : occlusion of major hepatic veins ± IVC
Type III : occlusion of small centrilobar veins
  • hepatosplenomegaly (early sign)
  • caudate lobe hypertrophy (88%) [DDx: cirrhosis]
  • ascites
  • gallbladder wall thickening >6 mm
  • nonvisualization of hepatic veins (75%)/vein diameter <3 mm (measured 2 cm from IVC)
  • communications between right/middle hepatic vein and inferior right hepatic vein
  • enlarged inferior right hepatic vein (18%)
  • portal vein diameter >12 mm (in adults), >8 mm (in children)
  • P.695

  • visualization of collateral pathways:
    • portosystemic: paraumbilical vein
    • bypassing IVC: azygos, hemiazygos
  • ± narrowing/obstruction of intrahepatic IVC
  • NECT:
    • global liver enlargement + diffuse hypoattenuation
  • CT:
    • “flip-flop” enhancement pattern:
      • prominent enhancement of central liver + weak enhancement of peripheral liver on early images
      • enhancement of liver periphery + wash-out of contrast from central liver on delayed images
    • normal enhancement of enlarged caudate lobe (due to separate venous drainage directly into IVC)
    • mottled liver enhancement pattern (due to hepatic congestion):
      • patchy liver enhancement (85%) with normal portal blood flow
      • hypodensity in atrophic areas/periphery (82%) with inversion of portal blood flow (= reversed portal venous blood flow due to increased postsinusoidal pressure produced by hepatic venous obstruction/rarely infarcts)
    • failure to identify hepatic veins
    • hepatic vein thrombi (18–53%)
  • MRI:
    • reduction in caliber/complete absence of hepatic veins
    • “comma sign” = multiple comma-shaped intrahepatic flow voids (due to intrahepatic collaterals)
  • Doppler US (85–100% sensitive, 85% specific):
    • one/more major hepatic veins reduced in size to <3 mm/filled with thrombus/not visualized
    • communicating intrahepatic venous collaterals
    • decreased/absent/reversed blood flow in hepatic veins
    • flat flow/loss of cardiac modulation in hepatic veins
    • demodulated portal venous flow = disappearance of portal vein velocity variations with breathing
    • slow flow (<11 cm/sec)/hepatofugal flow in portal vein
    • portal vein congestion index >0.1
    • portal vein thrombosis (20%)
    • compression of IVC by enlarged liver/caudate lobe
    • sluggish/reversed/absent blood flow within IVC
    • hepatic artery resistive index >0.75
  • NUC (Tc-99m sulfur colloid):
    • central region of normal activity (hot caudate lobe) surrounded by greatly diminished activity (venous drainage of hypertrophied caudate lobe into IVC by separate vein)
    • colloid shift to spleen + bone marrow
    • wedge-shaped focal peripheral defects
  • Angio (inferior venocavography, hepatic venography):
    • absence of main hepatic veins
    • spider web pattern of collateral + recanalized veins
    • high-pressure gradient between infra- and suprahepatic portion of IVC (due to enlarged liver)
    • stretching + draping of intrahepatic arteries with hepatomegaly
    • inhomogeneous prolonged intense hepatogram with fine mottling
    • large lakes of sinusoidal contrast accumulation
  • Portography:
    • central hepatic enhancement (normal hepatopetal flow)
    • reversed portal flow in liver periphery (supplied only by hepatic artery)
    • bidirectional/hepatofugal main portal vein flow
Dx: liver biopsy
Rx: control of ascites with diuretics + sodium restriction; anticoagulation, thrombolytic therapy, surgery/balloon dilatation (depending on etiology); transjugular portosystemic shunt; orthotopic liver transplantation (for advanced cases)
Acute Budd-Chiari Syndrome (1/3)
  • Caudate lobe has not had time to hypertrophy!
  • • rapid onset of abdominal pain (liver congestion)
  • • insidious onset of intractable ascites
  • hepatomegaly without derangement of liver function
  • ascites (97%)
  • CT:
    • diffuse hypodensity on NECT
    • early enhancement of caudate lobe + central portion around IVC with decreased enhancement peripherally
    • hypodense lumina of hepatic veins on CECT
    • decreased attenuation of enhancing areas with patchy inhomogeneous enhancement in liver periphery on delayed scans
  • MR:
    • peripheral liver parenchyma of moderately low signal intensity on T1WI + moderately high signal intensity on T2WI compared with central portion
    • diminished + mottled peripheral enhancement
Chronic Budd-Chiari Syndrome (2/3)
  • • insidious onset of jaundice, intractable ascites
  • • portal hypertension, variceal bleeding
  • enlargement of central region (= caudate lobe + adjacent central part of right lobe + medial segment of left lobe
  • nonsegmental/lobar atrophy of affected liver (due to extensive fibrosis) with diminished attenuation before + after contrast administration
  • progressive patchy enhancement radiating outward from major portal vessels (on dynamic bolus CT)
  • “reticulated mosaic” enhancement = diffuse patchy lobular enhancement separated by irregular linear areas of low density in central area
  • delayed homogeneous enhancement of entire liver after several minutes
  • ascites
  • Color Doppler:
    • “bicolored” hepatic veins (due to intrahepatic collateral pathways) are PATHOGNOMONIC
  • MR:
    • absence of flow within hepatic veins
    • minimal differences in signal intensity between central and peripheral portions of liver
    • intrahepatic collateral vessels
Candidiasis Of Liver
  • = almost exclusively seen in immunocompromised patients (acute leukemia, chronic granulomatous disease of childhood, renal transplant, chemotherapy for myeloproliferative disorders)
P.696

Prevalence: at time of autopsy in 50–70% of acute leukemia, in 50% of lymphoma patients
♢ Most common systemic fungal infection in immunocompromised patients!
  • • abdominal pain
  • • persistent fever in neutropenic patient whose leukocyte count is returning to normal
  • • elevated alkaline phosphatase
  • hepatomegaly
  • “target”/“bull’s-eye” sign = multiple small hypoechoic/hypoattenuating masses with centers of increased echogenicity/attenuation distributed throughout liver
    • Bull’s-eye lesion becomes visible only when neutropenia resolves!
  • hyperintense lesions on T2WI
  • NUC:
    • uniform uptake/focal photopenic areas
    • diminished Ga-67 uptake
Dx: biopsy evidence of yeast/pseudohyphae in central necrotic portion of lesion
DDx: metastases, lymphoma, leukemia, sarcoidosis, septic emboli, other infections (MAI, CMV), Kaposi sarcoma
Caroli Disease
  • [Jacques Caroli (1902–1979), surgeon in Paris, France]
  • COMMUNICATING CAVERNOUS ECTASIA OF INTRAHEPATIC DUCTS
  • rare congenital probably autosomal recessive disorder characterized by multifocal segmental saccular cystic dilatation of the large intrahepatic bile ducts, which retain their communication with the biliary tree
Etiology: (a)? perinatal hepatic artery occlusion
(b)? hypoplasia/aplasia of fibromuscular wall components
Age: childhood + 2nd–3rd decade, occasionally in infancy; M:F = 1:1
Associated with: benign renal tubular ectasia, medullary sponge kidney (in 80%), infantile polycystic kidney disease, choledochal cyst (rare), congenital hepatic fibrosis
  • • recurrent cramplike upper abdominal pain
  • • fever, transient jaundice
  • • cirrhosis/portal hypertension (very rare)
  • multiple cystic structures converging toward porta hepatis as either localized/diffusely scattered cysts communicating with bile ducts (DDx: polycystic liver disease)
  • sludge/calculi in dilated ducts
  • CT/US/ MR:
    • central dot sign = portal vein radicles completely surrounded by dilated bile ducts
  • Cholangiography (diagnostic):
    • segmental saccular/fusiform/beaded dilatation of intrahepatic bile ducts extending to periphery of liver up to 5 cm in diameter
    • bridge formation across dilated lumina
    • intraluminal bulbar protrusions
    • frequent ectasia of extrahepatic ducts + CBD
Cx: (1) Bile stasis with recurrent cholangitis
(2) Biliary calculi (predominantly bilirubin)
(3) Liver abscess
(4) Septicemia
(5) Increased risk for cholangiocarcinoma (7%)
DDx: polycystic liver disease (noncommunicating), biliary hamartoma (noncommunicating); primary sclerosing cholangitis, recurrent pyogenic cholangitis
Cholangiocarcinoma
Incidence: 0.5–1% of all cancers, 30% of hepatic primary malignancies
♢ Cholangiocarcinomas occur in 10–15% of patients with primary sclerosing cholangitis!
Location:
  • INTRAHEPATIC
    • PERIPHERAL distal to 2nd-order branches
    • HILAR/CENTRAL at bifurcation/in 1st-order branches = Klatskin tumor
      confluence of hepatic ducts in 10–26%
      left/right hepatic duct in 8–13%
  • EXTRAHEPATIC
    common hepatic duct in 14–37%
    proximal CBD in 15–30%
    distal CBD in 30–50%
    cystic duct in 6%
Path:
  • exophytic (= mass-forming/nodular) type:
    • commonly in peripheral cholangiocarcinoma
    • large irregular hypoattenuating mass
    • stippled/punctate hyperattenuating foci
    • thin rimlike/thick bandlike enhancement around the tumor (early)
    • progressive concentric filling in of contrast (late) due to slow diffusion into interstitial tumor spaces
  • diffuse = infiltrative (periductal) type:
    • commonly in hilar + extrahepatic cholangiocarcinoma
    • mural thickening/encircling mass of bile duct wall
    • focal or diffuse stricture/complete obstruction of bile ducts
  • polypoid = papillary (intraductal) type: infrequent
    • intraluminal polypoid mass
  • combination
Histo: well/moderately/poorly differentiated ductal (most common), papillary, mucinous, signet-ring cell, mucoepidermoid, adenosquamous, cystadenocarcinoma Unusual manifestation:
  1. Mucin-hypersecreting cholangiocarcinoma
    √severe diffuse dilatation of intra- and extrahepatic bile ducts proximal + distal to tumor
  2. Squamous cell carcinoma
    = metaplastic transformation of adenocarcinoma cells
Predisposed:
  • Inflammatory bowel disease (10 × increased risk); incidence of 0.4–1.4% in ulcerative colitis; latent period of 15 years; tumors usually multicentric + predominantly in extrahepatic sites; GB involved in 15% (simultaneous presence of gallstones is rare)
  • Biliary lithiasis: cholecystolithiasis (20–50%), intrahepatic lithiasis (5–10%)
  • Primary sclerosing cholangitis (10%)
  • P.697

  • Clonorchis sinensis infestation (Far East); most common cause worldwide
  • Choledochal cyst/congenital hepatic cyst/congenital biliary atresia
  • Ductal plate malformation:
    • Biliary hamartoma
    • Autosomal dominant polycystic disease
    • Congenital hepatic fibrosis
    • Caroli disease (due to chronic biliary stasis)
  • Papillomatosis of bile ducts
  • Recurrent pyogenic cholangitis
  • Choledochoenteric anastomosis
  • History of other malignancy (10%)
  • Thorotrast exposure
  • Alpha–1 antitrypsin deficiency
Prognosis: median survival of 7 months, 0–10% 5-year survival
Intrahepatic Cholangiocarcinoma
  • = CHOLANGIOCELLULAR CARCINOMA
Incidence: 1/3 of all malignancies originating in the liver; 8–13% of all cholangiocarcinomas; 2nd most common primary hepatic tumor after hepatoma
Histo: adenocarcinoma arising from the epithelium of a small intrahepatic bile duct with prominent desmoplastic reaction (fibrosis); ± mucin and calcifications
Average age: 50–60 years; M > F
  • abdominal pain (47%); painless jaundice (12%)
  • palpable mass (18%)
  • weight loss (18%)
Spread: (a) local extension along duct
(b) local infiltration of liver substance
(c) metastatic spread to regional lymph nodes (in 15%)
  • mass of 5–20 cm in diameter
  • satellite nodules in 65%
  • punctate/chunky calcifications in 18%
  • calculi in biliary tree
  • NUC:
    • cold lesion on sulfur colloid/IDA scans
    • segmental biliary obstruction
    • may show uptake on gallium scan
  • US:
    • dilated biliary tree
    • predominantly homo-/heterogeneous mass
    • hyper- (75%)/iso-/hypoechoic (14%) mass
    • mural thickening
  • CT:
    • single predominantly homogeneous round/oval hypodense mass with irregular borders
    • “peripheral washout sign” = early minimal/moderate rim enhancement with progressive concentric filling and clearing of contrast material in rim of lesion on delayed images
    • marked homogeneous delayed enhancement (74%)
  • MR:
    • large central heterogeneous hypointense mass on T1WI
    • hyperintense periphery (viable tumor) + large central hypointensity (fibrosis) on T2WI
    • gadolinium enhancement of lesion
  • Angiography:
    • avascular/hypo-/hypervascular mass
    • stretched/encased arteries (frequent)
    • neovascularity in 50%
    • lack of venous invasion
Prognosis: <20% resectable; 30% 5-year survival
Klatskin Tumor
  • [Gerald Klatskin (1910–1986), pathologist in yale, USA]
  • = INTRAhEPATIC CENTRAL ChoLANGIoCARCINoMA
  • = tumor at confluence of hepatic ducts (up to 70% of cholangiocarcinomas)
  • direct signs of Klatskin tumor:
    • iso- to hyperechoic central porta hepatis mass/focal irregularity of ducts (for infiltrating cholangiocarcinoma = more common subtype)
    • polypoid/smooth nodular intraluminal mass (for papillary + nodular types of cholangiocarcinoma) with associated mural thickening
  • indirect signs of Klatskin tumor:
    • segmental dilatation with nonunion of right and left ducts at porta hepatis + normal caliber of extrahepatic ducts
    • pressure effect/encasement/invasion/obliteration of portal vein and hepatic artery
    • lobar atrophy (14%) = dilated crowded ducts extending to liver surface ± geographic fatty change in one lobe
Intrahepatic Peripheral Cholangiocarcinoma
  • • no jaundice
Location: right lobe predilection
  • solitary mass (nodular form) without hypoechoic halo
  • diffusely abnormal liver texture (infiltrative form):
    • tumor more hypoechoic if <3 cm
    • tumor more hyperechoic if >3 cm
  • well-marginated cystic mass (papillary mucinproducing tumor) ± diffuse hyperechoic flecks of tumor calcification
  • dilatation of bile ducts peripheral to tumor (31%)
DDx: metastatic adenocarcinoma/leiomyosarcoma; sclerosing hepatocellular carcinoma
Extrahepatic Cholangiocarcinoma
  • = BILE DUCT CARCINoMA
Age peak: 6th–7th decade, M:F = 3:2
Incidence: <0.5% of autopsies; 90% of all cholangiocarcinomas; more frequent in Far East
Histo: well-differentiated sclerosing adenocarcinoma (2/3), anaplastic carcinoma (11%), cystadenocarcinoma, adenoacanthoma, malignant adenoma, squamous cell = epidermoid carcinoma, leiomyosarcoma
  • gradual onset of fluctuating painless jaundice
  • cholangitis (10%)
  • weight loss, fatigability
  • intermittent epigastric pain
  • elevated bilirubin + alkaline phosphatase
  • enlarged tender liver
  • Growth pattern:
    • Obstructive type (70–85%)
      • U-/V-shaped obstruction with nipple, rattail, smooth/irregular termination
    • P.698

    • Stenotic type (10–25%)
      • strictured rigid lumen with irregular margins + prestenotic dilatation
    • Polypoid/papillary type (5–6%)
      • intraluminal filling defect with irregular margins
    Spread: (a) lymphatic spread: cystic + CBD nodes (>32%), celiac nodes (>16%), peripancreatic nodes, superior mesenteric nodes
    (b) infiltration of liver (23%)
    (c) peritoneal seeding (9%)
    (d) hematogenous (extremely rare): liver, peritoneum, lung
  • UGI:
    • infiltration/indentation of stomach/duodenum Cholangiography (PTC or ERC best modality to depict bile duct neoplasm):
    • exophytic intraductal tumor mass (46%), 2–5 mm in diameter
    • frequently long/rarely short concentric focal stricture in infiltrating sclerosing cholangitic type with wall irregularities
    • prestenotic diffuse/focal biliary dilatation (100%)
    • progression of ductal strictures (100%)
  • US/CT:
    • dilatation of intrahepatic ducts without extrahepatic duct dilatation
    • failure to demonstrate the confluence of L + R hepatic ducts
    • mass within/surrounding the ducts at point of obstruction (21% visible on US, 40% visible on CT)
    • infiltrating tumor visible as highly attenuating lesion in 22% on CT, in 13% on US
    • exophytic tumor visible in 100% on CT as low-attenuation mass, in 29% on US
    • polypoid intraluminal tumor visible as isoechoic mass within surrounding bile in 100% on US, in 25% on CT
  • CECT:
    • hyperattenuating lesion at delayed imaging (due to delayed accumulation + washout of fibrous center)
  • Angiography:
    • hypervascular tumor with neovascularity (50%)
    • arterioarterial collaterals along the course of bile ducts associated with arterial obstruction
    • poor/absent tumor stain
    • displacement/encasement/occlusion of hepatic artery + portal vein
Cx: (1) Obstruction leading to biliary cirrhosis
(2) Hepatomegaly
(3) Intrahepatic abscess (subdiaphragmatic, perihepatic, septicemia)
(4) Biliary peritonitis
(5) Portal vein invasion
Dx: endoscopic brush biopsy (30–85% sensitive)
Prognosis: median survival of 5 months; 1.6% 5-year survival; 39% 5-year survival for carcinoma of papilla of Vater
DDx: sclerosing cholangitis, AIDS cholangitis, benign stricture, chronic pancreatitis, edematous papilla, idiopathic inflammation of CBD
Cholangitis
Acute Obstructive/Ascending Cholangitis
  • = biliary duct obstruction associated with biliary infection
Cause:
  • benign disease:
    • Stricture from prior surgery (36%) after bile duct exploration/bilioenteric anastomosis
    • Calculi (30%)
    • Sclerosing cholangitis
    • Obstructed drainage catheter
    • Parasitic infestation
  • malignant disease:
    • Ampullary carcinoma
Types:
  • ACUTE NONSUPPURATIVE ASCENDING CHOLANGITIS
    • bile remains clear
    • patient nontoxic
  • ACUTE SUPPURATIVE ASCENDING CHOLANGITIS (14%)
    Associated with: obstructing biliary stone or malignancy
    • • septicemia, CNS depression, lethargy, mental confusion, shock (50%)
    • √ purulent material fills biliary ducts
    Prognosis: 100% mortality if not decompressed;40–60% mortality with treatment;13–16% overall mortality rate
    Organism: gram-negative enteric bacteria = E. coli > Klebsiella > Pseudomonas > Enterococci
  • • recurrent episodes of sepsis + RUQ pain
  • • Charcot triad (70%): fever + chills + jaundice
  • • bile cultures in 90% positive for infection
  • may have gas in biliary tree
  • CECT:
    • transient hepatic parenchymal enhancement in periportal location on hepatic arterial phase
    • (= hyperemic changes around bile ducts)
Cx: miliary hepatic abscess formation; secondary sclerosing cholangitis
AIDS-related Cholangitis
  • = AIDS CHOLANGIOPATHY
  • = infectious cholangitis characterized by opportunistic organisms
Organism: Cryptosporidium (protozoan parasite typically infecting GI tract epithelium), CMV
Histo: marked periductal inflammatory response with interstitial edema + interstitial inflammatory cell infiltrates + necrotic biliary epithelium
  • • RUQ pain, fever, nausea, jaundice
  • • elevated WBC count
  • • abnormal LFTs (esp. serum alkaline phosphatase)
  • • opportunistic organism isolated from bile (in 50%)
  • irregular mild dilatation of intra- and extrahepatic bile ducts resembling sclerosing cholangitis
  • US:
    • stricture of distal CBD/papillary stenosis (due to papillitis)
    • P.699

    • echogenic nodule at the distal end of the CBD
    • mural thickening of gallbladder + bile ducts
    • periductal echogenicity
    • ± pericholecystic fluid
  • CT:
    • “pseudogallstone” appearance = marked circumferential edema of gallbladder wall + mucosal enhancement
    • periportal edema
  • Cholangiography:
    • strictures + beading of central intrahepatic bile ducts
    • pruning of peripheral bile ducts
    DDx: acalculous cholecystitis, papillary stenosis, sclerosing cholangitis
    Chemotherapy-induced Cholangitis
    • = inflammatory fibrosing process about the portal triads simulating primary sclerosing cholangitis
    Predisposed: patients with liver metastases from colon cancer
    Cause: direct effect of hepatic arterial infusion with chemotherapeutic agents (eg, floxuridine)/ischemia secondary to thrombosis of intrahepatic arterial branches
    • bile duct strictures as early as 2 months after therapy (in up to 15%)
    • stricture of common hepatic duct + sparing of distal CBD
    Primary Sclerosing Cholangitis
    • = insidious progressive obliterative fibrosing inflammation of the biliary tree causing multifocal strictures, bile duct obliteration, cholestasis, and biliary cirrhosis
    Etiology: idiopathic,? autoimmune process (speculative); altered bile acid metabolism with increase in lithocholic acid by bacterial overgrowth
    Prevalence: 1% as common as alcoholic liver disease
    Age: <45 years (2/3); mean 39 (range 21–67) years;M:F = 7:3
    Histo:
    Stage 1: degeneration of epithelial bile duct cells + infiltration with lymphocytes ± neutrophils; inflammation + scarring + enlargement of periportal triads (pericholangitis)
    Stage 2: fibrosis + inflammation infiltrating periportal parenchyma with piecemeal necrosis of hepatocytes; enlargement of portal triads; bile ductopenia
    Stage 3: portal-to-portal fibrous septa; severe degenerative changes + disappearance of bile ducts; cholestasis in periportal + paraseptal hepatocytes
    Stage 4: frank cirrhosis
    Associated with:
    • Inflammatory bowel disease (ulcerative colitis in 50–74%, Crohn disease in 13%)
      • 1–4% of patients with inflammatory bowel disease develop secondary sclerosing cholangitis!
      • 10% of patients with primary sclerosing cholangitis have Crohn disease
    • Cirrhosis, chronic active hepatitis, pericholangitis, fatty degeneration
    • Pancreatitis
    • Retroperitoneal/mediastinal fibrosis
    • Peyronie disease
    • Riedel thyroiditis, hypothyroidism
    • Retroorbital pseudotumor
    • Sjögren syndrome
    • abnormal liver function tests: serum bilirubin, serum alkaline phosphatase, γ-glutamyltransferase
    • progressive chronic/intermittent obstructive jaundice (75%)
    • history of previous biliary surgery (53%) + chronic/recurrent pancreatitis (14%)
    • fever, night sweats, chills, RUQ pain, pruritus (10–15%)
    • Location:
      • CBD almost always involved
      • Intra- and extrahepatic ducts (68–89%)
      • Cystic duct involved in 15–18%
      • Intrahepatic ducts only (1–11–25%)
      • Extrahepatic ducts only (2–3%)
    • intrahepatic bile duct calculi (8–30%): soft black crushable stones/sandlike grit
    • US:
      • brightly echogenic portal triads
      • echogenic biliary casts/punctate coarse calcifications along portal vein branches
      • ± gallbladder wall thickening
    • CT:
      • dilatation, stenosis, pruning (decreased arborization), beading of tortuous intrahepatic bile ducts = “tree-in-winter” appearance (80%)
      • wall nodularity, duct wall thickening, mural contrast enhancement of extrahepatic bile ducts (100%)
      • hepatic metastases + lymph nodes in porta hepatis
      • subtle foci of high attenuation in intrahepatic bile ducts
      • lobar atrophy in preferentially affected portions
    • Cholangiography:
      • multifocal strictures with predilection for bifurcations + skip lesions (uninvolved duct segments of normal caliber) involving intra- and extrahepatic bile ducts:
        • CLASSIC “string-of-beads” appearance
          • (= alternating segments of dilatation and focal annular stenoses)
        • “pruned tree” appearance (= opacification of central ducts + nonvisualization of peripheral smaller radicles due to diffuse obstruction)
        • “cobblestone” appearance (= coarse nodular mural irregularities) in 50%
        • new strictures + lengthening of strictures between 6 months and 6 years (<20%)
        • minimal duct dilatation due to periductal inflammation + fibrosis
        • marked ductal dilatation (24%)
          DDx: ascending cholangitis, cholangiocarcinoma
    • small eccentric saccular outpouchings (diverticula/pseudodiverticula) [up to 27%] = PATHOGNOMONIC
    • webs = focal 1–2-mm-thick areas of incomplete circumferential narrowing
    • angles formed between central and peripheral ducts change from acute to obtuse
    • polypoid mass (7%)
    • gallbladder irregularities uncommon
  • P.700

  • MR:
    • periportal intermediate intensity on T1WI + hyperintense on T2WI (due to inflammation)
  • NUC (Tc-99m-IDA scan):
    • multiple persistent focal areas of retention in distribution of intrahepatic biliary tree
    • marked prolongation of hepatic clearance
    • gallbladder visualized only in 70%
Cx: (1) Biliary cirrhosis (up to 49%)
(2) Portal hypertension
(3) Cholangiocarcinoma (clinically in 4–19%; in 7–36% at autopsy/liver transplantation)
(4) Secondary cholangitis
Rx: (1) Palliative: ursodeoxycholic acid, dilatation of dominant strictures
(2) Curative: liver transplantation (4th leading indication)
DDx: (1) Sclerosing cholangiocarcinoma (progressive cholangiographic changes within 0.5–1.5 years of initial diagnosis, marked ductal dilatation upstream from a dominant stricture, intraductal mass >1 cm in diameter)
(2) Acute ascending cholangitis (history)
(3) Primary biliary cirrhosis (disease limited to intrahepatic ducts, strictures less pronounced, pruning + crowding of bile ducts, normal AMA titer)
(4) AIDS cholangiopathy (same on cholangiography)
Recurrent Pyogenic Cholangitis
  • = PRIMARY CHOLANGITIS = RECURRENT PYOGENIC HEPATITIS/CHOLANGITIS = ORIENTAL CHOLANGIO-HEPATITIS = ORIENTAL CHOLANGITIS = HONG KONG DISEASE = INTRAHEPATIC PIGMENT STONE DISEASE
  • = chronic recurrent parasitic cholangitis resulting in progressive destructive cholangiopathy + liver failure
Etiology: ? Clonorchis sinensis infestation, coliform infection of bile, portal bacteremia, malnutrition
Incidence: 3rd most common cause of an acute abdomen in Hong Kong after appendicitis and perforated ulcer; uncommon in United States
Epidemiology: endemic to Southeast Asia (South China, Indochina, Taiwan, Japan, Korea); Asian immigrants in United States
Associated intrabiliary infestation:
  • Clonorchis sinensis, Ascaris lumbricoides, E. coli
Path: pericholangitis, periductal abscesses, fibrosis of bile duct walls, heavy infiltration of portal tracts by PMNs, intraductal bile pigment calculi
Age: 20–50 years; M:F = 1:1
  • recurrent attacks of fever, chills, abdominal pain, jaundice
Location: particularly in lateral segment of L lobe + posterior segment of R lobe
  • marked dilatation of proximal intrahepatic ducts (3–4 mm) in 100%
  • decreased arborization of intrahepatic radicles
  • intra- and extrahepatic bile ducts filled with nonshadowing soft mudlike pigment (= calcium bilirubinate) stones (74%)
  • dilatation of CBD (68%) + choledocholithiasis (30%)
  • multifocal bile duct strictures (22%)
  • pneumobilia (3–52%)
  • biloma
  • segmental hepatic atrophy (36%)
  • hepatic abscesses
  • CT:
    • high-attenuation biliary calculi
    • enhancement of bile duct wall
  • Associated findings:
    • gallstones
    • splenomegaly
    • varices
  • ERCP:
    • Worsening of cholangitis/sepsis if patients do not receive antibiotics!
    • acute tapering + straightening + rigidity of bile ducts
    • decreased arborization + increased branching angle of bile ducts
Cx: liver abscess (18%), splenomegaly (14%), biloma (4%), pancreatitis (4%), cholangiocarcinoma (2.5–6%)
Rx: endoscopic sphincterotomy, choledochoduodenostomy
DDx: (1) Caroli disease (saccular dilatation of intrahepatic bile ducts)
(2) Primary sclerosing cholangitis (focal discontinuous bile duct dilatation)
(3) Clonorchiasis (biliary ductal dilatation limited to intrahepatic bile ducts)
Secondary Sclerosing Cholangitis
Cause:
  • Chronic bacterial cholangitis from bile duct stricture/choledocholithiasis
  • Ischemic bile duct damage from treatment with floxuridine
  • Infectious cholangiopathy in AIDS
  • Previous biliary tract surgery
  • Congenital biliary tree anomalies
  • Bile duct neoplasm
Cholecystitis
Acute Calculous Cholecystitis
Etiology: (a) in 80–95% cystic duct obstruction by impacted calculus; 85% disimpact spontaneously if stone <3 mm
(b) in 10% acalculous cholecystitis
Pathogenesis: chemical irritation from concentrated bile, bacterial infection, reflux of pancreatic secretions
Age peak: 5th–6th decade; M:F = 1:3
Associated with: choledocholithiasis (15–25%)
  • persisting (>6 hours) RUQ pain radiating to right shoulder/scapula/interscapular area (DDx: biliary colic usually <6 hours)
  • nausea, vomiting, chills, fever
  • RUQ tenderness + guarding
  • ± leukocytosis, elevated levels of alkaline phosphatase and transaminase and amylase
  • mild hyperbilirubinemia (20%)
  • Murphy sign = inspiratory arrest upon palpation of GB area (falsely positive in 6% of patients with cholelithiasis)
Oral cholecystography:
P.701

  • nonvisualization/poor visualization of gallbladder
US (81ndash; 100% sensitivity, 60–100% specificity, 92% PPV, 95% NPV):
  • ± GB wall thickening >3 mm (45–72% sensitive, 76–88% specific):
    • hazy delineation of GB wall
    • “halo sign” = GB wall lucency (in 8%) = 3-layered configuration with sonolucent middle layer (edema)
    • striated wall thickening (62%) = several alternating irregular discontinuous lucent + echogenic bands within GB wall (100% PPV)
  • GB hydrops = distension with AP diameter >5 cm or enlargement of greater than 4 × 10 cm
  • positive sonographic Murphy sign (in 85–88%)
    • = maximum tenderness during compression with transducer directly over gallbladder (63–94% sensitive, 85–93% specific, 72% NPV)
    • False-negative sonographic Murphy sign:
      • lack of patient responsiveness, pain medication, inability to press directly on GB (position deep to liver/protected by ribs), GB wall necrosis
  • crescent-shaped/loculated pericholecystic fluid (in 20%)
    • = inflammatory intraperitoneal exudate/abscess
  • gallstones (83–98% sensitive, 52–77% specific):
    • impacted gallstone in GB neck/cystic duct
    • echogenic shadowing fat within hepatoduodenal ligament ± conspicuous color Doppler flow (due to inflammation)
      DDx: bowel gas
  • sludge
Color Doppler US:
  • visualization of cystic artery >50% of the length of the gallbladder (30% sensitive, 98% specific)
CECT:
  • distended gallbladder
  • gallbladder wall thickness >3 mm
  • increased gallbladder wall attenuation
  • transient focal increased attenuation around gallbladder fossa on hepatic arterial phase (due to hepatic arterial hyperemia + early venous drainage)
  • haziness of pericholecystic fat
  • pericholecystic fluid
  • increased attenuation of bile
NUC (86–97% sensitivity, 73–100% specificity, 95–98% accuracy):
  • = functional information about gallbladder + cystic duct patency
  • Tracer uptake hinges on adequate hepatic function+ fasting status
  • nonvisualization of GB during 1st hour (in 83%)
    • = evidence of cystic duct obstruction
  • nonvisualization of GB by 4 hours (99% specific)
  • nonvisualization of GB + CBD (in 13%)
  • pericholecystic rim sign (34% sensitive) on initial images = increased hepatic activity adjacent to empty GB fossa (= local hepatocyte inflammation + hyperemia in transmural process); 57% PPV for gangrenous GB + 94% PPV for acute cholecystitis
  • increased perfusion to GB fossa during “arterial phase” (in up to 80%)
Endpoint of imaging:
  • when tracer fills GB
  • 4 hours of delayed imaging after tracer injection
  • 45 minutes after morphine injection
False-positive scans (10–12%) = nonvisualization of GB without acute cholecystitis:
  • prolonged fasting, total parenteral nutrition, hyperalimentation, recent feeding <4–6 hours prior to study, severe intercurrent illness, CBD obstruction, congenital absence of GB, post-cholecystectomy, carcinoma of GB, chronic cholecystitis, acute pancreatitis, alcoholic liver disease, hepatocellular disease
  • Reduction to 2% false-positive scans through:
    • delayed images up to 4 hours
    • cholecystokinin (Sincalide®) injection 15 minutes prior to study
    • morphine IV (0.04 mg/kg) at 40 minutes + reimaging after 20 minutes (contraction of sphincter of Oddi + rise in intrabiliary pressure)
False-negative scans (4.8%) = visualization of GB despite acute cholecystitis:
  • rare calculous/acalculous cholecystitis without cystic duct obstruction
Cholangiography:
  • sharply defined filling defect in contrast-material filled lumen of cystic duct
MR cholangiopancreatogram (high sensitivity):
  • low-signal–intensity defect surrounded by high-signal–intensity bile on T2WI
Cx:
mnemonic: GAME BEG
  • Gangrene
  • Abscess (pericholecystic)
  • Mirizzi syndrome
  • Emphysematous cholecystitis
  • Bouveret syndrome (= gallstone erodes into duodenum leading to duodenal obstruction)
  • Empyema
  • Gallstone ileus
GANGRENE OF GALLBLADDER
  • • positive Murphy sign (33%)
  • irregular/absent gallbladder wall
  • shaggy, irregular, asymmetric wall (mucosal ulcers, intraluminal hemorrhage, necrosis)
  • hyperechoic foci within GB wall (microabscesses in Rokitansky-Aschoff sinuses)
  • intraluminal pseudomembranes (gangrene)
  • coarse nonshadowing nondependent echodensities (= sloughed necrotic mucosa/sludge/pus/clotted blood within gallbladder)
Pericholecystic Abscess
Cause: subacute perforation of gallbladder wall subsequent to gangrene + infarction due to acute cholecystitis
Prevalence: 2–20%
Location:
  • gallbladder bed (most common)
    • area of low-level echoes in liver adjacent to GB
  • P.702

  • intramural
    • small area of low-level echoes within thickened gallbladder wall
  • intraperitoneal
    • area of low-level echoes within peritoneal cavity adjacent to gallbladder
Rx:
  • Emergency operation
  • Antibiotic treatment + elective operation
  • Percutaneous abscess drainage
Perforation of Gallbladder (in 2–20%)
  • Types:
    • Acute free perforation with peritonitis causing pericholecystic abscess in 33%
    • Subacute localized perforation causing pericholecystic abscess in 48%
    • Chronic perforation resulting in internal biliary fistula causing pericholecystic abscess in 18%
Location: most commonly at fundus
  • gallstone lying free in peritoneal cavity
  • sonolucent/complex collection surrounding GB
  • collection in liver adjacent to gallbladder
Empyema of Gallbladder
  • multiple medium/coarse highly reflective intraluminal echoes without shadowing/layering/gravity dependence (purulent exudate/debris)
Acute Acalculous Cholecystitis
Frequency: 5–15% of all acute cholecystitis cases
Associated with: recent surgery in 50%
Etiology: probably caused by decreased blood flow within cystic artery
  • debilitated patients: depressed motility/starvation in trauma, burns, surgery, total parenteral nutrition, anesthesia, positive pressure ventilation, narcotics, shock, vasoactive amines, congestive heart failure, arteriosclerosis, polyarteritis nodosa, SLE, diabetes mellitus
    • Diagnosis in the ICU patient sonographically difficult due to fasting state, medications, CHF, etc.
  • obstruction of cystic duct by extrinsic inflammation, lymphadenopathy, metastases
  • infection (only in 50%) from Salmonella, Helicobacter, cholera, Kawasaki syndrome, cytomegalovirus, cryptosporidiosis
  • thickened gallbladder wall >4–5 mm
  • echogenic bile/sludge
  • gallbladder distension
  • pericholecystic fluid in absence of ascites
  • striated subserosal edema
  • sloughed mucosal membrane
  • Murphy sign = pain + tenderness with transducer pressure over the gallbladder (difficult to assess in ICU patient with altered mental status)
  • decreased response to cholecystokinin
  • intramural gas
  • CT:
    • pericholecystic stranding (= edema)
    • decreased attenuation in adjacent liver (= perihepatitis)
NUC: same criteria as for calculous cholecystitis
Cx: gallbladder perforation, gangrene, pericholecystic abscess
Rx: percutaneous cholecystostomy trial (low threshold for ICU patients)
Prognosis: 6.5% mortality rate
Chronic Cholecystitis
  • Most common form of gallbladder inflammation
  • gallstones
  • smooth/irregular GB wall thickening (mean of 5 mm)
  • mean volume of 42 mL
  • NUC:
    • normal GB visualization in majority of patients
    • delayed GB visualization (1–4 hours)
    • visualization of bowel prior to GB (sensitivity 45%, specificity 90%)
    • noncontractility/decreased response after CCK injection (decreased GB ejection fraction)
Emphysematous Cholecystitis
  • = ischemia of gallbladder wall + infection with gas-producing organisms
Etiology: small-vessel disease with cystic artery occlusion, complication of acute cholecystitis
Organism: Clostridium perfringens, Clostridium welchii, E. coli, staphylococcus, streptococcus
Age: >50 years; M:F = 5:1
Predisposed: diabetics (20–50%), debilitating diseases; calculous (70–80%)/acalculous cystic duct obstruction
  • • WBC count may be normal (1/3)
  • • point tenderness rare (diabetic neuropathy)
  • Plain film:
    • gas appears 24–48 hours after onset of symptoms
    • air-fluid level in GB lumen, air in GB wall within 24–48 hours after acute episode
    • pneumobilia (rare)
  • US:
    • arclike high-level echoes outlining GB wall
    • cholecystolithiasis (50%)
Cx: gangrene (75%); gallbladder perforation (20%)
Mortality: 15%
DDx: (1) Enteric fistula
(2) Incompetent sphincter of Oddi
(3) Air-containing periduodenal abscess
(4) Periappendiceal abscess in malpositioned appendix
(5) Lipomatosis of gallbladder
Xanthogranulomatous Cholecystitis
  • = FIBROXANTHOGRANULOMATOUS INFLAMMATION= CEROID GRANULOMAS OF THE GALLBLADDER
  • = uncommon inflammatory disease of gallbladder characterized by presence of multiple intramural nodules
  • Etiology:
    • rupture of occluded Rokitansky-Aschoff sinuses with subsequent intramural extravasation of inspissated bile + mucin attracting histiocytes to phagocytize the insoluble cholesterol
Incidence: 1–2%
Age: 7th + 8th decade
Histo: mixture of ceroid (waxlike) xanthogranuloma with foamy histiocytes + multinucleated foreign body giant cells + lymphocytes + fibroblasts containing areas of necrosis (in newer lesions)
May be associated with: gallbladder carcinoma (11%)
P.703

  • preservation of 2–3-mm thick mucosal lining (in 82%)
  • thickened gallbladder wall: 91% diffuse, 9% focal
  • infiltration of pericholecystic fat: in 45% focal, in 54% diffuse
  • hepatic extension (45%)
  • biliary obstruction (36%)
  • lymphadenopathy (36%)
  • US:
    • intramural hypoechoic nodules
  • CT:
    • 5–20-mm small intramural hypoattenuating nodules
    • poor/heterogeneous contrast enhancement
DDx: gallbladder carcinoma (in 59% focal, in 41% diffuse thickening of gallbladder wall, multiple masses within liver)
image
Choledochal Cysts
Choledochal Cyst
  • = CYSTIC DILATATION OF EXTRAHEPATIC BILE DUCT
  • = segmental aneurysmal dilatation of common bile duct without involvement of gallbladder/cystic duct; most common congenital lesion of bile ducts
Etiology: anomalous junction of pancreatic duct and CBD proximal to duodenal papilla; higher pressure in pancreatic duct and absent ductal sphincter allows free reflux of enzymes into CBD resulting in weakening of CBD wall
Classification:
  • malunion of pancreaticobiliary duct
Kimura type I = pancreatic duct enters the proximal/mid CBD (10–58%) at right angle
Kimura type II = CBD drains into pancreatic duct
Prevalence: 1:13,000 admissions; high prevalence in Japanese/Asian infants
Age: <10 years (60%) + young adulthood; 80% diagnosed in childhood; 7% during pregnancy; occasionally detected up to 8th decade; M:F = 1:4
Histo: fibrous cyst wall without epithelial lining
Associated with:
  • dilatation, stenosis or atresia of other portions of the biliary tree (2%)
  • gallbladder anomaly (aplasia, double GB)
  • failure of union of left + right hepatic ducts
  • pancreatic duct + accessory hepatic bile ducts may drain into cyst
  • polycystic liver disease
  • • Classic triad (20–30% of adult patients):
    • intermittent obstructive jaundice (33–50%)
      • Uncommon cause of obstructive jaundice!
    • recurrent RUQ colicky pain (>75–90%), back pain
    • intermittent palpable RUQ abdominal mass (<25%)
  • • recurrent fever, chills, weight loss, pruritus
  • Types:
    • marked cystic dilatation of CBD + CHD
    • focal segmental dilatation of CBD distally
    • cylindric dilatation of CBD + CHD
  • size: diameter of 2 cm up to 15 cm (the largest choledochal cyst contained 13 liters)
  • NO/mild peripheral intrahepatic bile duct dilatation
  • may contain stones/sludge
  • UGI:
    • soft-tissue mass in RUQ
    • anterior displacement of 2nd portion of duodenum + distal portion of stomach (on LAT view)
    • widening of C-loop with inferior displacement of duodenum (on AP view)
  • US:
    • ballooned/fusiform cyst beneath porta hepatis separate from gallbladder
      • Communication with common hepatic/intrahepatic ducts needs to be demonstrated!
    • abrupt change of caliber at junction of dilated segment to normal ducts
    • intrahepatic bile duct dilatation (16%) secondary to stenosis
  • OB-US (earliest diagnosis at 25 weeks MA):
    • right-sided cyst in fetal abdomen + adjacent dilated hepatic ducts
    DDx: duodenal atresia; cyst of ovary, mesentery, omentum, pancreas, liver
  • NUC with HIDA:
    • At times the choledochal cyst does not fill with radionuclide!
    • photopenic area within liver that fills within 60 minutes + stasis of tracer within cyst
    • lack of tracer passage into small intestine
    • prominent hepatic ductal activity (dilatation of ducts)
    DDx: often excludes hepatic cyst, pancreatic pseudocyst, enteric duplication, spontaneous loculated biloma
  • Cholangiography/MR cholangiography (confirms diagnosis):
    • anomalous junction of panreaticobiliary ductal system
    • dilated intrahepatic bile ducts
    • intraductal calculi
Cx: (1) Stones in gallbladder, in CBD, within cyst, in intrahepatic biliary tree, in pancreatic duct (8–50%)
(2) Malignant transformation into bile duct carcinoma + gallbladder carcinoma (increasing with age, <1% in 1st decade, 7–14% >age 20)
(3) Recurrent pancreatitis (33%)
(4) Cholangitis/cholecystitis (20%)
(5) Cyst rupture with bile peritonitis (1.8
%) (6) Bleeding
(7) Biliary cirrhosis + portal hypertension
(8) Portal vein thrombosis
(9) hepatic abscess
Rx: excision of cyst + Roux-en-Y hepaticojejunostomy
DDx: mesenteric, omental, ovarian, renal, adrenal, hepatic, enteric duplication cyst, pancreatic pseudocyst, hydronephrotic kidney, hepatic artery aneurysm, biloma (from spontaneous perforation of CBD)
P.704

Choledochocele
  • = DUODENAL DUPLICATION CYST = ENTEROGENOUS CYST OF AMPULLA OF VATER/DUODENUM = INTRADUODENAL CHOLEDOCHAL CYST = DIVERTICULUM OF COMMON BILE DUCT
  • = cystic dilatation of the distal/intramural duodenal portion of the CBD with herniation of CBD into duodenum (similar to ureterocele)
  • Etiology:
    • congenital:
      • originates from tiny bud/diverticulum of distal CBD (found in 5.7% of normal population)
      • stenosis of ductal orifice/weakness of ductal wall
    • acquired:
      • stone passage followed by stenosis + inflammation
Age: 33 years (manifestation usually in adulthood)
Types: (a) CBD terminates in cyst, cyst drains into duodenum (common)
(b) cyst drains into adjacent intramural portion of CBD (less common)
  • biliary colic, episodic jaundice, nausea, vomiting
Associated with: stones/sludge (frequent)
  • UGI:
    • smooth well-defined intraluminal duodenal filling defect in region of papilla
    • change in shape with compression/peristalsis
  • Cholangiography (diagnostic):
    • opacified smooth clublike/saclike dilatation of intramural segment of CBD prolapsed into duodenum
Cx: pancreatitis, duodenal obstruction
Rx: sphincterotomy/sphincteroplasty
DDx: choledochal cyst (involves more than only terminal portion of CBD)
Cholelithiasis
Prevalence:
  • 25 million adults in United States; 10% of population + 2% of children;
  • increasing with age (40% of women in 9th decade);
  • in 3rd decade M:F = 2%:4%
  • in 7th decade M:F = 10%:25%
Predisposing factors: “female, forty, fair, fat, fertile, flatulent”
Pathogenesis:
  • supersaturation of bile constituents, most notably cholesterol, related to defects in biliary lipid metabolism; biliary dysmotility; prolonged intestinal transit; aggravated by sedentary lifestyle + diet
  • Hemolytic disease:
    • sickle cell disease (7–37%), hereditary spherocytosis (43–85%), thalassemia, pernicious anemia (16–20%), prosthetic cardiac valves + mitral stenosis (hemolysis), cirrhosis (hemolysis secondary to hypersplenism), Rhesus/ABO blood group incompatibility (perinatal period)
  • Metabolic disorder = disruption of biliary lithogenic index:
    • diabetes mellitus, obesity, pancreatic disease, cystic fibrosis, hypercholesterolemia, type 4 hyperlipidemia, hemosiderosis (20%), hyperparathyroidism, hypothyroidism, prolonged use of estrogens/progesterone, pregnancy
  • Cholestasis
    • hepatic dysfunction: hepatitis, neonatal sepsis
    • biliary tree malformation: Caroli disease
    • biliary obstruction: parasitic infection, benign/malignant strictures, foreign bodies (sutures, ascariasis)
    • prolonged fasting (total parenteral nutrition)
    • methadone intake
  • Intestinal malabsorption
    • has a 10 × increased risk of stone formation
    • — Inflammatory bowel disease: Crohn disease (28–34%)
    • — ileal resection
    • — bypass surgery
  • Genetic predisposition = familial:
    • Navaho, Pima, Chippewa Indians
  • Others:
    • muscular dystrophy
Composition:
  • CHOLESTEROL STONE (70%)
    • = main component of most calculi
    • lucent (93%), calcified (7%)
    • slightly hypodense compared with bile
    • pure cholesterol stones (10%): yellowish, soft
      • buoyancy in contrast-enhanced bile
      • density of <100 HU
    • mixture of cholesterol + calcium carbonate/bilirubinate (70%)
      • laminated appearance
      • radiopaque on plain film (15–20%)
  • PIGMENT STONE (30%)
    • • brown (common) = granular precipitate of calcium bilirubinate containing <25% cholesterol (by definition)
    Cause: inflammation/infection of gallbladder, status post cholecystectomy
    • • black (less common) = compact “lacquer” of bilirubin derivatives with a high affinity for calcium carbonate
    • multiple tiny faceted/spiculated homogeneously radiopaque stones
    • CT:
      • usually denser than bile
  • GAS-CONTAINING GALLSTONE
    Mechanism: dehydration of older stones leads to internal shrinkage + dendritic cracks + subsequent nitrogen gas–filling from negative internal pressure
    • “crow-foot” = “Mercedes-Benz” sign = radiating streaklike lucencies within stone, also responsible for buoyancy
  • FLOATING GALLSTONE (20–25%)
    • relatively pure cholesterol stones
    • P.705

    • gas-containing stones
    • rise in specific gravity of bile (1.03) from oral cholecystopaques (specific gravity of 1.06) causing stones (specific gravity of 1.05) to float
  • GALLBLADDER SLUDGE
    • = calcium-bilirubinate granules + cholesterol crystals associated with biliary stasis
    Cause: prolonged fasting, parenteral nutrition, hyperalimentation, hemolysis, extrahepatic bile duct obstruction, cystic duct obstruction, acute + chronic cholecystitis
    • nonshadowing homogeneously echogenic material:
      • fluid-sludge level
    • “sludge ball” = tumefactive sludge:
      • slowly shifting with repositioning of patient
    DDx: gallbladder cancer
    Prognosis: may cause acute cholecystitis
    DDx: hemobilia with blood clot, parasitic infestation, mucus
Radiopacity:
  • lucent stones (84%):
    • cholesterol (85%), pigment (15%)
  • calcified stones (15–20% on plain film, 60% on CT):
    • cholesterol (33%), pigment (67%)
  • Location of calcium:
    • calcium phosphate deposited centrally within cholesterol stones
    • calcium carbonate deposited radially within aging cholesterol/peripherally around cholesterol + pigmented stones
Gallstones in Fetus
EGA: >28 weeks EGA
Cause: hemolytic disease, cholestasis, maternal drug use
Prognosis: usually resolve before/after delivery
Gallstones in Neonate
  • Rare without predisposing factors
Associated with: obstructive congenital biliary anomaly, total parenteral nutrition, furosemide, GI dysfunction (short-gut syndrome), prolonged fasting, phototherapy, dehydration, infection, hemolytic anemia
Gallstones in Older Children
Associated with: sickle cell disease, cystic fibrosis, malabsorption, total parenteral nutrition, Crohn disease, intestinal resection, hemolytic anemia, choledochal cyst
Cholecystolithiasis
  • • asymptomatic (60–65%); become symptomatic at a rate of 2% per year
  • biliary colic (misnomer) due to transient obstruction of cystic duct/common bile duct develops in 33% (18% overall risk in 20 years):
    • = acute RUQ/epigastric/LUQ/precordial/lower abdominal pain increasing over seconds/minutes + remaining fairly steady for 1–3(–6) hours associated with nausea + vomiting
    • • no tenderness upon palpation
  • Abdominal plain film (10–16% sensitive):
    • calcified gallstones
  • OCG (65–90% sensitive):
    • filling defect in contrasted gallbladder lumen:
      • allows determination of size + number of gallstones
      • demonstrates cystic duct patency
      • shows contractility after a fatty meal
    • nonvisualization of gallbladder (25%) = inconclusive
  • CT (80% sensitive):
    • hyperdense calcified gallstones in 60%
    • hypodense cholesterol stones ≤140 HU = pure cholesterol stone (= ≥80% cholesterol content):
      • Inverse relationship between CT attenuation number + cholesterol content
    • gallstones isointense to bile in 21–24% and thus undetectable by CT (<30 HU)
  • US (91–98% sensitive; in 5% falsely negative):
    • bright (= highly reflective) echo from anterior surface of gallstone within gallbladder:
      • marked posterior acoustic shadowing
      • mobile upon repositioning of patient (may infrequently be adherent to wall)
      • reverberation artifact
      • Small calcifications <2 mm may not shadow
    • nonvisualization of GB + collection of echogenic echoes with acoustic shadowing (15–25%):
      • “wall-echo-shadow” = “double-arc shadow” sign = 2 echogenic curvilinear parallel lines separated by sonolucent line (ie, anterior GB wall + bile + stone with acoustic shadowing)
    • focal nonshadowing opacities <5 mm in diameter (in 70% gallstones)
    • False-negative US (5%):
      • contracted GB, GB in anomalous/unusual location, small gallstone, gallstone impacted in GB neck/cystic duct, immobile patient, obese patient, extensive RUQ bowel gas
Prognosis: stones <3 mm may pass through cystic duct
Cx: acute cholecystitis (in 30%), choledocholithiasis, cholangitis, pancreatitis, duodenitis, biliary fistula, gallstone ileus, Mirizzi syndrome; cancer of GB + bile ducts (2–3 × more frequent)
Cholangiolithiasis
Choledocholithiasis
  • Most common cause of bile duct obstruction!
Etiology: (a) passed stones originating in GB
(b) primary development in intra-/extrahepatic ducts
Incidence: in 12–15% of cholecystectomy patients; in 3–4% of postcholecystectomy patients; in 75% of patients with chronic bile duct obstruction
  • Risk indicators for CBD stone:
    • recent history of jaundice
    • recent history of pancreatitis
    • elevated serum bilirubin >17 μmol/L
    • P.706

    • elevated serum amylase >120 IU/L
    • dilated CBD >6 mm (16%)
    • obscured bile duct
  • • asymptomatic: 10% of patients treated with cholecystectomy have unsuspected CBD calculi
  • • recurrent episodes of right upper quadrant pain, jaundice, chills, fever (25–50%)
  • • elevated serum bilirubin + alkaline phosphate levels
  • • elevated transaminase (75%)
  • • spontaneous passage with stones <6 mm size
  • Cholangiography (most specific technique):
    • stone visualization in 92%
    • dependent round filling defects
    DDx: air bubbles, neoplasm, concentrated bile
    • Peroperative cholangiography:
      • prolongs operation by 30 minutes;
      • 4% false-negatives; 4–10% false-positives
  • US (22–82% sensitive):
    • stone visualization in 13–75% (more readily with CBD dilatation + good visibility of pancreatic head)
    • dilated ducts in 64–77%/duct <8 mm in diameter in 24–36%
    • increased dilatation of CBD with administration of fatty meal/cholecystokinin
    • no stone in gallbladder (1.2–11%)
  • CT (88% sensitive, 97% specific, 94% accurate):
    • stone visualization in 75–88% (isoattenuating to bile in 12–25%)
    • target sign = intraluminal mass with crescentic ring (= stone of soft-tissue density) in 85%
    • subtle alternating low- and high-attenuation rings (= mixed cholesterol-calcium stones)
  • MRCP (81–100% sensitive, 85–100% specific):
    • dark filling defect within hyperintense fluid (stone must be >2 mm in diameter) (DDx: tumor, edematous papilla of Vater
    • signal void on moderately T2WI (TE of 100 msec) BUT tumors have intermediate signal intensity
    • no enhancement of calculus
    • obscured/missed calculi:
      • visible signal intensity on T1WI due to sufficient water content
      • isointensity relative to bile
  • NUC:
    • delayed bowel activity beyond 2 hours
    • persistent hepatic + common bile duct activity to 24 hours
    • prominent ductal activity beyond 90 minutes with visualization of secondary ducts
Stone in Cystic Duct Remnant
  • retained in 0.4% after surgery for choledocholithiasis
Chronic Granulomatous Disease Of Childhood
  • = recessive X-linked (60%)/autosomal (40%) immunodeficiency disorder resulting in purulent infections + granuloma formation primarily involving lymph nodes, skin, lungs
Etiology: polymorphonuclear leukocyte dysfunction characterized by inability to generate hydrogen peroxide causing prolonged intracellular survival of phagocytized catalase-positive bacteria with dissemination in reticuloendothelial system
Organism: most commonly staphylococcus, Serratia marcescens, Nocardia species, mycobacteria, fungi
Path: chronic infection with granuloma formation/caseation/suppuration
Age: onset in childhood; M > F (more severe in boys)
  • • recurrent chronic infections
  • • nitroblue tetrazolium test: low percentage of WBCs that reduce the dye after stimulation by phagocytosis/contact with endotoxin (normally >90%)
  • @ Bone
    • osteomyelitis (commonly of spine, ribs, metatarsals)
  • @ Chest
    • chronic pneumonia
    • hilar lymphadenopathy
    • pleural + pericardial effusions
  • @ Liver
    • hepatosplenomegaly
    • hepatic abscess (most common abdominal process)
    • liver calcifications
  • @ GI tract
    • • chronic diarrhea with malabsorption
    • • vomiting, anorexia, heartburn, weight loss
    • esophageal dysmotility, esophagitis, stricture
    • gastric antral narrowing ± gastric outlet obstruction
    • perianal fistula + abscess
  • @ GU tract
    • • dysuria
    • cystitis
    • obstruction of urethra + ureters
  • @ Lymph nodes
    • suppurative lymphadenitis
  • @ Skin
    • pyoderma
Rx: prophylactic long-term trimethoprim-sulfamethoxazole + interferon gamma therapy
Cirrhosis
  • = chronic liver disease characterized by diffuse parenchymal necrosis, regeneration and scarring with abnormal reconstruction of preexisting lobular architecture
  • Etiology:
    • TOXIC
      • Alcoholic liver disease in 75%
      • Drug-induced (prolonged methotrexate, oxyphenisatin, alpha-methyldopa, nitrofurantoin, isoniazid)
      • Iron overload (hemochromatosis, hemosiderosis)
    • INFLAMMATION
      • Viral hepatitis B/C
      • Schistosomiasis
    • BILIARY OBSTRUCTION
      • Cystic fibrosis
      • Inflammatory bowel disease
      • Primary biliary cirrhosis
      • obstructive infantile cholangiopathy
    • VASCULAR
      P.707

      • Prolonged CHF = cardiac cirrhosis
      • hepatic venoocclusive disease (Budd-Chiari syndrome)
    • NUTRITIONAL
      • Intestinal bypass
      • Severe steatosis
      • Abetalipoproteinemia
    • HEREDITARY
      • Wilson disease
      • Alpha-1 antitrypsin deficiency
      • Juvenile polycystic kidney disease
      • Galactosemia
      • Type IV glycogen storage disease
      • hereditary fructose intolerance
      • Tyrosinemia
      • hereditary tetany
      • Osler-Weber-Rendu syndrome
      • Familial cirrhosis
    • IDIOPATHIC/CRYPTOGENIC (15%)
    • Cirrhosis in children:
      • chronic hepatitis, congenital hepatic fibrosis, cystic fibrosis, biliary atresia, alpha-1 antitrypsin deficiency, tyrosinemia, galactosemia, hemochromatosis, Wilson disease, schistosomiasis, total parenteral nutrition
  • Morphology:
    • micronodular cirrhosis (<3 mm): usually due to alcoholism, biliary obstruction, hemochromatosis, venous outflow obstruction, previous small-bowel bypass surgery, Indian childhood fibrosis
    • macronodular cirrhosis (3–15 mm, up to several cm): usually due to chronic viral hepatitis, Wilson disease, alpha-1 antitrypsin deficiency
    • mixed cirrhosis
  • Nodular lesions:
    • regenerative nodule = localized proliferation of hepatocytes + supporting stroma
    • dysplastic nodule
      • = cluster of hepatocytes >1 mm in diameter with evidence of dysplasia; common in hepatitis B and C, alpha-1 antitrypsin deficiency, tyrosinemia
      • — low grade (macroregenerative nodule, type I/ordinary adenomatous hyperplasia)
      • — high grade (macroregenerative nodule type II/adenomatous hyperplasia with atypia)
      • — dysplastic nodule with subfocus of HCC (adenomatous hyperplasia with microscopic HCC)
    • hepatocellular carcinoma (adenomatous hyperplasia with macroscopic HCC)
Associated with: anemia, coagulopathy, hypoalbuminemia, cholelithiasis, pancreatitis, peptic ulcer disease, diarrhea, hypogonadism
  • • anorexia, weakness, fatigue, weight loss
  • • jaundice, continuous low-grade fever
  • • ascites, bleeding from esophageal varices, hepatic encephalopathy
  • enlarged (early stage)/normal/shrunken liver
  • shrinkage of right lobe (segments 5–8) and medial segment of left lobe (segments 4a + 4b) with concomitant hypertrophy of lateral segment of left lobe (segments 2 + 3) and caudate lobe (segment 1):
    • ratio of width of caudate to right lobe >0.65 on transverse images [sensitivity 43–84%, least sensitive in alcoholic cirrhosis, most sensitive in cirrhosis caused by hepatitis B; specificity 100%; 26% sensitivity; 84–96% accuracy] (DDx: Budd-Chiari syndrome)
    • diameter of quadrate lobe (segment 4) <30 mm (= distance between left wall of gallbladder and ascending portion of left portal vein) due to selective atrophy (95% specific)
  • widened porta hepatis + interlobar fissure
  • surface nodularity + indentations (regenerating nodules)
  • signs of portal hypertension
  • splenomegaly
  • ascites (failure of albumin synthesis, overproduction of lymph due to increased hydrostatic pressure in sinusoids/decreased splanchnic output due to portal hypertension)
  • associated with fatty infiltration (in early cirrhosis)
  • US (sensitivity 65–80%; DDx: chronic hepatitis, fatty infiltration):
    • Hepatic signs:
      • surface nodularity (54% sensitive, 95% specific)
      • caudate lobe hypertrophy (41% sensitive, 91% specific)
      • “portalization” of hepatic vein waveform = dampened oscillations of hepatic veins resembling portal vein flow (57% sensitive, 76% specific)
      • hepatomegaly (in 63%)
      • increased hepatic parenchymal echogenicity in 66% (as a sign of superimposed fatty infiltration):
        • increased sound attenuation (9%)
        • decreased/normal definition of walls of portal venules (sign of associated fatty infiltration NOT of fibrosis)
      • heterogeneous coarse (usually)/fine echotexture (in 7%)
      • occasional depiction of isoechoic regenerative nodules
      • dilatation of hepatic arteries (increased arterial flow) with demonstration of intrahepatic arterial branches (DDx: dilated biliary radicals)
      • increase in hepatic artery resistance (mean RI of 0.58–0.66 in normals to 0.63–0.85 in cirrhotics):
        • blunted increase in RI after meal ingestion (from 42% in normals to 7% in cirrhotics)
    • Extrahepatic signs:
      • splenomegaly
      • ascites
      • signs of portal hypertension
  • CT:
    • native + enhanced parenchymal inhomogeneity
    • decreased attenuation (steatosis) in early cirrhosis
    • isodense/hyperdense (siderotic) regenerative nodules
    • nodular/lobulated liver contour
    • predominantly portal venous supply to dysplastic nodules
    • hypodense area adjacent to portal vein (= peribiliary cysts from obstructed extramural peribiliary glands)
    • rapid tapering of intrahepatic portal + hepatic venous branches
  • CECT:
    • enlarged tortuous hepatic artery (compensatory increase in arterial blood flow)
    • arterioportal shunts (through trans-sinusoidal shunts in liver periphery + transplexal shunts with hypertrophy of peribiliary plexus) in hepatic arterial phase:
    • P.708

    • poorly demarcated transient peripheral wedge-shaped hepatic parenchymal enhancement
      DDx: hepatocellular carcinoma (defect on portal venous phase)
    • early retrograde enhancement of portal vein branches
    • hepatofugal flow
      Cause: with occlusion of small hepatic venules the portal vein turns from a supplying vein into a draining vein
  • MR (problem-solving tool):
    • no alteration of liver parenchyma
    • regenerative nodules ((due to iron deposits within nodules):
      • hypo-/isointense relative to liver on T1WI
      • hypointense on T2WI
      • no enhancement
    • dysplastic nodule = iso-/hyperintense on T1WI + iso-/hypointense on T2WI
    • HCC nodule = hypo-/iso-/hyperintense on T1WI + usually hyperintense on T2WI with marked enhancement during arterial phase
    • generalized decreased hepatic signal intensity on T2WI (mild iron deposition for unknown reasons)
  • Angio:
    • stretched hepatic artery branches (early finding)
    • enlarged tortuous hepatic arteries = “corkscrewing” (increase in hepatic arterial flow)
    • shunting between hepatic artery and portal vein
    • mottled parenchymal phase
    • delayed emptying into venous phase
    • pruning of hepatic vein branches (normally depiction of 5th order branches) = postsinusoidal compression by developing nodules
  • NUC (Tc-99m–labeled sulfur colloid):
    • high blood pool activity secondary to slow clearance
    • colloid shift to bone marrow + spleen + lung
    • shrunken liver with little or no activity + splenomegaly
    • mottled hepatic uptake (pseudotumors) on colloid scan (normal activity on IDA scans!)
    • displacement of liver + spleen from abdominal wall by ascites
Cx: (1) Ascites: cause/contributor to death in 50%
(2) Portal hypertension
(3) Hepatocellular carcinoma (in 7–12%)
(4) Cholangiocarcinoma
Fatality from:
  • esophageal variceal bleeding (in 25%), hepatorenal syndrome (10%), spontaneous bacterial peritonitis (5–10%), complications from treatment of ascites (10%)
Primary Biliary Cirrhosis
  • = CHRONIC NONSUPPURATIVE DESTRUCTIVE CHOLANGITIS
Histo: idiopathic progressive destructive cholangitis of interlobar and septal bile ducts, portal fibrosis, nodular regeneration, shrinkage of hepatic parenchyma
Age: 35–55 years; M:F = 1:9
Associated autoimmune disorders:
  • rheumatoid arthritis, Hashimoto thyroiditis, Sjögren syndrome, scleroderma, sarcoidosis
  • 66–100% of patients with primary biliary cirrhosis have sicca-complex signs of the Sjögren syndrome
  • • fatigue, pruritus
  • • xanthelasma/xanthoma (25%)
  • • hyperpigmentation (50%)
  • • insidious onset of pruritus (60%)
  • • IgM increased (95%)
  • • positive antimitochondrial antibodies (AMA) in 85–100%
  • normal extrahepatic ducts
  • cholelithiasis in 35–39%
CT:
  • scattered dilated intrahepatic ducts with no apparent connection to main bile ducts
  • caudate lobe hypertrophy (in 98%):
    • hypertrophied hyperattenuating caudate lobe surrounded by hypoattenuating rindlike right lobe (pseudotumor)
  • atrophy of lateral segment of left hepatic lobe
  • intrahepatic biliary calculi (20%)
NUC:
  • marked prolongation of hepatic Tc-99m IDA clearance
  • uniform hepatic isotope retention
  • normal visualization of GB and major bile ducts in 100%
DDx: (1) Sclerosing cholangitis (young men)
(2) CBD obstruction
Prognosis: mean survival 6 (range 3–11) years after onset of cholestatic symptoms
Complications of End-Stage Liver Disease
Hepatopulmonary Syndrome
Dx: (1) chronic liver disease
(2) increased alveolar-arterial gradient
(3) intrapulmonary vascular dilatation
  • • hypoxemia (in 1/3 of decompensated cirrhotic patients)
  • Pathomechanism:
    • elevation of unknown vasoactive substances in cirrhotic patient cause pulmonary vascular dilatation (from 8–15 μm to 15–500 μm) + result in diffusion-perfusion mismatch
  • basilar nodular/reticulonodular areas of increased opacity (in 46–100%)
  • dilated arterioles with an increased number of terminal branches extending to pleura
  • intrapulmonary arteriovenous shunt (demonstrated with Tc-99m macroaggregated albumin imaging, microbubble echocardiography)
Hepatic Hydrothorax
  • = large pleural effusion in cirrhotic patient without primary pulmonary/cardiac disease
Prevalence: 10%
Mechanism: pressure gradient favors fluid movement from peritoneal to pleural cavity through small diaphragmatic defects
  • pleural fluid: right in 67%, left in 17%, bilateral in 17%
Pulmonary Hypertension
Prevalence: 0.73% in patients with liver cirrhosis (versus 0.13% in all patients)
P.709

  • Cause:
    • thromboembolic: portal venous thrombus reaches lung through spontaneous/surgically created portosystemic shunts
    • plexogenic: vasoactive substances (serotonin, thromboxane, neuropeptide Y, elastase) bypass the liver through portosystemic shunts
Prognosis: mean survival of 15 months
Clonorchiasis
  • Rarely of clinical significance
Country: endemic to Southeast Asia: Japan, Korea, Central + South China, Taiwan, Indochina
Organism: Chinese liver fluke = Clonorchis sinensis
Cycle: parasite cysts digested by gastric juice, larvae migrate up the bile ducts, remain in small intrahepatic ducts until maturity (10–30 mm in length), travel to larger ducts to deposit eggs
Infection: snail + freshwater fish serve as intermediate hosts; infection occurs by eating raw fish; hog, dog, cat, man are definite hosts
Path: (a) desquamation of epithelial bile duct lining with adenomatous proliferation of ducts + thickening of duct walls (inflammation, necrosis, fibrosis)
(b) bacterial superinfection with formation of liver abscess
  • • remittent incomplete obstruction + bacterial superinfection
  • multiple crescent-/stiletto-shaped filling defects within bile ducts:
    • echogenic focus/cast on US
  • diffusely thickened bile ducts
Cx: (1) Bile duct obstruction (conglomerate of worms/adenomatous proliferation)
(2) Calculus formation (stasis/dead worms/epithelial debris)
(3) Jaundice in 8% (stone/stricture/tumor)
(4) Generalized dilatation of bile ducts (2%)
Congenital Biliary Atresia
Etiology: ? variation of same infectious process as in neonatal hepatitis with additional component of sclerosing cholangitis or vascular injury
Prevalence: <10 in 100,000 live births
Age: neonate; M:F = 2:1
Histo: periportal fibrosis, proliferation of small intrahepatic bile ducts, mixed inflammatory infiltrates
In 15% associated with: polysplenia, trisomy 18
Types:
I Focal = intrauterine vascular insult (extremely rare)
II Intrahepatic biliary atresia = paucity of intrahepatic bile ducts (uncommon)
III Extrahepatic biliary atresia = atresia of CBD + patent intrahepatic bile ducts
  • Subtype 1 = perinatal type (66%)
    • • jaundice develops after regression of physiologic jaundice
    • bile duct remnant in porta hepatis
  • Subtype 2 = embryonic/fetal type (34%)
    • • normal decline in bilirubin does not occur
    • NO bile duct remnant in porta hepatis
  • Associated with: polysplenia (10–12%), intestinal malrotation, azygos continuation of IVC, symmetric bilobed liver, situs inversus, preduodenal portal vein, anomalous hepatic arteries, bilobed right lung, complex CHD
image
Biliary Atresia
US:
  • normal/increased size of liver
  • normal/increased liver echogenicity
  • decreased visualization of peripheral portal veins (due to fibrosis)
  • “triangular cord”/tubular echogenic structure in porta hepatis (due to fibrous tissue) = PATHOGNOMONIC
  • gallbladder findings:
    • nonvisualization of gallbladder
    • small gallbladder <1.5 cm in length + varying degrees of luminal compromise (DDx: hepatitis)
    • normal gallbladder >1.5 cm in length (19%) when atresia of CBD distal to insertion of cystic duct
  • bile duct findings:
    • no dilatation of intrahepatic bile ducts (due to panductal sclerosis)
    • ± visualization of bile duct remnant in porta hepatis (depending on type of biliary atresia)
    • small focal cystic dilatation of extrahepatic bile duct (= choledochal cyst) = patent segment of CBD with other parts being occluded due to fibrosis ± communication with gallbladder/intrahepatic bile ducts
NUC [phenobarbital-augmented cholescintigraphy] (90–97% sensitive, 60–94% specific, 75–90% accurate):
  • ⇒ preparation of patient with 5 ng/kg/d phenobarbital twice a day for 3–7 days to stimulate biliary secretion (via induction of hepatic enzymes + increase in conjugation + excretion of bilirubin)
  • good hepatic activity within 5 min (infants of <3 months of age have a normal hepatic extraction fraction)
  • NO biliary excretion:
    • NO visualization of bowel on delayed images at 6 and 24 hours
  • delayed clearance from cardiac blood pool
  • increased renal excretion + bladder activity
DDx: severe hepatocellular dysfunction (DDx from neonatal hepatitis impossible in the absence of small bowel activity) requires liver biopsy
P.710

MR cholangiography:
  • nonvisualization of extrahepatic bile ducts
  • atrophic gallbladder
  • periportal thickening
Cholangiography (percutaneous/endoscopic/intraoperative) Liver Bx (60–97% accurate)
Rx:
  1. Roux-en-Y choledochojejunostomy (20%);
  2. Kasai procedure = portoenterostomy (80%)
    1. child <60 days of age: 91% success rate
    2. child between 60 and 90 days of age: 50% success rate (due to developing cirrhosis)
    3. child >90 days of age: 17% success rate
  3. Liver transplant
DDx:
  • Neonatal hepatitis
  • Sclerosing cholangitis
  • Alagille syndrome = arteriohepatic dysplasia (abnormal facies, butterfly vertebra, pulmonic stenosis, complex CHD)
Congenital Hepatic Fibrosis
= congenital cirrhosis with rapid + fatal progression
Histo: fibrous tissue within hepatic parenchyma with excess numbers of distorted terminal interlobular bile ducts + cysts that rarely communicate with bile ducts
Age: early childhood–6th decade; majority diagnosed in adolescence/early adulthood
Associated with:
  • autosomal recessive polycystic kidney disease (invariably), Meckel-Gruber syndrome, vaginal atresia, tuberous sclerosis, nephronophthisis, medullary sponge kidney (80%), autosomal dominant polycystic kidney disease (rare)
  • • liver function tests normal/mildly elevated
  • • portal hypertension
  • • predisposed to cholangitis + calculi
  • “lollipop-tree” = ectasia of peripheral biliary radicles
  • atrophy of right lobe + normal/enlarged medial segment of left lobe + hypertrophy of left lateral segment and caudate lobe
  • splenomegaly
  • portosystemic varices
  • enlarged hepatic artery associated with large multiacinar regenerative nodules
Cx: cirrhosis, portal hypertension, hepatocellular carcinoma, cholangiocellular carcinoma
Echinococcal Disease Of Liver
Echinococcus Granulosus
  • = HYDATID DISEASE = unilocular form
  • = E. cysticus (more common); man is accidental host
    • pastoral (European) form: dog is definite host; intermediate hosts are cattle, sheep, horses, hogs; endemic in sheep-raising countries: Australia, New Zealand, North + East Africa, USSR, Mediterranean countries, Near + Middle East, Japan, Argentina, Chile, Uruguay
    • sylvatic (northern) form: wolf is definite host; intermediate hosts are deer, moose; endemic in northwestern Canada, Alaska
Cycle: ingestion of contaminated material (eggs passed in feces of dog/other carnivore); eggs hatch in duodenum; larvae penetrate intestinal wall + mesenteric venules; larvae carried into portal circulation; larvae are filtered in capillaries of liver (first line of defense) > lung > other organs
Histo:
  • CYST FLUID = antigenic clear/pale yellow fluid with neutral ph containing sodium chloride, proteins, glucose, ions, lipids, polysaccharides
  • ENDOCYST (parasitic component of capsule) = inner GERMINATIVE LAYER (resembling wet tissue paper) giving rise to brood capsules (daughter vesicles), which may
    • remain attached to cyst wall harboring up to 400,000 scolices
    • detach + form sediment in cyst fluid = “hydatid sand”
    • break up into numerous self-contained daughter cysts
  • ECTOCYST = CYST MEMBRANE = acellular laminated chitinlike substance secreted by parasite, allowing passage of nutrients
  • PERICYST = dense fibrous protective zone of host granulation tissue replacing tissue necrosis (from compression by the expanding cyst); marginal vascular rim of 0.5–4 mm
  • pain/asymptomatic
  • recurrent jaundice + biliary colic (transient obstruction by membrane fragments + daughter cysts expelled into biliary tree)
  • blood eosinophilia (20–50%)
  • urticaria + anaphylaxis (following rupture)
  • Tests:
    • Casoni intradermal test (60% sensitivity; may be falsely positive)
    • Complement fixation double diffusion (65% sensitivity)
    • Immunoelectrophoresis (most specific)
    • Indirect hemagglutination (85% sensitivity)
image
Parasitic Cycle Of Echinococcus Granulosus
Time to diagnosis: 11–81 (mean 51) years
Affected organs:
  • liver (73%); lung (14%); peritoneum (12%); kidney (3–6%); spleen (0.9–8%); CNS (1%); orbit (1%); bone (0.5–4%); bladder; thyroid; prostate; heart
P.711

Location: right lobe > left lobe of liver; multiple cysts in 20%
Size: up to 50 cm (average size of 5 cm), up to 16 liters of fluid; grows 2–3 cm annually
Stages of cyst growth:
  • Unilocular cyst
  • Cyst with daughter vesicles/daughter cysts
  • Partially/completely calcified
Plain film:
  • peripheral crescentic/curvilinear/polycyclic calcifications (10–20–33%), located in pericyst:
    • Only complete calcification of all layers implies death of parasite!
  • pneumohydrocyst (infection/communication with bronchial tree)
US:
  • complex heterogeneous mass mimicking a solid mass (most common):
    • Look for membranes/peripheral daughter vesicles
  • well-defined anechoic cyst (common):
    • cyst wall of double echogenic lines separated by hypoechoic layer
    • “snowstorm sign” = multiple internal echogenic foci settling to most dependent portion of cyst (= hydatid sand)
  • multivesicular cyst of “racemose”/honeycomb appearance = multiple septa between daughter cysts inside mother cyst, CHARACTERISTIC but rare:
    • “wheel spoke” pattern = daughter cysts separated by echogenic material of hydatid matrix composed of broken daughter vesicles + scolices + hydatid sand
    • HIGHLY SPECIFIC serpentine linear structures within hydatid matrix
  • partial/complete detachment of endocyst from pericyst (due to decreasing intracystic pressure as a sign of degeneration/trauma/host response/response to therapy):
    • localized split in wall with floating undulating membrane, CHARACTERISTIC but rare
    • “water lily sign” = complete detachment of membrane
    • Floating membrane does not indicate death of parasite!
  • eggshell calcification in cyst wall (least common)
CT:
  • well-demarcated round low-density mass of fluid attenuation (3–30 HU):
    • cyst wall of high attenuation on NECT
    • linear areas of increased attenuation = detached laminated membrane
    • round peripheral fluid collection of lower attenuation (= daughter cysts)
  • enhancement of cyst wall + septations
  • calcification of cyst wall/internal septa
MR:
  • cyst with hypointense rim (= collagenous pericyst) on T1WI + T2WI
  • peripheral cysts within cyst hypointense on T1WI + hyperintense on T2WI (= daughter cysts)
  • twisted linear structures within cyst = collapsed parasitic membrane
Angio:
  • avascular area with splaying of arteries
  • halo of increased density around cyst (inflammation/compressed liver)
Cholangiography:
  • cyst may communicate with bile ducts: right hepatic duct (55%), left hepatic duct (29%), CHD (9%), gallbladder (6%), CBD (1%)
Percutaneous aspiration:
  • • fluid analysis positive for hydatid disease in 70% (fragments of laminated membrane in 54%; scolices in 15%; hooklets in 15%)
  • Risk of anaphylactic shock (0.5%), asthma (3%), implantation of spilled protoscoleces
Local Cx:
  • Rupture (50–90%)
    • contained = rupture of laminated membrane of endocyst, pericyst remains intact
      • floating membranes
    • communicating = cyst contents escapes through biliary (5–15%)/bronchial tree
    • direct = tear of endocyst + ectocyst + pericyst with cyst contents spilling into pleural/peritoneal cavity (anaphylaxis, metastatic hydatidosis)
  • Infection (5–8%) following rupture
  • Transdiaphragmatic growth (0.6–16%) through bare area of liver
    • rupture into pleural cavity
    • seeding in pulmonary parenchyma
    • chronic bronchial fistula
  • Perforation into hollow viscus (0.5%)
  • Peritoneal seeding (13%) = encysted peritoneal hydatidosis
  • Compression of vital structures (bile ducts, portal vein)
Rx: (1) Surgery (in 10% recurrence)
(2) Anthelmintics (albendazole, medendazole)
(3) Injection of scolecidal agents (silver nitrate, 20/30% hypertonic saline solution,0.5% cetrimide solution, 95% ethanol)
Echinococcus Multilocularis
  • = E. alveolaris = less common but more aggressive form of echinococcal disease
Primary host: fox, wolf
Secondary host: rodents (moles, lemmings, wild mice); domestic cat; dog
Endemic to: eastern France, southern Germany, western Austria, much of Soviet Union, Japan, Alaska, Canada, some areas in Turkey
Infection: eating wild fruits contaminated with fox/wolf feces; direct contact with fox/wolf; contact with dogs/cats that have ingested infested rodents
Path: larvae proliferate by exogenous extension + penetration of surrounding tissue (= diffuse + infiltrative process resembling malignancy); chronic granulomatous reaction with central necrosis, cavitation, calcification
Histo: daughter cysts with thick lamellar wall arising on outer surface of original cyst, rarely containing scolices
Location: liver (access via portal vein); widespread hematogenous dissemination not uncommon
P.712

  • • clinical manifestation 5–20 years after ingestion
  • • abdominal discomfort, jaundice, hepatomegaly
  • • eosinophilia
  • aggressive growth pattern:
    • geographic infiltrating lesion with ill-defined margins
    • invasion of IVC, diaphragm
  • metastases to lung, heart, brain (in 10%)
  • faint/dense amorphous coalescent nodular/flame-shaped calcifications (dystrophic central calcifications scattered throughout necrotic + granulomatous tissue)
US:
  • echogenic geographic ill-defined single/multiple solid masses
  • ± irregular cystic areas
  • propensity of spread to liver hilum
CT:
  • heterogeneous hypodense poorly marginated infiltrating masses
  • pseudocystic necrotic regions of near water density surrounded by hyperdense solid component
  • little/no enhancement
Angio:
  • intrahepatic arterial tapering + obstruction
Cx: Budd-Chiari syndrome, IVC thrombosis, portal hypertension
Prognosis: fatal within 10–15 years (if left untreated)
DDx: hepatocellular carcinoma (biopsy!), large hemangioma (characteristic enhancement pattern), metastasis, epithelial hemangioendothelioma
Embryonal Rhabdomyosarcoma Of Biliary Tree
rare tumor most commonly arising from CBD
Median age: 3 years; M > F
Path: intraluminal biliary mass/cluster of grapelike masses (similar to rhabdomyosarcoma of bladder)
Histo: same as sarcoma botryoides
  • • malaise, fever, jaundice
  • • elevation of conjugated bilirubin
  • Metastases (in up to 30%) to:
    • retroperitoneal +mesenteric lymph nodes, lung
    Location: common bile duct (most frequently)
  • 8–20-cm bulky heterogeneous mass in porta hepatis
  • intrahepatic bile duct dilatation
  • displacement of duodenum, stomach, pancreas
  • Cholangiography:
    • large bulky intraluminal mass/grapelike cluster of intraluminal masses focally distending common bile duct + obstructing proximal bile ducts
Epidermoid Cyst Of Spleen
EPITHELIAL CYST = PRIMARY CYST OF SPLEEN
Incidence: 10% of all benign nonparasitic cysts
Cause: infolding of peritoneal mesothelium/collection of peritoneal mesothelial cells trapped within splenic sulci
Histo: (1) mesothelial lining
(2) squamous epithelial lining = epidermoid cyst = squamous metaplasia from embryonic inclusions within preexisting mesothelial surface epithelium
Age: 2nd–3rd decade (average age of 18 years)
May be associated with: polycystic kidney disease
  • unilocular + solitary (80%)
  • multiple + multilocular (20%)
  • well-defined thin-walled anechoic lesion of water density
  • average size of 10 cm
  • peripheral septations/cyst wall trabeculations (in 86%)
  • curvilinear calcification in wall (9–25%)
  • may contain cholesterol crystals, fat, blood
Cx: trauma, rupture, infection
Eosinophilic Cholangiopathy
rare benign cause of biliary obstruction
Incidence: 15 cases in literature
Cause: unknown
Histo: transmural eosinophilic infiltration of biliary tract
  • Eosinophilic cholecystitis
  • Eosinophilic cholangitis
  • both
May be associated with: multiple organ involvement (in 50%) of GI tract, urinary tract, bone marrow, pancreas, lymph nodes
  • • jaundice
  • • ± peripheral eosinophilia
  • thickened bile duct wall ± biliary dilatation
  • wall irregularities in beaded pattern
Rx: steroids
DDx: lymphoma, AIDS cholangiopathy, collagen vascular disease, cholangiocarcinoma, amyloidosis
Epithelioid Hemangioendothelioma
rare primary malignant vascular tumor of liver (soft tissue, bone, lung)
Age: average age of 45 years; M:F = 1:2
May be associated with: oral contraceptives, exposure to vinyl chloride
Path: multifocal nodules varying in size from a few mm to several cm involve both lobes of the liver (due to rapid perivascular extension); nodules may coalesce in liver periphery
Histo: dendritic spindle-shaped cells + epithelioid round cells in a matrix of myxoid + fibrous stroma; neoplastic endothelial cells invade sinusoids + terminal hepatic + portal veins cutting off the tumor’s blood supply
  • in 80%: abdominal pain, weakness, anorexia, jaundice
Metastases to: spleen, mesentery, lymph nodes, lung, bone
  • multiple nodules (nodular form)
  • peripheral subcapsular growth (diffuse form) without deforming liver contour
  • increased tumor vascularity
  • hypertrophy of uninvolved liver
Plain film:
  • hepatic calcifications within myxoid stroma (15%)
US:
  • typically hypoechoic lesions (due to central core of myxoid stroma)
P.713

CT:
  • low-attenuation masses on NECT, may become isoattenuating with rest of liver on CECT (due to vasoformative growth + compensatory hepatic arterial flow with portal vein occlusion)
Angio:
  • hyper- and hypovascularity (dependent upon degree of sclerosis + hyalinization)
  • invasion ± occlusion of portal + hepatic veins
NUC:
  • decreased perfusion to central myxoid tumor portion + increased perfusion to cellular areas on sulfur colloid scan
  • photopenic defect on static sulfur colloid scan
  • NOT gallium avid
Prognosis: 20% die within 2 years, 20% survive for 5–28 years ± treatment
DDx of multiple nodules: metastatic disease
DDx of diffuse form: sclerosing carcinoma, vasoocclusive disease
Fatty Liver
FATTY INFILTRATION OF THE LIVER = HEPATIC STEATOSIS
Cause:
  • METABOLIC DERANGEMENT
    • poorly controlled diabetes mellitus (50%), obesity, hyperlipidemia, acute fatty liver of pregnancy, protein malnutrition, total parenteral hyperalimentation (TPN), malabsorption (jejunoileal bypass), glycogen storage disease, glycogen synthetase deficiency, cystic fibrosis, Reye syndrome, corticosteroids, severe hepatitis, trauma, chronic illness (TB, CHF)
  • HEPATOTOXINS
    • alcohol (>50%), carbon chlorides, phosphorus, amiodarone, chemotherapy
Histo: hepatocytes with large cytoplasmic fat vacuoles containing triglycerides; >5% fat of total liver weight
  • • No abnormal liver function tests
  • rapid change with time (few days to >10 months) depending on clinical improvement (abstinence from alcohol, improved nutrition) + degree of severity
Diffuse fatty infiltration
  • hepatomegaly (75–80%)/normal sized liver
  • Plain film:
    • radiolucent liver sign = enlarged radiolucent liver
  • US (sensitivity >90%, accuracy 85–97%):
    • increased sound attenuation (scattering of sound beam) = poor definition of posterior aspect of liver
    • fine (more typical)/coarsened hyperechogenicity (compared with kidney)
    • impaired visualization of borders of hepatic vessels
    • attenuation of sound beam (feature of fat, NoT fibrosis)
  • CT:
    • areas of lower attenuation than normal portal vein/IVC density
    • reversal of liver-spleen density relationship (liver density is normally 6–12 hU greater than spleen)
    • hyperdense intrahepatic vessels
  • NUC:
    • Tc-99m sulfur colloid scan:
      • diffuse heterogeneous uptake (68%)
      • reversal of liver-spleen uptake (41%)
      • increased bone marrow uptake (41%)
    • Xe-133 ventilation scan:
      • increased activity during washout phase (38%)
  • MR:
    • slightly increased signal on T1WI + T2WI; relatively insensitive (10% fat by weight will alter SE signal intensities only by 5–15%)
    • fat turns black with Dixon technique
Fat-Spared Area in diffuse fatty infiltration
Cause: direct drainage of systemic blood into liver
Location:
  • posterior edge of segment 4 = anterior to portal vein bifurcation (drainage of aberrant gastric vein)
  • next to gallbladder bed (drainage of cystic vein)
  • subcapsular skip areas
  • hypoechoic ovoid/spherical/sheetlike mass
  • No mass effect (undisplaced course of vessels)
DDx: tumor mass
Focal Fatty Infiltration
Etiology: ? vascular origin, focal tissue hypoxia
Distribution: (a) lobar/segmental uniform lesions
(b) lobar/segmental nodular lesions
(c) perihilar lesions
(d) diffuse nodular lesions
(e) diffuse patchy lesions
predominantly in centrilobar + periportal regions, subcapsular distribution may be due to variants of blood supply (due to “third inflow” from connection between peripheral portal radicles + perforating capsular/accessory cystic veins)
Location: right lobe, caudate lobe, perihilar region
  • fan-shaped lobar/segmental distribution with angulated/interdigitating geographic margins
  • lesions extend to periphery of liver
  • NO mass effect (undisplaced course of vessels, no bulging of liver contour)
  • US:
    • hyperechoic area with poorly defined/sharp margins
    • multiple/rarely single echogenic nodules simulating metastases (rare)
  • CT:
    • patchy areas of decreased attenuation ranging from–40 to +10 HU (DDx: liver tumor)
    • NO contrast enhancement
  • MR (not sensitive for fat):
    • high signal on T1WI + low/isointense signal on T2WI
  • NUC with colloid:
    • no significant changes on sulfur colloid images (SPECT imaging may detect focal fatty infiltration)
DDx: primary/secondary hepatic tumor
Focal Nodular Hyperplasia
FNH = rare benign congenital hamartomatous malformation or reparative process in areas of focal injury; SPECIFIC DIAGNOSIS RARELY POSSIBLE
P.714

Prevalence: 0.9%; 2nd most common benign tumor of liver after hemangioma; 3–8% of all primary hepatic tumors in adult population, 4% in pediatric population; twice as common as hepatocellular adenoma
Cause: (?) congenital arteriovenous malformation triggers focal hepatocellular hyperplasia owing to a regional increase in blood flow
♢ Oral contraceptives DO NOT cause FNH, but exert a trophic effect on its growth!
Path: localized, well-delineated, usually solitary (80–95%), subcapsular mass composed of numerous small nodules within an otherwise normal liver; no true capsule; frequently central fibrous scar in area of interconnection of fibrous bands (HALLMARK); angioarchitecture typically has one/more thick-walled arteries within fibrous septa dividing into numerous capillaries connected to sinusoids, which are drained by large hepatic veins (no portal veins!); FNH hepatocytes contain steatosis in 50%
Histo: composed of multiple spherical aggregates of hepatocytes often containing increased amounts of fat (in 50%) + triglycerides + glycogen; Kupffer cells line sinusoids; bile duct proliferation within fibrous septa without connection to biliary tree; thick-walled arteries within fibrous septa radiating from the center toward the periphery; absent portal triads + central veins; difficult differentiation from regenerative nodules of cirrhosis + hepatocellular adenoma
Pathologic classification:
  • Classic FNH (80%):
    • abnormal nodular architecture, malformed vessels, cholangiolar proliferation
  • Nonclassic FNH (20%) without septa/central scar:
    • globally resembling hepatic adenoma
    • no prominent septa
    • vaguely lobulated contours
    • central scar (in only 4%)
      • telangiectatic FNH (15%)
      • FNH with cytologic atypia (3%)
      • mixed hyperplastic + adenomatous FNH (2%)
    • Difficult to differentiate from other liver masses with imaging
Age peak: 3rd–4th decade (range: 7 months to 75 years);
M:F = 1:8
Associated with: hepatic hemangioma (in 23%), meningioma, astrocytoma, arterial dysplasia of other organs in case of multiple FNH
  • initially often asymptomatic (in 50–90% incidental discovery)
  • vague abdominal pain (10–15%) due to mass effect
  • normal liver function
  • hepatomegaly/abdominal mass
Location: right lobe:left lobe = 2:1; multiple in 20%
Size: <5 cm (in 85%)
  • well-circumscribed nonencapsulated nodular cirrhotic-like mass in an otherwise normal liver:
    • often near liver surface
    • pedunculated mass (in 5–20%)
    • multiple masses (in 20%)
  • central stellate scar = central fibrous core with radiating fibrous septa containing arteriovenous malformation= spoke-wheel pattern (in 50%)
  • highly vascular tumor:
    • supplied by enlarged anomalous hepatic artery
    • venous drainage always into hepatic veins(DDx: HCC drains into portal vein system in 98%)
    • hemorrhage is unlikely
  • pseudocapsule of a few mm in thickness (due to surrounding compressed hepatic parenchyma, perilesional vessels, inflammatory reaction)
  • calcifications are EXTREMELY rare
NECT:
  • iso-/slightly hypoattenuating homogeneous mass
CECT (3 phases necessary!):
  • transient intense hyperdensity of most of the lesion during arterial phase (30–60 sec after bolus injection) except for central scar
  • hypodense central scar during arterial phase (15–33%) (DDx: fibrolamellar HCC)
  • lesion becomes isodense during portal venous + equilibrium phase
  • hyperdense central scar on delayed images (delayed washout of contrast from myxomatous scar tissue)
US:
  • iso-/mildly hypo-/mildly hyperechoic (33%) homogeneous mass
  • hypoechoic halo (of compressed liver parenchyma/displaced hepatic vessels)
  • hyperechoic central scar in 18%
Doppler:
  • enlarged afferent blood vessel with central arterial hypervascularity + centrifugal filling to the periphery in a “spoke-wheel” pattern
  • large draining veins at tumor margins
  • may show high-velocity Doppler signals with arterial pulsatility from arteriovenous shunts
MR (70% sensitive, 98% specific, requires 3 phases):
  • usually homogeneous signal intensity of lesion
  • T1WI:
    • iso- to hypointense (94–100%)
    • atypically hyperintense lesion in 6%
  • T2WI: slightly hyper- to isointense (94–100%)
  • central scar (more often detected than on US/CT)
    • hypointense on T1WI
    • hyperintense on T2WI in 75–84% (due to vascular channels + edema)
    • hypointense on T2WI in 25% (absent or minimal edema)
CEMR (2-D/3-D GRE):
  • intense enhancement in arterial phase
  • isointense during portal venous phase
  • late + prolonged enhancement of central scar (due to increased interstitial space + fluid content gradually taking up contrast material)
  • occasionally prolonged enhancement (due to entrapment of Gd-DTPA by functioning hepatocytes inside tumor followed by 1% excretion into biliary tree)
  • enhancement of pseudocapsule on delayed images
  • less uptake of IV superparamagnetic iron oxide (ferucarbotran, mangafodipir trisodium) than surrounding
    P.715

    liver (uptake mechanism similar to that of sulfur colloid)
    • Use iron oxide in lesions with atypical features!
NUC:
  • Sulfur colloid scan:
    • Only FNH contains sufficient Kupffer cells to cause normal/increased uptake
    • normal uptake (33%)
    • increased uptake (33%) = virtually DIAGNOSTIC
    • cold spot (33%) due to less Kupffer cells (DDx: hepatic adenoma, hemangioma, hepatoblastoma, liver herniation, hepatocellular carcinoma)
Tc-HIDA:
  • normal/increased uptake (40–70%), cold spot (60%)
Tc-99m–tagged RBCs:
  • increased uptake during early phase
  • defect relative to liver on delayed images
Angio:
  • discretely marginated hypervascular mass (90%) with intense capillary blush/hypovascular (10%)
  • enlargement of main feeding artery with central blood supply (= “spoke-wheel” pattern in 33%)
  • homogeneous parenchymal stain
  • decreased vascularity in central stellate fibrous scar
Rx: (1) Discontinuation of oral contraceptives
(2) Resection of pedunculated mass
(3) Diagnostic excisional biopsy for extensive tumor (FNH seldom requires surgery)
Cx: rarely rupture with hemoperitoneum (increased incidence in patients on oral contraceptives — 14%)
DDx:
  • Fibrolamellar carcinoma (scar calcified, metastases, retroperitoneal adenopathy, tumor hemorrhage + necrosis causing pain, hypointense scar on T2WI)
  • Hepatic adenoma (10 cm large tumor, symptomatic due to propensity for hemorrhage in 50%, central scar atypical)
  • Well-differentiated hepatocellular carcinoma (internal necrosis + hemorrhage, vascular invasion, metastases, persistent rim-enhancement of tumor capsule)
  • Giant cavernous hemangioma (larger tumor, may calcify, globular peripheral enhancement followed by centripetal filling, retention of contrast on delayed images, central scar with CSF-like behavior on MRI)
  • Hypervascular metastasis (hypovascular during portal venous phase, older patient)
  • Intrahepatic cholangiocarcinoma (less vascular, dominant large central scar, metastases)
Telangiectatic Focal Nodular Hyperplasia
Frequency: 10% of all FNH
Age: mean age 38 years; women
Associated with: oral contraceptives (mean time, 15 years)
Mean size: 7 cm
  • multiple lesions in 20–50%
  • strong arterial enhancement
  • persistent lesion enhancement (61%) due to sinusoidal dilatation
  • absence of a central scar (92%)
  • heterogeneous pattern (43%) due to necrosis, sinusoidal dilatation, hemorrhagic foci
MR:
  • hyperintensity on T1WI (53%) due to intrasinusoidal dilatation
  • strong hyperintensity on T2WI (44%)
DDx: hepatic adenoma
Gallbladder Carcinoma
Incidence: 0.4–4.6% of biliary tract operations; most common biliary cancer (9 × more common than extrahepatic bile duct cancer); 6th most common gastrointestinal malignancy (after colon, pancreas, stomach, liver, esophagus); 3% of all intestinal neoplasms; 7,000 new cases/year in United States
Demographics: most common in Israel, Bolivia, Chile, northern Japan, New Mexico
Ethnicity: Native Americans + Hispanic Americans (associated with increased prevalence of gallstones)
Median age: 72 years; M:F = 1:3–1:4; whites > blacks
♢ 85% occur in 6th decade or later!
Risk factors: increased body mass, female gender, postmenopausal status, cigarette smoking, chronic Salmonella typhi infection, exposure to chemicals (rubber, automobile, wood finishing, metal fabricating industries)
Associated with:
  • Disorder of gallbladder:
    • Cholelithiasis in 74–92%
      • Gallbladder carcinoma occurs in only 1% of all patients with gallstones!
    • Porcelain gallbladder (in 4–60%): prevalence of gallbladder carcinoma in 10–25% of autopsies
    • Chronic cholecystitis
    • Gallbladder polyp: a polyp >2 cm is likely malignant!
  • Disorder of bile ducts:
    • Primary sclerosing cholangitis
    • Congenital biliary anomalies: cystic dilatation of biliary tree, choledochal cyst, anomalous junction of pancreaticobiliary ducts, low insertion of cystic duct
  • Inflammatory bowel disease (predominantly ulcerative colitis, less common in Crohn disease)
  • Familial polyposis coli
Path: diffusely infiltrating lesion (68%), intraluminal polypoid growth (32%)
Histo:
  1. (a) adenocarcinoma (76%):
    –papillary (6% with tendency to fill gallbladder lumen)
    –intestinal type (variant of well-differentiated adenocarcinoma with intestinal glands)
    –mucinous (5%, with >50% extracellular mucin)
    –signet-ring cell (abundant intracytoplasmic mucin)
    –clear cell (well-defined cytoplasmic borders)
  2. (b) rare epithelial cell types:
    –adenosquamous carcinoma (3%)
    –squamous cell carcinoma (1%)
    –small (oat) cell carcinoma (0.5%, highly aggressive, ± paraneoplastic Cushing syndrome)
    –undifferentiated carcinoma
  3. (c) nonepithelial cell types (2%):
    carcinoid, carcinosarcoma, basal cell carcinoma, lymphoma
P.716

Modified Nevin Stage:
I mucosa only (in situ carcinoma)
II mucosal + muscular invasion
III mucosa + muscularis + serosa
IV gallbladder wall + lymph nodes
V hepatic/distant metastases
  • Early diagnosis usually unsuspected due to lack of specific signs + symptoms:
    • history of past GB disease (50%)
    • malaise, vomiting, weight loss
    • chronic RUQ pain (54–76%)
    • obstructive jaundice (35–74%)
    • abnormal liver function tests (20–75%)
    • ± elevated α-fetoprotein and CEA
Location: fundus (60%), body (30%), neck (10%)
Growth types:
  • mass replacing the gallbladder (40–65%)
  • thickening of GB wall (20–30%) due to submucosal spread:
    • focal (59%)/diffuse (41%) wall thickening
    DDx: acute/chronic inflammation (usually <10 mm)
  • intraluminal polypoid/fungating “cauliflower-like” mass with wide base (15–25%)
  • replacement of gallbladder by mass (37–70%)
  • pericholecystic infiltration: in 76% focal, in 24% diffuse
  • dilatation of biliary tree (38–70%):
    • infiltrative tumor growth along cystic duct
    • lymph node enlargement causing biliary obstruction
    • intraductal tumor spread
  • fine granular/punctate flecks of calcification (mucinous adenocarcinoma)
  • lymph node enlargement in porta hepatis
N.B.: misdiagnosis by US/CT in 50%, especially in the presence of gallstones
Abdominal radiograph:
  • calcified gallstones
  • porcelain gallbladder
  • RUQ gas collection (after invasion of adjacent bowel)
Cholangiography:
  • malignant stricture/obstruction of extrahepatic bile ducts/right and left bile duct confluence, intrahepatic duct of right lobe
  • intraluminal GB filling defect (= tumor/stones)
  • mass displacing/invading gallbladder
  • intraductal filling defects (= tumor/stones)
US:
  • gallbladder replaced by mass with irregular margins + heterogeneous echotexture (= tumor necrosis)
  • immobile intraluminal well-defined round/oval mass
    DDx: tumefactive sludge
  • echogenic foci = coexisting gallstones/wall calcifications/tumoral calcification
  • tumor inseparable from liver
CT:
  • hypo-/isoattenuating mass in gallbladder fossa:
    • low-attenuation areas of necrosis
    • areas of enhancement (= viable tumor)
  • subtle extension beyond wall of GB
  • invasion of liver with protrusion of anterior surface of medial segment of left lobe
MR:
  • hypointense mass on T1WI + ill-defined early contrast enhancement
Metastases: in 75–77% at time of diagnosis
  • direct extension (most common mode): invasion of liver (34–65–89%), duodenum (12–15%), colon (9–15%), pancreas (6%), stomach, bile duct, right kidney, abdominal wall
    Cause: thin GB wall with only a single muscle layer + no substantial lamina propria + perimuscular connective tissue continuous with interlobular connective tissue of liver
  • lymphatic spread (26–41–75%): cystic, pericholedochal, celiac, superior mesenteric, foramen of Winslow, paraaortic nodes, superior + posterior pancreaticoduodenal
  • intraperitoneal seeding (common)
  • hematogenous spread (less common): liver, lung, bones, heart, pancreas, kidney, adrenal, brain
  • neural spread (frequent): associated with more aggressive tumors
  • intraductal spread (least common): particularly in papillary adenocarcinoma
Cx: perforation of gallbladder + abscess formation
√gallstones located within abscess
Prognosis: 75% unresectable at presentation; average survival is 6 months; 5% 1-year survival rate; 6% 5-year survival rate
DDx: (1) Xanthogranulomatous cholecystitis (lobulated mass filling gallbladder + stones)
(2) Acute/chronic cholecystitis (generalized gallbladder wall thickening <10 mm)
(3) Liver tumor invading gallbladder fossa
(4) Tumors from adjacent organs (pancreas, duodenum)
(5) Metastases (melanoma, leukemia, lymphoma)
(6) Polyps: cholesterol polyp, hyperplastic polyp, granulation polyp
(7) Adenomyomatosis
Glycogen Storage Disease
  • autosomal recessive diseases with varying severity and clinical syndromes
Von Gierke Disease (Type I)
Etiology: defect in glucose-6-phosphatase with excess deposition of glycogen in liver, kidney, intestines
Dx: failure of rise in blood glucose after glucagon administration
Age at presentation: infancy
  • hepatomegaly
  • US:
    • increased echogenicity (glycogen/fat)
  • CT:
    • increased (glycogen)/normal/decreased (fat) parenchymal attenuation
Prognosis: death in infancy, may survive into adulthood with early therapy
Cx: (1) Hepatic adenoma
(2) Hepatocellular carcinoma
P.717

Pompe Disease (Type II)
  • = abnormal metabolism with enlargement of myocardial cells due to glycogen deposition; similar to endocardial fibroelastosis
Etiology: defect in lysosomal glucosidase
  • massive cardiomegaly with CHF
  • hepatomegaly
Prognosis: sudden death in 1st year of life (due to conduction abnormalities); survival rarely beyond infancy
Cori Disease (Type III)
 
Andersen Disease (Type IV)
 
McArdle Disease (Type V)
 
Hers Disease (Type VI)
 
Hemochromatosis
excess iron deposition in various parenchymal organs (liver, pancreas, spleen, kidneys, heart) leading to cirrhosis with portal hypertension
Cause: excess iron deposition from
  1. increased GI absorption:
    1. Genetic hemochromatosis
    2. Erythropoietic hemochromatosis
    3. Bantu siderosis
  2. IV blood transfusion
  3. intravascular (extrasplenic) hemolysis
CT (60% sensitivity for iron):
  • diffuse/rarely focal increase in liver density (up to 75–130 HU)
  • depiction of portal + hepatic veins against background of hyperattenuating liver on NECT
  • dual energy CT (at 80 + 120 kVp) can quantitate amount of iron deposition
Genetic Hemochromatosis
  • = IDIOPATHIC/PRIMARY/HEREDITARY HEMOCHROMATOSIS
  • = excessive duodenal absorption + parenchymal retention of dietary iron that favors accumulation within non-RES organs (liver, pancreas, heart, pituitary gland)
Cause: autosomal recessive disorder (abnormal HFE gene located near human-leukocyte antigen [HLA] on short arm of chromosome 6) with increased absorption of intestinal iron
Prevalence: 1:220 whites of northern European ancestry; homozygote frequency up to 0.25–0.50%; heterozygote carriers >10%
Pathophysiology:
  • absorbed iron is selectively bound to transferrin; increased transferrin saturation in portal circulation favors selective iron uptake by periportal hepatocytes as initial site of iron accumulation; RES cells are incapable of storing excess iron
Path: excess iron stored as crystalline iron oxide (ferric oxyhydroxide) within cytoplasmic ferritin + lysosomal hemosiderin; iron overload affects parenchymal cells (liver, pancreas, heart) NOT Kupffer cells/RE cells of bone marrow + spleen (abnormal function of RES)
Age: after middle age; female iron loss during menses and pregnancy provides some protection
  • asymptomatic during 1st decade of disease
  • symptomatic in 80–90% if iron deposits >10 g
  • hyperpigmentation (90%)
  • hepatomegaly (90%)
  • arthralgias (50%)
  • diabetes mellitus (30%) secondary to insulin resistance by hepatocytes + pancreatic β-cell damage from iron deposition
  • CHF + arrhythmia (15%)
  • loss of libido, impotence, amenorrhea, testicular atrophy, loss of body hair
  • liver iron index > 2 (= liver iron concentration [μmol per gram of dry weight] per patient’s age)
  • serum Fe >300 mg/dL
  • serum transferrin saturation > 50%
MR:(skeletal muscle = good signal intensity reference)
  • significant signal loss in liver on T2WI with signal intensity equal to background noise (paramagnetic susceptibility of ferritin + ferric ions leads to profound shortening of T1 + T2 relaxation times of adjacent protons)
  • normal pancreatic signal intensity in noncirrhotics
  • pancreatic signal intensity equal to/less than muscle (in 90% of cirrhotic patients)
  • normal signal intensity of spleen (in 86%) due to abnormal RES function
  • normal bone marrow signal
Dx: liver biopsy
Cx: (1) Periportal fibrosis resulting in cirrhosis (if iron concentration >22,000 μg/g of liver tissue)
(2) Hepatocellular carcinoma (14–30%)
(3) Insulin-dependent diabetes mellitus (30–60%)
(4) Congestive cardiomyopathy (15%)
Rx: phlebotomies in precirrhotic stage
Prognosis: normal life expectancy with early diagnosis and treatment
Secondary Hemochromatosis
  • [= HEMOSIDEROSIS = increased iron deposition without organ damage]
  • Cause:
    • Erythrogenic hemochromatosis = increased duodenal absorption of iron secondary to erythroid hyperplasia in ineffective erythropoiesis (eg, thalassemia, congenital dyserythropoietic anemia, sideroblastic anemia [= impaired protoporphyrin production], myelodysplasia, NOT in sickle cell anemia)
      Path: no excess Kupffer cell iron
    • Bantu siderosis = excessive dietary iron from food preparation in iron containers (Kaffir beer)
    • Iron overload siderosis
Path: iron deposition initially in RES (phagocytosis of intact RBC) with sparing of parenchymal cells of pancreas; after saturation of RES storage capacity parenchymal cells of other organs accumulate iron (liver, pancreas, myocardium)
Age: 4th–5th decade; M:F = 10:1
P.718

MR:
  • signal loss in liver on T2WI with signal intensity greater than background noise (iron in Kupffer cells with sparing of parenchymal liver cells)
  • splenic signal intensity less than muscle
  • low signal intensity of bone marrow (= siderotic marrow)
Transfusional Siderosis
  • = iron deposited in liver, spleen, and bone marrow in patients receiving >40 units of blood (iron storage capacity of RES = 10 g of iron)
  • • abnormal iron deposition in RES is clinically of little significance (no damage of affected organs)
  • parenchymal iron deposition can cause organ dysfunction
  • low signal intensity of bone marrow (= siderotic marrow)
  • strong signal decrease in spleen
  • low signal intensity of liver + pancreas
Rx: iron chelation therapy to remove excess iron
Hepatic Abscess
  • LIVER ABSCESS
  • localized collection of pus in the liver resulting from any infectious process with destruction of the hepatic parenchyma + stroma
Types: pyogenic (85%), fungal (9%), amebic (6%)
Location: multiple in 50% ♢ A pyogenic abscess tends to be centrally located, an amebic abscess peripherally!
  • hepatomegaly
  • elevation of right hemidiaphragm
  • pleural effusion
  • right lower lobe atelectasis/infiltration
  • gas within abscess (esp. Klebsiella)
MR:
  • hypointense on T1WI + hyperintense on T2WI (72%)
  • perilesional edema (35%)
  • “double target sign” on T2WI = hyperintense center (fluid) + hypointense sharply marginated inner ring (abscess wall) + hyperintense poorly marginated ring (perilesional edema)
  • rim enhancement (86%)
Amebic Abscess
Organism: Entamoeba histolytica
Etiology: spread of viable amebae from colon to liver via portal system
Incidence: in 1–25% of intestinal amebiasis
Age: 3rd–5th decade; M:F = 4:1
  • amebic dysentery
  • amebic hepatitis (15%)
Location: liver abscess (right lobe) in 2–25%; systemic dissemination by invasion of lymphatics/portal system (rare); liver:lung:brain = 100:10:1
Size: 2–12 cm; multiple liver abscesses in 25%
  • nonspecific variable appearance
  • nodularity of abscess wall (60%)
  • internal septations (30%)
  • not gas-containing (unless hepatobronchial/hepatoenteric fistula present)
  • ± disruption of diaphragm
CT:
  • nonspecific hypoattenuating area
  • enhancing wall
US:
  • homogeneous hypoechoic area
  • posterior acoustic enhancement
  • well-defined smooth thin wall
NUC:
  • sensitivity of sulfur colloid scan is 98%
  • photon-deficient area surrounded by rim of uptake on Ga-67 scan
Aspiration:
  • typically opaque reddish/dirty brown/pink material (“anchovy paste”/“chocolate sauce”), usually sterile, parasite confined to margin of abscess
Cx: (1) Diaphragmatic disruption (rare) is strongly suggestive of amebic abscess
(2) Fistulization into colon, right adrenal gland, bile ducts, pericardium
Rx: conservative treatment with chloroquine/metronidazole (Flagyl®); percutaneous drainage for left hepatic abscess (spontaneous rupture into pericardium + tamponade possible)
Prognosis: resolution under therapy may take from 1 month to 2 years; permanent cysts may remain behind
Pyogenic Liver Abscess
  • Most common type of liver abscess
Organism: E. coli, aerobic streptococci, St. aureus, anaerobic bacteria (45%); polymicrobial (>50%)
Incidence: 0.016%
Predisposed: steroids, immunosuppressed state, excessive antibiotics usage
Etiology:
  • Biliary disease (60%):
    • ascending cholangitis from obstructive biliary tract disease (malignant/benign stricture), Crohn disease (sclerosing cholangitis, gallstones), cholecystitis
  • Portal phlebitis:
    • suppurative appendicitis, colitis, diverticular disease
  • Disseminated sepsis via hepatic artery:
    • infarction from sickle cell/embolism/postembolization/septicemia; indwelling arterial catheters
  • Direct contiguous spread from a local infection:
    • cholecystitis, peptic ulcer, subphrenic sepsis
  • Trauma:
    • rupture, penetrating wounds, biopsy, surgery or liver transplantation
  • Cryptogenic in 45%:
    • invasion of cysts; superinfection of dead tissue (eg, primary/secondary hepatic tumor) by pyogenic intestinal flora
Age: 6th–7th decade; M > F
  • pyrexia (79%)
  • abdominal pain (68%)
  • nocturnal sweating (43%)
  • vomiting/malaise (39%)
  • jaundice (0–20%)
  • elevated WBCs
  • P.719

  • elevated alkaline phosphatase
  • positive blood culture (50%)
Location: solitary abscess in right lobe (40–75%), in left lobe (2–10%); multiple abscesses in 10–34–73% (more often of biliary than hematogenous origin)
US:
  • hypoechoic round lesion with well-defined mildly echogenic rim
  • posterior acoustic enhancement
  • coarse clumpy debris/low-level echoes/fluid-debris level with internal movement
  • intensely echogenic reflections with reverberations (from gas) in 20–30%
CT:
  • inhomogeneous hypoattenuating (0–45 HU) single/multiloculated cavity
  • “double target sign” = wall-enhancement + surrounding hypodense zone (6–30%)
  • “cluster sign” = several microabscesses each <2 cm within the same anatomic area; suggestive of biliary origin
  • air density
MR:
  • decreased T1 signal + increased T2 signal (varies with protein content)
  • enhancement of peripheral rim
NUC:
  • photon-deficient area on sulfur colloid + IDA scan
  • Ga-67 citrate uptake in 80%
  • In-111 tagged WBC uptake is highly specific (since WBCs normally go to liver, may need sulfur colloid test for correlation)
Cx: (1) Septicemia
(2) Rupture into right subphrenic space
(3) Rupture into abdominal cavity
(4) Rupture into pericardium
(5) Empyema
(6) Common hepatic duct obstruction
Mortality: 20–80%; 100% if unrecognized/untreated
Hepatic Adenoma
  • = HEPATOCELLULAR ADENOMA = LIVER CELL ADENOMA
  • The most frequent hepatic tumor in young women after use of contraceptive steroids!
Prevalence: half as common as FNH
Path: pseudocapsule due to compression of liver tissue containing multiple large vessels; high incidence of hemorrhage + necrosis + fatty change; no scar
Histo: solitary spherical benign growth of hepatocytes; sheets of hepatocytes; sheets of hepatocytes without portal veins or central veins; scattered thin-walled vascular channels + bile canaliculi; decrease in number of abnormally functioning Kupffer cells; hepatocytes contain increased amounts of glycogen ± fat
Age: young women in childbearing age; not seen in males unless on anabolic steroids; rare in children
Associated with:
  • oral contraceptives (2.5 × risk after 5-year use, 7.5 × risk after 9-year use, 25 × risk >9-year use)
  • anabolic steroids
  • pregnancy
  • diabetes mellitus
  • type Ia glycogen storage disease (von Gierke) in 60%
  • Fanconi anemia
  • Pregnancy may increase tumor growth rate + lead to tumor rupture!
  • Tumor regression may occur with dietary therapy leading to normal insulin, glucagon, and serum glucose levels
  • • asymptomatic (20%)
  • • RUQ pain as sign of mass effect (40%)/intratumoral or intraperitoneal hemorrhage (40%)
  • • hepatomegaly
Location: right lobe of liver in subcapsular location (75%); multiple in 20–30% (eg, hepatic adenomatosis without risk factors)
Size: between 6 and 30 cm in size (average size of 8–10 cm)
  • round well-circumscribed pseudo-encapsulated mass
  • intraparenchymal/pedunculated (in 10%)
  • unusual “nodule-in-nodule” appearance in large tumors (DDx: hepatocellular carcinoma)
  • occasional eccentric dystrophic calcifications
CT:
  • round isoattenuating mass
  • mass of decreased density due to fat + areas of necrosis (30–40%)
  • hyperdense areas of fresh intratumoral hemorrhage (22–50%)
CECT:
  • transient avid enhancement on arterial-phase images in small adenomas/initial peripheral enhancement with centripetal filling in larger adenomas (due to supply by hepatic artery)
  • iso-/hypoattenuating on delayed-phase images
US:
  • usually small well-demarcated solid heterogeneous mass of variable echogenicity (echogenic for areas of fat or hemorrhage/complex hyper- and hypoechoic):
    • hyperechoic lesion with well-defined hypoechoic rim
    • anechoic cystic areas if large
    • color flow in peripheral peritumoral sinusoids
MR:
  • inhomogeneous on all pulse sequences (indistinguishable from HCC)
  • often hyperintense areas on T1WI (due to presence of fatladen hepatocytes/hemorrhage) in 35–77%
  • isointense sheets of hepatocytes on T2WI
  • hyperintense areas of necrosis/hemorrhage on T2WI in 47–74%
  • usually signal loss with out-of-phase imaging
NUC:
  • focal photopenic lesion on sulfur colloid scan (because lesion composed of hepatocytes + nonfunctioning Kupffer cells) surrounded by rim of increased uptake (due to compression of adjacent normal liver containing Kupffer cells); may show uptake equal to/slightly less than liver (23%)
  • usually increased activity on hIDA scan
  • No gallium uptake
P.720

Angio:
  • usually hypervascular mass
  • homogeneous but not intense stain in capillary phase
  • enlarged hepatic artery with feeders at tumor periphery (50%)
  • hypo-/avascular regions (secondary to hemorrhage/necrosis)
  • neovascularity
CAVE: percutaneous biopsy carries high risk of bleeding!
Cx: (1) Spontaneous hemorrhage with subcapsular hematoma/hemoperitoneum (41%)
(2) Malignant transformation (? contiguous development of hepatocellular carcinoma)
(3) Recurrence after resection
Rx: hormone therapy stopped; screening for malignant degeneration with α-fetoprotein; surgical resection (to prevent rupture)
DDx: FNH, hemangioma, fibrolamellar hepatocellular carcinoma; metastasis
Hepatic Angiomyolipoma
rare benign mesenchymal tumor
Associated with: tuberous sclerosis
Histo: smooth muscle cells, fat, proliferating blood vessels
  • • asymptomatic
  • intratumoral fat is DIAGNOSTIC
  • soft-tissue component may enhance
Cx: intratumoral hemorrhage
Hepatic Angiosarcoma
HEMANGIOENDOTHELIAL SARCOMA = KUPFFER CELL SARCOMA = HEMANGIOSARCOMA
Prevalence: 0.14–0.25 per million; <2% of all primary liver neoplasms; most common sarcoma of liver (followed by fibrosarcoma > malignant fibrohistiocytoma > leiomyosarcoma)
Etiology:
  • thorotrast = thorium dioxide (7–10%) with latent period of 15–24 years
  • arsenic
  • polyvinyl chloride (latent period of 4–28 years)
Associated with: hemochromatosis, anabolic steroids, cirrhosis, von Recklinghausen disease
Path:
  • multifocal/multinodular lesions (71%) of up to >5 cm in size
  • large solitary mass with hemorrhage + necrosis
Histo:
  • vessels lined with malignant endothelial cells (eg, sinusoids) causing atrophy of surrounding liver
  • vasoformative = forming poorly organized vessels (responsible for RBC trauma + platelet trapping)
  • forming solid nodules of malignant spindle cells
Age: 6th–7th decade; M:F = 4:1
  • abdominal pain, weakness, fatigue, weight loss
  • spontaneous hemoperitoneum (27%)
  • jaundice
  • microangiopathic hemolytic anemia (23%), thrombocytopenia (54%), DIC (31%)
  • NO elevation of α-fetoprotein
Early metastases to:
  • lung (23%), spleen (16–46%), porta hepatis nodes, portal vein, thyroid, peritoneal cavity, bone marrow (rapid metastatic spread)
  • portal vein invasion
  • hemorrhagic ascites
Plain film:
  • circumferential displacement of residual thorotrast
NUC:
  • single/multiple photopenic areas on sulfur colloid scan
  • increased gallium uptake
  • perfusion blood pool mismatch (initial decrease followed by slow increase in RBC concentration) as in hemangioma on 3-phase red blood cell scan
US:
  • solid/mixed mass with anechoic areas (hemorrhage/necrosis)
  • multiple nodules
CT:
  • hypodense masses with high-density regions (hemorrhage)/low-attenuation regions (old hemorrhage/necrosis)
  • focal areas of peripheral enhancement on dynamic CT as in large hemangioma (60%)
MR:
  • hypointense on T1WI with irregular areas of high signal (hemorrhage)
  • hyperintense on T2WI + fluid-fluid levels
  • peripheral Gd-pentetate enhancement on T1WI
Angio:
  • hypervascular stain around tumor periphery in late arterial phase with puddling; NO arterial encasement
CAVE: Biopsy may lead to massive bleeding in 16%! Have surgical backup available!
Prognosis: rapid deterioration with median survival of 6 months (13 months under chemotherapy)
DDx for multiple lesions: hypervascular metastases
DDx for single lesion: cavernous hemangioma, HCC (no splenic metastases)
Hepatic Cyst
  • Second most common benign hepatic lesion after hemangioma
Prevalence: 2–7%; increasing with age; M < F
  • ACQUIRED HEPATIC CYST
    • secondary to trauma, inflammation, parasitic infestation, neoplasia
  • CONGENITAL HEPATIC CYST
    • = defective development of aberrant/obstructed intrahepatic bile ducts; derived from bile duct hamartoma
    Incidence: liver cysts detected at autopsy in 50%;
    in 22% detected during life
    Age of detection: 5th–8th decade
    Histo: cyst surrounded by fibrous capsule + lined by columnar epithelium, related to bile ducts within portal triads; no communication with bile duct
    Associated with:
    • Tuberous sclerosis
    • Polycystic kidney disease (25–33% have liver cysts)
    • Polycystic liver disease: autosomal dominant
  • hepatomegaly (40%); pain (33%); jaundice (9%)
P.721

Size of cyst: range from microscopic to huge (average 1.2 cm; in 25% largest cyst <1 cm; in 40% largest cyst >4 cm; maximal size of 20 cm)
Number of cysts: multiple cysts spread throughout liver (in 60%)/solitary cyst
  • unilocular simple cyst:
    • imperceptible wall
    • may show fluid-fluid interface
  • water attenuation (0–10 HU)
  • no enhancement
  • “cold spot” on IDA, Ga-68, Tc-99m sulfur colloid scans
Rx: sclerosing therapy with minocycline hydrochloride (Dose: 1 mg per 1-mL cyst content up to 500 mg in 10 mL of 0.9% saline + 10 mL 1% lidocaine) following contrast opacification of cyst to confirm absence of communication with biliary tree/leakage into peritoneal cavity
Hepatic Hemangioma
Cavernous Hemangioma of Liver
  • = most common benign liver tumor (78%); second most common liver tumor after metastases
Incidence: 1–4%; autopsy incidence 0.4–7.3%; increased with multiparity
Cause: ? enlarging hamartoma present since birth,? true vascular neoplasm
Age: rarely seen in young children; M:F = 1:5
Path: large vascular channels filled with slowly circulating blood; lined by single layer of mature flattened endothelial cells separated by thin fibrous septa; no bile ducts; thrombosis of vascular channels common resulting in fibrosis + hemorrhage + myxomatous degeneration + calcifications
Pathophysiology: large blood volume with low blood flow
Associated with: (1) Hemangiomas in other organs
(2) Focal nodular hyperplasia
(3) Rendu-Osler-Weber disease
  • asymptomatic if tumor small (50–70%)
  • may present with spontaneous life-threatening hemorrhage if large (5%)
  • hepatomegaly
  • may enlarge during pregnancy
  • abdominal discomfort + pain (from thrombosis in large hemangioma)
  • Kasabach-Merritt syndrome (= hemangioma + thrombocytopenia) rare
Location: frequently peripheral/subcapsular in posterior right lobe of liver; 20% are pedunculated; multiple in 10–20%
Size: <4 cm (90%); >4–6–12 cm = giant cavernous hemangioma
  • well-circumscribed lobulated mass
  • blood supply from hepatic artery
  • may have central area of fibrosis = areas of nonenhancement/nonfilling/cystic space (occurrence increases with age)
  • central septal calcifications within areas of fibrosis/phleboliths (5–20%)
US:
  • uniformly hyperechoic (60–70%) mass due to multiple interfaces created by blood-filled spaces separated by fibrous septa
  • inhomogeneous hypoechoic mass (up to 40%) in larger hemangiomas with well-defined thick/thin echogenic lobulated border due to hemorrhagic necrosis, scarring, myxomatous change centrally
  • homogenous (58–73%)/heterogeneous (fibrosis, thrombosis, hemorrhagic necrosis)
  • hypoechoic center possible
  • may show acoustic enhancement (37–77%)
  • unchanged in size/appearance (82%) on 1–6-year follow-up
  • no Doppler signals/signals with peak velocity of <50 cm/sec
CT (combination of precontrast images, good bolus, dynamic scanning):
  • well-circumscribed spherical/ovoid low-density mass:
    • may have areas of higher/lower density within mass
  • typical pattern of low density on NECT + peripheral enhancement + complete fill-in on delayed images 3–30 minutes post IV bolus (55–89%):
    • peripheral (72%)/central (in 8%)/diffuse dense (in 8%) enhancement
    • complete (75%)/partial (24%)/no (2%) fill-in to isodensity in delayed phase
  • rapid contrast filling (16%), more often in small lesions (in 42% of hemangiomas <1 cm)
    DDx: hypervascular tumor (do not remain hyperattenuating on delayed-phase images)
  • central scar may not enhance at any time
MR (90–95% accuracy):
  • spheroid/ovoid (87%) mass with smooth well-defined lobulated margins (87%); no capsule
  • homogeneous internal architecture if <4 cm, hypointense internal inhomogeneities if >4 cm (due to fibrosis)
  • hypo-/isointense mass on T1WI
  • markedly hyperintense “light bulb” appearance (due to slow flowing blood) increasing with echo time) o T2WI (DDx: hepatic cyst, hypervascular tumor, necrotic tumor, cystic neoplasm)
  • same enhancement pattern as CT:
    • uniform enhancement at 1 second in 40% of small hemangiomas <1.5 cm after gadolinium-DTPA
    • peripheral nodular enhancement progressing centripetally with centrally uniform enhancement (50%)/persistent hypointensity (30%)
    • mildly hyperintense on T2WI for hyalinized hemangioma + lack of enhancement in early phase + slight peripheral enhancement in late phase (DDx: malignant hepatic tumor)
Angio (historical gold standard):
  • dense opacification of well-circumscribed, dilated, irregular, punctate vascular lakes/puddles in late arterial + capillary phase starting at periphery in ring-/C-shaped configuration
  • normal-sized feeders; AV shunting (very rare)
  • contrast persistence late into venous phase
NUC (95% accuracy with SPECT):
Indication: lesions >2 cm (detectable in 70–90%)
  • initially cold lesion on Tc-99m labeled RBC scans (dose of 15–20 mCi) with increased activity on delayed images at 1–2 hours
  • cold defect on sulfur colloid scans
Bx: may be biopsied safely provided normal liver is present between tumor + liver capsule
√nonpulsatile blood (73%)
√endothelial cells without malignancy (27%)
Prognosis: no growth when <4 cm in diameter; giant cavernous hemangiomas may enlarge
Cx (rare): (1) Spontaneous rupture (4.5%)
(2) Abscess formation
(3) Kasabach-Merritt syndrome (platelet sequestration)
DDx: hypervascular malignant neoplasm/metastasis (quick homogeneous filling during arterial phase of small hemangiomas)
P.722

Giant Hepatic Cavernous Hemangioma
  • = at least one dimension exceeding 8–10 cm (in literature no agreement on size)
Associated with: coexistent smaller <5 cm hemangioma in 13%
Histo: hemorrhage, thrombosis, extensive hyalinization, liquefaction, fibrosis; central cleft due to cystic degeneration/liquefaction
  • RUQ pain/fullness; abdominal mass
US:
  • heterogeneous mass
NECT:
  • heterogeneous hypoattenuating mass with marked central areas of low attenuation
CECT:
  • early peripheral globular enhancement
  • incomplete filling of central portions
MR:
  • sharply marginated hypointense mass with cleftlike area of lower intensity on T1WI
  • large markedly hyperintense cleftlike area with some hypointense internal septa inside a hyperintense mass on T2WI
CEMR:
  • peripheral nodular enhancement
  • central cleftlike area remains hypointense
DDx: metastasis, hepatocellular carcinoma, cholangiocarcinoma, hepatic adenoma, FNH (smaller and less hyperintense central scar on T2WI), focal fatty infiltration
Infantile Hemangioendothelioma of Liver
  • = INFANTILE HEPATIC HEMANGIOMA = CAPILLARY/CAVERNOUS HEMANGIOMA
  • Most common benign hepatic tumor during first 6 months of life!
Histo: multiple anastomosing thick-walled vascular spaces similar to cavernous hemangioma lined by plump immature endothelial cells in single or (less often) multiple cell layers; areas of extramedullary hematopoiesis/thrombi; scattered bile ducts; involutional changes (infarction, hemorrhage, necrosis, scarring)
Classification:
  • hemangioendothelioma type 1 (more common): orderly proliferation of small blood vessels
  • hemangioendothelioma type 2: more aggressive histologic pattern
    DDx: angiosarcoma
  • Cavernous hemangioma:
    • dilated vascular spaces lined by flat endothelial cells
    • Relationship to adult cavernous hemangioma unknown!
Age at presentation: <6 months in 85%, during 1st month in 33%, >1 year in 5%; M: F = 1:1.4-1:2
  • abdominal mass secondary to hepatomegaly
  • cutaneous hemangiomas (9-45-87%) occur with multinodular form
  • may present with high-output ChF secondary to AV shunts within tumor (8 -15-25%)
  • Kasabach-Merritt syndrome (in 11%)
    • = hemorrhagic diathesis due to platelet sequestration by tumor/disseminated intravascular coagulation; characterized by an association of hemangioma, or hemangioendothelioma, or angiosarcoma with thrombocytopenia and purpura (secondary to increased systemic fibrinolysis)
    Prognosis: fatal outcome in 20-30%
  • hemolytic anemia
Size: several mm up to 20 cm (average size of 3 cm)
  • diffuse involvement of entire liver, rarely focal
  • single mass (50%)/multiple masses (50%)
  • enlargement of celiac + hepatic arteries + proximal aorta
  • rapid decrease in aortic caliber below celiac trunk
  • enlarged hepatic veins (increased venous flow)
Plain film:
  • fine speckled/fibrillary calcifications in 16-25% (DDx: hepatoblastoma, hamartoma, metastatic neuroblastoma)
US:
  • heterogeneous predominantly hypoechoic/complex/hyperechoic lesion
  • multiple sonolucent areas (= enlarging vascular channels secondary to initial rapid growth) (DDx: mesenchymal hamartoma):
    • vascular components demonstrated by color Duplex
  • calcifications (in up to 50%)
OB-US:
  • polyhydramnios + fetal hydrops
NECT:
  • large well-defined hypoattenuating mass
  • hemorrhage (not uncommon)
  • calcifications (in up to 16%)
CECT (similar to cavernous hemangioma):
  • early peripheral enhancement (72%)
  • variable delayed central enhancement
MR:
  • heterogeneous hypointense multinodular lesion on T1WI ± hyperintense areas of hemorrhage
  • P.723

  • varying degrees of hyperintensity on T2WI (resembling adult hemangioma)
  • decreasing signal intensity with fibrotic replacement on T2WI
NUC (sulfur colloid, tagged RBC):
  • increased flow in viable portions of lesion during angiographic phase
  • increased activity mixed with central photopenic areas (hemorrhage, necrosis, fibrosis) on delayed tagged RBC images
  • photopenic defect on delayed sulfur colloid images
Angio:
  • enlarged, tortuous feeding arteries and stretched intrahepatic vessels
  • hypervascular tumor with inhomogeneous stain; clusters of small abnormal vessels
  • pooling of contrast material in sinusoidal lakes with rapid clearing through early draining veins (AV shunting)
Prognosis: rapid growth in first 6 months followed by tendency to involute within 6–8 months; 32–75% survival rate in complicated cases
Cx: (1) Congestive heart failure
(2) Hemorrhagic diathesis
(3) Obstructive jaundice
(4) Hemoperitoneum (rupture of tumor) (5) Malignant transformation into angiosarcoma (rare)
Rx: (1) No treatment if asymptomatic
(2) Reduction in size with steroids/radiotherapy/chemotherapy
(3) Embolization(4) Surgical resection/liver transplantation
DDx: (1) Hepatoblastoma (>1 year of age, elevated α±-fetoprotein, more heterogeneous)
(2) Mesenchymal hamartoma (usually multilocular cystic mass) (3) Metastatic neuroblastoma (elevated catecholamines in urine, adrenal mass, nonenhancing multiple liver masses)
Hepatic Venoocclusive Disease
  • = occlusion of small centrilobular veins without involvement of major hepatic veins
Etiology: radiation and chemotherapy in bone-marrow transplant patients; bush tea (alkaloid) consumption in Jamaica
  • main hepatic veins + IVC normal
  • bidirectional/reversed portal venous flow
  • gallbladder wall thickening
Hepatitis
Cause: alcohol, medication, viral infection, NASH (nonalcoholic steatohepatitis)
Acute Hepatitis
  • • markedly elevated AST + ALT
  • • increase in serum-conjugated bilirubin
  • hepatomegaly/normal size of liver
  • gallbladder wall thickening
  • lymphadenopathy
CT:
  • periportal low attenuation (lymph edema)
US:
  • diffuse decrease in liver echogenicity
  • increased brightness of portal triads (“starry sky” pattern) = centrilobular pattern due to edema in hepatocytes (DDx: leukemic infiltrate, diffuse lymphomatous involvement, toxic shock syndrome)
  • edema of gallbladder fossa + gallbladder wall thickening
  • thickening + increase in echogenicity of fat within falciform ligament, ligamentum venosum, porta hepatis, periportal connective tissue
Chronic Hepatitis
  • = process present for at least 6 months
Cause: autoimmune hepatitis; hepatitis B, C, D; cryptic hepatitis; chronic drug hepatitis; primary biliary cirrhosis; primary sclerosing cholangitis; Wilson disease; alpha-1 antitrypsin deficiency
US:
  • increased liver echogenicity
  • coarsening of hepatic echotexture
  • silhouetting/loss of definition of portal venules = decreased visualization of the walls of the peripheral portal veins
  • NO sound attenuation
Cx: cirrhosis (10% for hepatitis B; 20–50% for hepatitis C)
Neonatal Hepatitis
Cause:
  • INFECTION: virus, protozoa, spirochete, toxoplasmosis, rubella, CMV, herpes, hepatitis A/B, syphilis
  • METABOLIC: alpha-1 antitrypsin deficiency, familial recurrent cholestasis, errors of metabolism (nesidioblastosis = idiopathic hyperinsulin hypoglycemia of infancy)
  • IDIOPATHIC
Age: 1–4 weeks of age; M > F
Histo: multinucleated giant cells with hepatic parenchymal disruption, relatively little bile within bile duct canaliculi
US:
  • normal-sized/enlarged liver
  • increase in parenchymal echogenicity
  • decreased visualization of peripheral portal veins
  • normal bile duct system
  • gallbladder of normal size/small (with decrease in bile volume in severe hepatocellular dysfunction)
  • decrease in gallbladder size after milk feeding (DDx: congenital biliary atresia)
NUC:
Technique: often performed after pretreatment with phenobarbital (5 mg/kg × 5 days) to maximize hepatic function
  • normal/decreased hepatic tracer accumulation
  • prolonged clearance of tracer from blood pool
  • bowel activity faint/delayed usually by 24 hours (best seen on lateral view; covering liver activity with lead shielding is helpful)
  • P.724

  • gallbladder may not be visualized
Prognosis: spontaneous remission
DDx: biliary atresia (NO small bowel activity)
Radiation Hepatitis
Acute Radiation-induced Hepatitis
Time of onset: 2–6 weeks after completion of radiation therapy with dose >3,500 rad (35 Gy)
  • • abnormal liver function tests
  • • right upper quadrant discomfort
  • hepatomegaly
  • ascites
Prognosis: complete recovery in majority
Chronic Radiation-induced Hepatitis
  • increased attenuation in irradiated parenchyma (no fatty infiltration)
  • geographic areas of hypointensity on T1WI + hyperintensity on T2WI (due to increased water content)
Viral Markers of Hepatitis
Virus Tests Interpretation
HAV Anti-HAV IgM acute hepatitis (can remain positive for >1 year)
Anti-HAV IgG past hepatitis, lifelong immunity
HBV HBsAg acute/chronic disease
Anti-HBc IgM acute infection (if titer high); chronic infection (if titer low)
Anti-HBc IgG past/recent HBV contact (may be only serum indicator of past infection)
HBe active viral replication
Anti-HBe low/absent replicative state (typically present in long-standing HBV carriers)
Anti-HBs immunity after vaccination
HBV-DNA active viral replication
HCV Anti-HCV past/current infection
RIBA test for various viral components
HCV-RNA active viral replication
HDV Anti-HDV IgM acute/chronic infection
Anti-HDV IgG chronic infection (if titer high + IgM positive); past infection if titer low + IgM negative)
HDV-RNA active viral replication
HEV Anti-HEV IgM acute hepatitis
Anti-HEV IgG past hepatitis
HEV-RNA viral replication
Hepatoblastoma
Incidence: 3rd most common abdominal tumor in children; most frequent malignant hepatic tumor in infants + children <3 years of age
Incidence increased with: hemihypertrophy, Beckwith syndrome
Histo:
  • epithelial type = small cells resembling embryonal/fetal liver
  • mixed type = epithelial cells + mesenchymal cells (osteoid, cartilaginous, fibrous tissue)
Age: <3 years; <18 months (in 50%); peak age between 18 and 24 months; range from newborn to 15 years; M:F = 2:1
  • upper abdominal mass, weight loss, nausea, vomiting
  • jaundice, pain
  • precocious puberty (production of endocrine substances)
  • persistently + markedly elevated α-fetoprotein (66%)
Metastases to: lung (frequent)
Location: right lobe of the liver
  • usually solitary mass with an average size of 10–12 cm
  • multifocal (20%)
  • coarse calcifications/osseous matrix (12–30%)
US:
  • large heterogeneous echogenic mass, often with calcifications, occasionally cystic areas (necrosis/extramedullary hematopoiesis)
CT:
  • hypointense tumor with peripheral rim enhancement
MR:
  • inhomogeneously hypointense on T1WI with hyperintense foci (hemorrhage)
  • inhomogeneously hyperintense with hypointense bands (fibrous septa) on T2WI
NUC:
  • photopenic defect
Angio:
  • hypervascular mass with dense stain
  • marked neovascularity; NO AV-shunting
  • vascular lakes may be present
  • avascular areas (secondary to tumor necrosis)
  • may show caval involvement (= unresectable)
Prognosis: 60% resectable; 75% mortality; better prognosis than hepatoma; better prognosis for epithelial type than mixed type
DDx: hemangioendothelioma (fine granular calcifications), metastatic neuroblastoma, mesenchymal hamartoma, hepatocellular carcinoma (>5 years of age, no calcifications)
Hepatocellular Carcinoma
  • = HEPATOMA
  • = most frequent primary visceral malignancy in the world; 80–90% of all primary liver malignancies; 2nd most frequent malignant hepatic tumor in children (39%) after hepatoblastoma
Incidence: (a) in industrialized world: 0.2–0.8%
(b) in sub-Saharan Africa, Southeast Asia, Japan, Greece, Italy: 5.5–20%
Peak age: (a) industrialized world: 6th–7th decade; M:F = 2.5:1; fibrolamellar subtype (in 3–10%) below age 40 years
(b) high incidence areas: 30–40 years; M:F = 5:1
(c) in children: >5 years of age (peak at 12–14 years); M:F = 4:3
P.725

Etiology:
  • Cirrhosis (60–90%)
    • alcohol
    • hemochromatosis
    • cardiac
    • biliary atresia
    Latent period: 8 months to 14 years from onset of cirrhosis
    Incidence of HCC:
    • — 44% in macronodular (= postnecrotic) cirrhosis due to hepatitis B virus, alcoholism, hemochromatosis
    • — 6% in micronodular cirrhosis due to alcoholism
    • 5% of alcoholic cirrhotics develop HCC!
  • Chronic hepatitis B/C: 12% develop HCC
  • Carcinogens
    • aflatoxin
    • siderosis
    • thorotrast
    • oral contraceptives/anabolic androgens
  • Inborn errors of metabolism
    • alpha-1 antitrypsin deficiency
    • galactosemia
    • type I glycogen storage disease (von Gierke)
    • Wilson disease
    • tyrosinosis
mnemonic: WHAT causes HCC?
  • Wilson disease
  • Hemochromatosis
  • Alpha-1-antitrypsin deficiency
  • Tyrosinosis
  • Hepatitis
  • Cirrhosis (alcoholic, biliary, cardiac)
  • Carcinogens (aflatoxin, sex hormones, thorotrast)
Path: soft tumor due to lack of stroma, often hemorrhagic + necrotic
Histo: HCC cells resemble hepatocytes in appearance + structural pattern (trabecular, pseudoglandular = acinar, compact, scirrhous);
(a) expansive encapsulated HCC: collapsed portal vein branches at capsule
(b) infiltrative nonencapsulated HCC: portal venules communicate with tumoral sinusoids = often invasion of portal ± hepatic veins
Growth pattern:
  • solitary massive (27–50–59%):
    • bulk in one (most often right) lobe with satellite nodules
  • multifocal small nodular (15–25%):
    • small foci of usually <2 cm (up to 5 cm) in both hepatic lobes
  • diffuse microscopic infiltrating form (10–15–26%):
    • tiny indistinct nodules closely resembling cirrhosis
Vascular supply: hepatic artery, portal vein in 6%
  • α -fetoprotein elevated in 75–90% (DDx: negative α-fetoprotein in cholangiocarcinoma)
  • elevated liver function tests
  • persistent RUQ pain, hepatomegaly, ascites
  • fever, weight loss, malaise
  • Paraneoplastic syndromes:
    • sexual precocity/gynecomastia
    • hypercholesterolemia
    • erythrocytosis (tumor produces erythropoietin)
    • hypoglycemia
    • hypercalcemia
    • carcinoid syndrome
Metastases to: lung (most common = 8%), adrenal, lymph nodes, bone
  • portal vein invasion (25–33–48%)
  • arterioportal shunting (4–63%)
  • invasion of hepatic vein (16%)/IVC (= Budd-Chiari syndrome)
  • occasionally invasion of bile ducts
  • calcifications in ordinary HCC (2–9–25%); however, common in fibrolamellar (30–40%) and sclerosing HCC
  • hepatomegaly and ascites
  • tumor fatty metamorphosis (2–17%)
CT (sensitivity of 63% in cirrhosis, 80% without cirrhosis):
  • hypodense mass/rarely isodense/hyperdense in fatty liver:
    • dominant mass with satellite nodules
    • mosaic pattern = multiple nodular areas with differing attenuation on CECT (up to 63%)
    • diffusely infiltrating neoplasm
  • encapsulated HCC = circular zone of radiolucency surrounding the mass (12–32–67%)
False-positive: confluent fibrosis, regenerative nodule
Biphasic CECT:
  • enhancement during hepatic arterial phase (80%)
  • decreased attenuation during portal venous phase with inhomogeneous areas of contrast accumulation
  • isodensity on delayed scans (10%)
  • thin contrast-enhancing capsule (50%) due to rapid washout
  • wedge-shaped areas of decreased attenuation (segmental/lobar perfusion defects due portal vein occlusion by tumor thrombus)
CT with intraarterial ethiodol injection:
  • hyperdense mass detectable as small as 0.5 cm US (86–99% sensitivity, 90–93% specificity, 50–94% accuracy)
US:
  • variable echogenicity:
    • hyperechoic HCC (13%) due to fatty metamorphosis or marked dilatation of sinusoids
    • hypoechoic HCC (26%) due to solid tumor
    • HCC of mixed echogenicity (61%) due to nonliquefactive tumor necrosis
  • Doppler peak velocity signals >250 cm/sec
  • calcifications (rare)
MR:
  • hypointense (50%)/iso- to hyperintense (with fatty metamorphosis) on T1WI
  • ring sign = well-defined hypointense capsule on T1WI (24–44%), double layer of inner hypointensity (fibrous tissue) + outer hyperintensity (compressed blood vessels + bile ducts) on T2WI in expansive type of HCC
  • moderately hyperintense on T2WI
  • may contain central scar of fibrosis/calcifications/necrosis hypointense on T1WI + T2WI
CEMR:
  • Gd-DTPA enhancement peripherally (21%)/centrally (7%)/mixed (10%)/no enhancement (21%)
  • P.726

  • central scar without much enhancement
  • improved lesion detectability after intravenous administration of superparamagnetic iron oxide
NUC:
  • Sulfur colloid scan: single cold spot (70%), multiple defects (15-20%), heterogeneous distribution (10%)
  • Tc-HIDA scan: cold spot/atypical uptake in 4% (delayed images)
  • Gallium-scan: avid accumulation in 70-90% (in 63% greater, in 25% equal, in 12% less uptake than liver)
Angio:
  • “thread and streaks” = linear parallel vascular channels coursing along portal venous radicles seen with portal venous involvement
  • in differentiated HCC: enlarged arterial feeders, coarse neovascularity, vascular lakes, dense tumor stain, arterioportal shunts
  • in anaplastic HCC: vascular encasement, fine neovascularity, displacement of vessels + corkscrew-like vessels of cirrhosis
Prognosis: >90% overall mortality; 17% resectability rate; 6 months average survival time; 30% 5-year survival time
Cx: spontaneous rupture (in 8%)
Rx: (1) Resection
(2) I-131 antiferritin IgG (remission rate >40% up to 3 years)
DDx: hepatocarcinoma, cholangiocarcinoma, focal nodular hyperplasia, hemangioma, hepatic adenoma
Fibrolamellar Carcinoma of Liver
  • = uncommon variant of hepatocellular carcinoma
Prevalence: 1-9% of all HCCs; up to 35% of hCCs in patients <50 years of age
Age: 5-69 (mean 23) years; mostly 2nd-3rd decade; M:F = 1:1
Path: large well-circumscribed lobulated nonencapsulated strikingly desmoplastic tumor with calcifications + fibrous central scar
Histo: large hepatocyte-like cells with granular eosinophilic cytoplasm growing in sheets/cords/trabeculae separated by broad bands of fibrous stroma arranged in parallel lamellae resulting in compartmentalized appearance
Risk factors: NONE known; underlying cirrhosis or hepatitis in <5%
Demographics: less common in Europe; rare in Japan + China
  • • pain, cachexia; palpable RUQ mass, hepatomegaly
  • • gynecomastia (rare) from conversion of androgens to estrogens by tumor-elaborated enzyme aromatase
  • • jaundice (5%) from biliary compression
  • • alpha;-fetoprotein usually negative/mildly elevated to <200 ng/μL (in up to 10%)
  • • transaminase levels <100 IU/L
  • partially/completely encapsulated solitary mass (in 80-90%):
    • intrahepatic (80%)/pedunculated (20%)
    • 5-20 (mean 13) cm in diameter
    • prominent central fibrous scar (45-60%)
    • capsular retraction (10%)
    • punctate/nodular/stellate calcifications located within scar (33-55%)
    • intratumoral hemorrhage + necrosis (10%)
    • vascular invasion (<5%)
  • mass + small peripheral satellite lesions (10-15%)
  • diffuse multifocal masses (<1%)
  • regional adenopathy (50–70%): porta hepatis
  • distant metastases (20%): lung, peritoneal implants
US:
  • mixed echogenicity (60%)
  • central hyperechoic scar (33–60%)
CT:
  • mass of low attenuation
  • enhancement of non-scar portion:
    • prominent heterogeneous enhancement in arterial + portal venous phase
    • less pronounced enhancement during equilibrium phase
  • delayed enhancement of scar (25%) + pseudocapsule of compressed liver tissue (15%)
MRI:
  • large lobulated mass
    • T1WI:
      • hypointense (86%)/isointense (14%)
      • homogeneous (80%)/heterogeneous (20%)
    • T2WI:
      • hyperintense/heterogeneous (85%)
      • isointense/homogeneous (15%)
  • hypointense central scar on T1WI + T2WI
Angio:
  • dense tumor stain
  • enlarged feeding arteries
  • NO arteriovenous/arterioportal shunting
  • avascular central scar
NUC:
  • photopenic defect on sulfur colloid scan
  • increased activity during arterial phase + photo-penic during delayed imaging on labeled RBC scan
Prognosis: 48% resectability rate; 32 months average survival time; 67% 5-year survival time
DDx: focal nodular hyperplasia (young + middle-aged women, <5 cm in size, calcifications uncommon, isointense to liver on all CT + MR images with pronounced homogeneous enhancement during arterial phase, hyperintense central scar on T2WI, uptake of sulfur colloid/super paramagnetic iron oxide)
Hyperplastic Cholecystosis
  • = variety of degenerative + proliferative changes of gallbladder wall characterized by hyperconcentration, hyperexcitability, and hyperexcretion
Incidence: 30–50% of all cholecystectomy specimens; M:F = 1:6
Adenomyomatosis of Gallbladder
  • = increase in number + height of mucosal folds
Histo: hyperplasia of epithelial + muscular elements with mucosal outpouching of epithelium-lined cystic spaces into (46%) or all the way through (30%) a thickened muscular layer as tubules/crypts/2–8 mm saccules (= intramural diverticula = Rokitansky-Aschoff sinus); develop with increasing age
[Karl Rokitansky (1804–1878), pathologist in Vienna, Austria]
[Carl Aschoff (1866–1942), pathologist in Bonn, Germany]
Incidence: 2–5% of all cholecystectomy specimens
Age: >35 years; M:F = 1:3
Associated with: (1) Gallstones in 25–75%
(2) Cholesterolosis in 33%
P.727

Types:
  • generalized form = ADENOMYOMATOSIS
    • “pearl necklace gallbladder” = tiny extraluminal extensions of contrast on OCG (enhanced after contraction with fatty meal)/MRCP
    • “comet-tail” = sound reverberation artifact between cholesterol crystals in Rokitansky-Aschoff sinuses (PATHOGNOMONIC)
    N.B.: Rokitansky-Aschoff sinuses of <5 mm cannot be identified
  • segmental form
    • compartmentalization most often in neck/distal 1/3
  • localized form in fundus = ADENOMYOMA
    • smooth sessile mass in GB fundus
    • = solitary adenomyoma + extraluminal diverticula-like formation
  • annular form
    • “hourglass” configuration of GB with transverse congenital septum
DDx: gallbladder carcinoma
Cholesterolosis
  • = abnormal deposits of cholesterol esters in macrophages within lamina propria (foam cells) + in mucosal epithelium
Strawberry Gallbladder
  • = LIPID CHOLECYSTITIS = cholesterosis
  • = planar form = seedlike patchy/diffuse thickening of the villous surface pattern (disseminated micronodules)
Associated with: cholesterol stones in 50–70%
  • • not related to serum cholesterol level
  • radiologically not demonstrable
Cholesterol Polyp (90%)
  • = polypoid form
  • = abnormal deposit of cholesterol esters and triglycerides producing a villouslike structure covered with a single layer of epithelium and attached via a delicate stalk
Prevalence: 4%; most common (50%) fixed filling defect of gallbladder
Age: 40–50 years; M:F=1:3
Location: commonly in middle 1/3 of gallbladder
  • multiple (on average 8) small filling defects <10 mm (rarely up to 20 mm) in diameter
DDx: papilloma, adenoma, inflammatory granuloma
Inspissated Bile Syndrome
  • = uncommon cause of jaundice in neonate
Associated with: massive hemolysis (Rh incompatibility), hemorrhage (intraabdominal, intracranial, retroperitoneal), increased enterohepatic circulation (Hirschsprung disease, intestinal atresia, stenosis)
US:
  • sludge in gallbladder
  • sludge within bile ducts + partial/complete obstruction (affected ducts may blend with surrounding hepatic parenchyma)
Intraductal Papillary Mucinous Tumor Of Pancreas
  • = IPMT = MUCINOUS DUCTAL ECTASIA = DUCTECTATIC MUCINOUS CYSTIC TUMOR OF PANCREAS = INTRADUCTAL MUCIN-HYPERSECRETING NEOPLASM = MUCIN-PRODUCING PANCREATIC TUMOR = MUCINOUS VILLOUS ADENOMATOSIS
  • = rare intraductal tumor originating from papillary epithelial lining typified by voluminous mucin secretions
Path: conglomeration of communicating cysts covered by a rim of normal pancreatic parenchyma + thin fibrous capsule
Histo: cysts represent a dilated duct lined with innumerable papillae coated with hyperplastic/atypical/malignant epithelium (adenoma-carcinoma sequence)
Age: elderly patients; M>F
  • • recurrent episodes of dull pain/acute pancreatitis (due to impaired outflow of pancreatic secretions):
    • hyperamylasemia (occasionally)
  • viscosity of fluid greater than normal serum (89% sensitive, 100% specific)
Prognosis: low-grade malignancy with better prognosis than pancreatic adenocarcinoma
Dx: ERCP (bulging ampulla, mucin pouring from papilla, communication between pancreatic duct + cystic cavity)
Rx: Whipple operation (main duct IPMT/partial pancreatectomy (branch duct IPMT)
DDx: chronic obstructive pancreatitis, serous/mucinous cystic tumors, pseudocyst
Main Duct IPMT
Age: 57 (range, 34–75) years; M:F = 1:1
  • hyperechoic, hyperdense, T2-hypointense filling defect within dilated duct (= enhancing papillary mural nodule/gravity-dependent mucin glob)
  • dilatation of main pancreatic duct:
    • dilatation of entire main pancreatic duct
      • homogeneous hypoechoic, hypodense, T1-hypointense and T2-hyperintense main duct
      • pancreatic parenchymal atrophy
      • dilatation of branch ducts (usually in pancreatic tail + uncinate process)
      • dilatation of major ± minor papilla bulging into duodenal lumen
      • ± obstruction of CBD (due to tumor/impacted mucin)
      Cx: pancreaticobiliary/-duodenal fistula, pseudomyxoma peritonei
      DDx: chronic obstructive pancreatitis
    • segmental dilatation of main pancreatic duct
      • cyst in pancreatic body/tail + normal remaining pancreatic parenchyma
      • cyst in pancreatic head + upstream dilatation of main pancreatic duct
DDx: peripheral mucinous cystic tumor (main duct almost always normal)
P.728

ERCP:
  • • thick jellylike mucus protruding from a bulging patulous duodenal papilla
  • plugging of the papilla of Vater
  • amorphous intraluminal filling defects in main pancreatic duct
  • usually small mural polypoid/flat tumor
  • dilated main + branch pancreatic ducts without obstructive ductal stricture
N.B.: reflux of contrast material due to excess of mucin/patent papillary orifice hinders filling of ductal tree
Branch Duct IPMT
Age: 63 (range, 37–76) years; M:F=1:1
  • usually incidental finding when tumor small
  • symptoms mimicking acute/chronic pancreatitis
Location: mainly in uncinate process >> pancreatic tail > pancreatic body
Path: macrocystic/microcystic pattern; malignancy suggested by irregular thick wall + septa and solid nodules
  • round/ovoid small lobulated intraductal mass (frequently not visualized):
    • dilated main pancreatic duct
    • normal main pancreatic duct (almost always normal in small tumor)
      • Secretin administration distends ducts and enhances detection of communication with main pancreatic duct!
  • uni-/multilocular cyst 10-20 mm large with sparse septa
DDx: mucinous cystadenoma (no communication with main pancreatic duct); pseudocyst (no intraluminal filling defects)
  • multiple thin septa separating fluid-filled lacunae
DDx: serous cystadenoma (no communication with main pancreatic duct)
  • ± severe pancreatic atrophy
  • protrusion of papilla into duodenum
ERCP:
  • contrast spills from main duct into cystically dilated branch ducts
  • elongated band-/threadlike or nodular filling defects in dilated ducts (= depiction of mucin)
Cx: seeding to main pancreatic duct resulting in main duct IPMT
Lipoma of Liver
  • Extremely rare
  • • asymptomatic
May be associated with: tuberous sclerosis
Size: few mm–13 cm
US:
  • echogenic mass
  • striking acoustic refraction (sound velocity in soft tissue 1,540 m/sec, in fat 1,450 m/sec)
Prognosis: no malignant potential
Liver Transplant
Indication:
  • –chronic viral hepatitis: chronic active hepatitis (4% in childhood)
  • –metabolic disease: alpha-1 antitrypsin deficiency (9% in childhood), hemochromatosis, Wilson disease
  • –cholestatic liver disease: primary biliary cirrhosis, primary sclerosing cholangitis, biliary atresia (52% in childhood)
  • –autoimmune hepatitis
  • –cryptogenic cirrhosis (6% in childhood)
  • –alcoholic liver disease
  • –acute fulminant hepatic failure (11% in childhood): viral hepatitis, drug-induced hepatitis (eg, by acetaminophen, isoniazid), hepatotoxins (eg, mushrooms)
Contraindications: AIDS, extrahepatic malignant tumors, active IVDA/alcohol abuse
Normal posttransplant findings
  • Periportal edema (21%)
    Cause: lymphedema in early posttransplantation period (= dilatation of lymphatic channels due to lack of normal lymphatic drainage)
    • “periportal collar” of low attenuation on CT + hyperechogenicity on US
    • resolution within weeks to months
  • Fluid collection around falciform ligament (11%), at vascular anastomoses (liver hilum, IVC), biliary anastomosis, lesser sac
  • Small right pleural effusion
  • Peri-/subhepatic hematoma/free intraabdominal fluid
Vascular Complications in Liver Transplant (9%)
  • Most frequent cause of graft loss
  • • liver failure, bile leak, abdominal bleeding, septicemia
  • 1. Anastomotic narrowing of IVC/portal vein
    • Discrepancies in caliber between donor + recipient vessel have no pathologic significance!
    • • venous hypertension of lower part of body
    • • portal hypertension
    • narrowing of portal vein + poststenotic dilatation
    • 3–4-fold velocity increase compared with prestenotic segment
  • 2. Thrombosis/stenosis of portal vein (1–3%)
    Cause: faulty surgical technique, vessel misalignment, differences in vessel caliber creating turbulent flow, hypercoagulable state, prior portal vein surgery, prior thrombosis in recipient portal vein
    • • portal hypertension, liver failure, massive ascites, edema
    • filling defect/focal narrowing at anastomosis
    Rx: percutaneous transluminal angioplasty ± stent placement, surgical thrombectomy, venous jump graft, creation of portosystemic shunt, retransplantation
  • 3. Thrombosis/stenosis of IVC (<1%)
    • • pleural effusions, hepatomegaly, ascites, extremity edema
    • compression of IVC (due to swelling of graft)
    • size discrepancy between donor + recipient IVC
  • 4. Hepatic artery stenosis (5–13%)
    Location: at/near anastomotic site
    Time of onset: within 3 months
    • marked focal increase in velocity >200–300 cm/sec + poststenotic turbulence (in >50% stenosis)
    • P.729

    • intrahepatic tardus et parvus waveform = slowed systolic acceleration time (SAT >0.08 sec) distal to stenosis (73% sensitive)
    • diminished pulsatility (RI <0.5) due to ischemia
      DDx: normal in early post-transplantation period
    • biliary dilatation (due to stricture), infarction, biloma
    Rx: revascularization surgery, balloon angioplasty
  • 5. hepatic artery thrombosis (3–9–16% in adults, 9–19–42% in children)
    Risk factors: significant caliber difference between donor + recipient artery, preexisting celiac artery stenosis, prolonged cold ischemia of donor liver, ABo blood type incompatibility, rejection
    Time of onset: usually within first 2 months
    • • Three types of clinical presentation:
      • fulminant hepatic necrosis + rapid deterioration
      • bile leak, bile peritonitis, bacteremia, sepsis
      • relapsing bacteremia
    • absence of hepatic artery flow
      False-positive Doppler (10%):
      • low flow state, small vessel size, severe liver edema (in first 72 hours after transplantation, viral hepatitis, rejection)
      False-negative Doppler: arterial collaterals
    • multiple hypoechoic lesions in liver periphery (= infarcts)
    Mortality: 27-58%
  • 6. hepatic artery pseudoaneurysm (uncommon)
    Location: at vascular anastomosis
    Cx: massive intraperitoneal hemorrhage, portal vein fistula, biliary fistula
    Rx: surgical resection, embolization, exclusion by stent placement
Parenchymal Complications in Liver Transplant
  • Rejection
    • Can ONLY be diagnosed with liver biopsy!
  • Infarction (10%)
    • may calcify
    • may liquefy developing into intrahepatic biloma
  • Graft infection
Biliary Complications in Liver Transplant (6-34%)
  • Second most common cause of liver dysfunction after rejection
Time of onset: within first 3 months
  • Biliary obstruction
    • anastomotic stricture (extrahepatic)
      Cause: iatrogenic trauma resulting in ischemia + scar formation
    • nonanastomotic (intrahepatic) stricture
      Cause: hepatic arterial thrombosis/stenosis (in 50%), prolonged preservation time, bacterial/viral cholangitis, rejection, recurrent primary sclerosing cholangitis, cholangiocarcinoma, kinking of redundant CBD, sphincter of oddi dysfunction
    • tension mucocele of allograft cystic duct remnant
      Cause: ligation of cystic duct proximally + distally
    • extrinsic mass compressing ChD
    • fluid collection adjacent to ChD
    Cx: ascending cholangitis
  • Bile leak
    • T-tube exit site: 50% within 10 days
    • anastomosis of choledochocholedochostomy: 70% within 1st month
    • bile duct necrosis (hepatic artery occlusion)
      • The intrahepatic biliary epithelium is perfused solely by the hepatic artery!
    • after liver biopsy
    • common hepatic duct leak
    Incidence: 4.3-23%
  • Stone/sludge formation
    Cause: alteration in bile composition
Lymphoma of liver
  • PRIMARY LYMPHOMA (rare)
    • solid solitary mass
  • SECONDARY LYMPHOMA (common)
    • autoptic incidence of liver involvement:
      • 60% in hodgkin disease
      • 50% in non-hodgkin lymphoma
Pattern:
  • infiltrative diffuse (most common): no alteration in hepatic architecture
  • focal nodular: detectable by cross-sectional imaging
  • combination of diffuse + nodular (3%)
Detection rate (for CT, MRI): <10%
Mesenchymal Hamartoma Of Liver
  • = rare developmental cystic liver tumor
Histo: disordered arrangement of primitive fluid-filled mesenchyme, bile ducts, hepatic parenchyma; stromal/cystic predominance with cysts of a few mm up to 14 cm in size; no capsule
Age peak: 15–24 months (range from newborn to 19 years); M:F = 2:1
  • slow progressive abdominal enlargement
  • ± respiratory distress and lower extremity edema
Location: right lobe:left lobe = 6:1; 20% pedunculated
Size: 5–29 (mean 16) cm
  • grossly discernible cysts in 80%
US:
  • multiple rounded cystic areas on an echogenic background
  • may appear solidly echogenic in fetus/younger infant (with microcysts creating innumerable tissue-fluid interfaces)
CT:
  • multiple lucencies of variable size + attenuation (depending on composition of stromal versus cystic elements)
  • hemorrhage (rare)
  • enhancement of stromal component
MR:
  • varying signal intensity (varying concentrations of protein in cystic predominance type)/hypointense on T1WI (mesenchymal predominance type)
  • marked hyperintensity of cystic locules/hypointense fibrosis on T2WI
NUC:
  • one/more areas of diminished uptake on sulfur colloid scan
P.730

Angio:
  • hypovascular mass
  • may show patchy areas of neovascularity
  • enlarged irregular tortuous feeding vessels
Metastases To Gallbladder
Organ of origin: melanoma, renal cell carcinoma (late in course of disease), lymphoma (in AIDS), malignant fibrous histiocytoma
–in children: embryonal cell sarcoma, rhabdomyosarcoma
Metastases To Liver
  • Most common malignant lesion of the liver
Incidence: the liver is the most common metastatic site after regional lymph nodes; incidence of metastatic carcinoma is 20 × greater than primary carcinoma; metastases represent 22% of all liver tumors in patients with known malignancy
Organ of origin: colon (42%), stomach (23%), pancreas (21%), breast (14%), lung (13%)
  • involvement of liver + spleen typical in leukemia/lymphoma + melanoma
in children: neuroblastoma, Wilms tumor
  • hepatomegaly (70%)
  • abnormal liver enzymes (50–75%)
Location: both lobes (77%), right lobe (20%), left lobe (3%)
Number: multiple (50–98%), solitary (2%)
Size: >33% smaller than 2 cm
Enhancement characteristics compared with normal liver:
  • lesion enhancement during arterial phase (metastases are supplied by hepatic artery)
  • less enhancement during portal venous phase (metastases have a negligible portal venous supply)
  • extracellular space agents accumulate more in tumor tissue (metastases have a larger interstitial space)
NUC: 80–95% sensitivity in lesions >1.5 cm;
lesions <1.5 cm are frequently missed; sensitivity increases with metastatic deposit size, peripheral location, and use of SPECT
NECT: important for hypervascular tumors (eg, renal cell carcinoma, carcinoid, islet cell tumors), which may be obscured by CECT
CECT:
Technique:
  • optimal is bolus technique with dynamic incremental scanning; sensitivity is decreased relative to NCCT if scans are obtained during equilibrium phase of contrast administration
  • circumferential bead- or bandlike enhancement during arterial phase + peripheral washout on delayed images
  • no (35%), peripheral (37%), mixed (20%), central (8%) enhancement
  • complete isodense fill-in on delayed scans in 5% (DDx: hemangioma)
  • CT-sensitivity 88–90%; specificity 99%; lesions of approx. 1 cm can usually be detected!
CT-Angiography (most sensitive imaging modality):
Indication: patients with potentially resectable isolated liver metastases/preoperative to partial hepatectomy for detection of additional metastases (additional lesions detected in 40–55%)
  • CT arteriography = angiography catheter in hepatic artery, detects lesions by virtue of increased enhancement
  • CT arterial portography = angiography catheter in SMA, detects hypodense lesions on a background of increased enhancement of normal surroundings in portal venous phase
CT-delayed iodine scanning:
  • = CT performed 4–6 hours following administration of 60 mg iodine results in detection of additional lesions in 27%
Rx: Exclusion criteria for metastasectomy:
(1) advanced stage of primary tumor
(2) >4 metastases
(3) extrahepatic disease
(4) <30% normal liver tissue/function available after resection
Calcified Liver Metastases
Incidence: 2–3%
  • Mucinous carcinoma of GI tract (colon, rectum, stomach)
  • Endocrine pancreatic carcinoma
  • Leiomyosarcoma, osteosarcoma
  • Malignant melanoma
  • Papillary serous ovarian cystadenocarcinoma
  • Lymphoma
  • Pleural mesothelioma
  • Neuroblastoma
  • Breast cancer
  • Medullary carcinoma of the thyroid
  • Renal cell carcinoma
  • Lung carcinoma
  • Testicular carcinoma
mnemonic for mucinous adenocarcinoma: COBS
  • Colon carcinoma
  • Ovarian carcinoma
  • Breast carcinoma
  • Stomach carcinoma
Hypervascular Liver Metastases
  • Renal cell carcinoma
  • Carcinoid tumor
  • Pancreatic islet cell tumor
  • Melanoma
  • Thyroid cancer
  • Choriocarcinoma
  • Ovarian cystadenocarcinoma
  • Sarcomas
  • Pheochromocytoma
mnemonic: CHIMP
  • Carcinoid
  • Hypernephroma
  • Islet cell carcinoma
  • Melanoma
  • Pheochromocytoma
Hypovascular Liver Metastases
  • Stomach
  • Colon
  • P.731

  • Pancreas
  • Lung
  • Breast
Hemorrhagic Liver Metastases
mnemonic: CT BeComes MR
  • Colon carcinoma
  • Thyroid carcinoma
  • Breast carcinoma
  • Choriocarcinoma
  • Melanoma
  • Renal cell carcinoma
Echogenic Liver Metastases
Incidence: 25%
  • Colonic carcinoma (mucinous adenocarcinoma) 54%
  • Hepatoma 25%
  • Treated breast carcinoma 21%
Liver Metastases of Mixed Echogenicity
Incidence: 37.5%
  • Breast cancer 31%
  • Rectal cancer 20%
  • Lung cancer 17%
  • Stomach cancer 14%
  • Anaplastic cancer 11%
  • Cervical cancer 5%
  • Carcinoid 1%
Cystic Liver Metastases
  • Mucinous ovarian carcinoma
  • Colonic carcinoma
  • Sarcoma
  • Melanoma
  • Lung carcinoma
  • Carcinoid tumor
mnemonic: LC GOES
  • Leiomyosarcoma (and other sarcomas)
  • Choriocarcinoma
  • Gastric carcinoma
  • Ovarian carcinoma
  • Endometrial carcinoma
  • Small cell carcinoma
Echopenic Liver Metastases
Incidence: 37.5%
  • Lymphoma 44%
  • Pancreas 36%
  • Cervical cancer 20%
  • Lung (adenocarcinoma)
  • Nasopharyngeal cancer
Metastases To Pancreas
Frequency: 3–10% (autopsy)
Organ of origin: renal cell carcinoma (30%), bronchogenic carcinoma (23%), breast carcinoma (12%), soft-tissue sarcoma (8%), colonic carcinoma (6%), melanoma (6%)
  • solitary (78%)/multiple (17%) ovoid masses with discrete smooth margins
  • diffuse pancreatic enlargement (5%)
CECT:
  • heterogeneously (60%)/homogeneously (17%) hyperattenuating relative to pancreas
  • hypoattenuating relative to pancreas (20%)
  • isoattenuating relative to pancreas (5%)
Concomitant intraabdominal metastases to:
  • liver (36%), lymph nodes (30%), adrenal glands (30%)
DDx: ductal pancreatic adenocarcinoma (uniformly nonenhancing mass, encasement of vessels)
Milk Of Calcium Bile
  • = LIMY BILE = CALCIUM SOAP
  • = precipitation of particulate material with high concentration of calcium carbonate, calcium phosphate, calcium bilirubinate
Associated with: chronic cholecystitis + gallstone obstruction of cystic duct
  • diffuse opacification of GB lumen with dependent layering
  • usually functionless GB on oral cholecystogram
US:
  • intermediate features between sludge + gallstones
Mirizzi Syndrome
  • = extrinsic right-sided compression of common hepatic duct by large gallstone impacted in cystic duct/gallbladder neck/cystic duct remnant; accompanied by chronic inflammatory reaction
Frequently associated with: formation of fistula between gallbladder and common hepatic duct
  • • jaundice
  • cystic duct course usually parallel to CHD
  • normal CBD below level of impacted stone
  • TRIAD:
    • gallstone impacted in GB neck
    • dilatation of bile ducts above level of cystic duct
    • smooth curved segmental stenosis of CHD
Cholangiography:
  • partial obstruction of CHD due to external compression on lateral side of duct/eroding stone
DDx: lymphadenopathy, neoplasm of GB/CHD
Mucinous cystic neoplasm
  • = MACROCYSTIC ADENOMA OF PANCREAS
  • = thick-walled uni-/multilocular low-grade malignant tumor composed of large mucin-containing cystic spaces
Frequency: 10% of pancreatic cysts; 1% of pancreatic neoplasms
Mean age: 50 years (range of 20–95 years); in 50% between 40–60 years; M:F = 1:9
Path: large smooth round/lobulated multiloculated cystic mass encapsulated by a layer of fibrous connective tissue
Histo: similar to biliary and ovarian mucinous tumors; cysts lined by tall columnar, mucin-producing cells subtended by a densely cellular mesenchymal stroma (reminiscent of ovarian stroma), often in papillary arrangement, lack of cellular glycogen
(a) mucinous cystadenoma
(b) mucinous cystadenocarcinoma = stratified papillary epithelium
P.732

image
Intraductal Papillary Mucinous Tumor (IPMT)
  • All mucinous cystic neoplasms should be considered as low-grade malignant neoplasms
  • asymptomatic
  • abdominal pain, anorexia
Location: often in pancreatic tail (90%)/body, infrequently in head
  • well-demarcated thick-walled mass of 2–36 (mean, 10–12) cm in diameter
  • multi-/unilocular large cysts >2 cm with thin septa <2 mm:
    • A tumor with <6 cysts of >2 cm in diameter is in 93–95% a mucinous cystic neoplasm!
  • solid papillary excrescences protrude into the interior of tumor (sign of malignancy)
  • amorphous discontinuous peripheral mural calcifications (10–15%)
  • hypovascular mass with sparse neovascularity
  • vascular encasement and splenic vein occlusion may be present
  • great propensity for invasion of adjacent organs
US:
  • cysts may contain low-level echoes
CT:
  • internal septations may not be visualized without contrast enhancement
  • cysts with attenuation values of water; may have different levels of attenuation within different cystic cavities
  • enhancement of cyst walls
Angio:
  • predominantly avascular mass
  • cyst wall + solid components may demonstrate small areas of vascular blush + neovascularity
  • displacement of surrounding arteries + veins by cysts
Metastases:
  • round thick-walled cystic lesions in liver
Prognosis: invariable transformation into cystadenocarcinoma; 17-63% 5-year survival rate
Rx: complete surgical excision (5-year survival rate of 74-90%)
DDx:
  • Pseudocyst (most common pancreatic cyst): inflammatory changes in peripancreatic fat, pancreatic calcifications, temporal evolution, history of alcoholism, elevated levels of amylase
  • Lymphangioma/hemangioma
  • Variants of ductal adenocarcinoma:
    • mucinous colloid adenocarcinoma/ductectatic mucinous tumor of pancreas = mucin-hypersecreting carcinoma
    • papillary intraductal adenocarcinoma
    • adenosquamous carcinoma: squamous component predisposes to necrosis + cystic degeneration
    • anaplastic adenocarcinoma: lymphadenopathy + metastases at time of presentation
  • Solid and cystic papillary epithelioid neoplasm: hemorrhagic cystic changes in 20%
  • Cystic islet cell tumor: hypervascular component
  • Cystic metastases: history of malignant disease
  • Atypical serous cystadenoma: smaller tumor with greater number of smaller cysts
  • Sarcoma
  • Infection: amebiasis, Echinococcus multilocularis
image Mirizzi Syndrome
Multiple Bile Duct Hamartomas
  • = BILIARY MICROHAMARTOMAS = VON MEYENBURG COMPLEX
Incidence: 0.15-2.8% of autopsies
Etiology: failure of involution of embryonic bile ducts
Histo: cluster of proliferated bile ducts lined by single layer of cuboidal cells embedded in fibrocollagenous tissue with single ramified lumen, communication with biliary system usually obliterated
Associated with: fibropolycystic liver disease
Size: 0.1-10 mm
  • • asymptomatic
  • nonspecific imaging appearance
CT:
  • multiple scattered round/irregular hypodense lesions of up to 15 mm in diameter
  • rim of little peripheral/no enhancement
US:
  • multiple small cysts/echogenic areas (if size not resolved) up to 10 mm ± comet-tail artifact
MR:
  • hypointense on T1WI
  • iso-/slightly hyperintense on T2WI
P.733

  • hypointense after gadopentetate dimeglumine
Angio:
  • multiple areas of abnormal vascularity in form of small grapelike clusters persisting into venous phase
DDx:
  • Metastatic liver disease (more variable in size and attenuation/signal intensity)
  • Simple hepatic cysts (not as numerous or uniformly small)
  • Autosomal dominant polycystic disease (cysts usually larger and more numerous)
Multiple Endocrine Neoplasia
  • = MEN = MULTIPLE ENDOCRINE ADENOMAS (MEA)
  • = familial autosomal dominant adenomatous hyperplasia characterized by neoplasia of more than one endocrine organ
Theory: cells of involved principal organs originate from neural crest and produce polypeptide hormones in cytoplasmic granules, which allow amine precursor uptake and d ecarboxylation = APUD cells
    reminder:
Type 1 = Wermer syndrome PPP
Type 2 = Sipple syndrome (type 2A) PMP
Type 3 = Mucosal neuroma syndrome (type 2B) MPM
MEN 1 Syndrome
  • = WERMER SYNDROME
  • = autosomal dominant trait with high penetrance; M:F = 1:1
Cause: genetic defect on chromosome 11
Organ involvement (PPP):
  • Parathyroid hyperplasia (97%): multiglandular
    • primary HPT (in 95%) is usually presenting feature
  • Pancreatic islet cell tumor (30–80%):
    • Likely multiple + behaving malignant!
    • Primary cause of morbidity + mortality!
    • gastrinoma (most common type, in 50–60%)
      • • Zollinger-Ellison syndrome
      • multiple masses associated with diffuse gastric wall thickening
      • multiple duodenal microgastrinomas (<5 mm) account for >50% of gastrinomas
    • insulinoma (in 30%)
      • coexistence with gastrinomas in 10%
    • VIPoma = WDHH-syndrome (watery diarrhea, hypokalemia, hypochlorhydria)
  • Anterior pituitary gland tumor (15–30–50%):
    • nonfunctioning
    • prolactin (60%), growth hormone (<25%), adrenocorticotropic hormone (5%), TSH
      • presenting feature of the syndrome in 10%
  • Combination of parathyroid + pancreas + pituitary involvement (40%)
  • Adrenocortical hyperplasia/adenomas (up to 33–40%)
    • rarely functional
  • Carcinoid (2–5%)
    Location: thymus, bronchus, stomach (30-fold increased incidence), duodenum
  • Lipoma
  • usually asymptomatic
  • multiple facial angiofibromas (in 85–90% of MEN 1 patients)
May be associated with:
  • thyroid tumor (20%), thymoma, buccal mucosal tumor, colonic polyposis, Ménétrier disease
Screening population: <35-year old patient with HPT, ≥2 endocrine organ tumors, 1st-degree relative of MEN 1 patient
Imaging surveillance:
  • renal US + abdominal radiograph for abdominal calculi; abdominal MR for islet cell + adrenal tumors + liver mets; pituitary MR for adenoma (every 3 years)
Types of Multiple Endocrine Neoplasia
MEA Type 1 Type 2 Type 3
Pituitary adenoma +
Parathyroid adenoma + +
Medullary thyroid carcinoma + +
Pancreatic island cell tumor +
Pheochromocytoma + +
Ganglioneuromatosis +
MEN 2 Syndrome
  • = SIPPLE DISEASE = MEN Type 2A
  • = autosomal dominant cancer syndrome
Cause: genetic defect on chromosome 10
Organ involvement (PMP):
  • Parathyroid hyperplasia/neoplasia in multiple glands
    • ± hyperparathyroidism (later onset than in MEN 1)
  • Medullary carcinoma of thyroid (almost 100%)
    • serum calcitonin commonly elevated
  • Pheochromocytoma (50%): bilateral in 50%; malignant in 3% diagnosed before (in 10%)/after detection (in 17%) of medullary thyroid carcinoma
May be associated with: carcinoid tumors, Cushing disease
Screening population: all patients with medullary thyroid cancer/pheochromocytoma, 1st-degree relative of MEN 2 patient
Imaging surveillance:
  • abdominal MR for pheochromocytoma (every 3 years); MIBG scintigraphy (optional)
MEN 3 Syndrome
  • = MUCOSAL NEUROMA SYNDROME = MEN Type 2B
Cause: new mutation
Organ involvement (MPM):
  • Medullary carcinoma of thyroid
  • Pheochromocytoma
  • Mucosal neuroma = oral + intestinal neuroganglioneuromatosis
    • Mucosal neuromas are PATHOGNOMONIC
    • Usually precede the appearance of thyroid carcinoma + pheochromocytoma!
  • long slender extremities (marfanoid appearance)
  • thickened lips (due to submucosal nodules)
  • nodular deformity of tongue (mucosal neuromas of tongue often initially diagnosed by dentists)
  • prognathism
  • corneal limbus thickening
  • constipation alternating with diarrhea
P.734

  • @ GI tract
    • thickened/plaquelike colonic wall
    • chronic megacolon = dilated colon with abnormal haustral markings
    • alternating areas of colonic spasm + dilatation (rarely associated with Hirschsprung disease)
    • multiple submucosal neuromas throughout small bowel, may act as lead point for intussusception
Pancreas Divisum
  • = most common anatomic variant of pancreas due to failure of fusion of the ventral and dorsal anlage at 8th week of fetal life with main dorsal pancreatic duct (Santorini) draining through minor (accessory) papilla + ventral pancreatic duct (Wirsung) with CBD draining through major papilla
Prevalence: 4–9–14% in autopsy series; 2–8% in ERCP series; 3–7% in normal population; 12–26% in patients with idiopathic recurrent pancreatitis
Hypothesis: relative/actual functional stenosis of minor papilla predisposes to nonalcoholic recurrent pancreatitis in dorsal segment
Age: young/middle-aged adult
  • chronic relapsing pancreatitis (clinical relevance continues to be debated)
Pancreatography:
  • The ONLY reliable means for diagnosis
  • contrast injection into major papilla demonstrates CBD + only short ventral pancreatic duct with early arborization
  • contrast injection into minor papilla fills dorsal pancreatic duct
  • no communication between ventral + dorsal ducts
CT:
  • oblique fat cleft between ventral + dorsal pancreas (25%)
  • failure to see union of dorsal + ventral pancreatic ducts (rare)
Pancreatic Acinar Cell Carcinoma
  • = rare neoplasm of exocrine origin
Age: 40–81 (mean 62) years; M:F = 86:14; 87% Caucasian
  • • increased serum lipase ± amylase
  • • syndrome of elevated lipase:
    • disseminated subcutaneous + intraosseous fat necrosis (usually distal to knees/elbows)
    • polyarthropathy
    • skin lesions resembling erythema nodosum
  • • biliary obstruction distinctly uncommon
  • lobulated well-defined mass of 2–15 cm in diameter
  • thin enhancing capsule
  • tumor necrosis usually present
  • moderately vascular tumor + neovascularity + arterial and venous encasement
Prognosis: median survival of 7–9 months
DDx: (1) pancreatic adenocarcinoma (small, irregular, locally invasive, without capsule, biliary obstruction if located in head of pancreas)
(2) Nonfunctioning islet-cell tumor
(3) Microcystic cystadenoma
(4) Solid and papillary epithelial neoplasm (5) Oncocytic tumor of pancreas
Pancreatic Ductal Adenocarcinoma
  • = DUCT CELL ADENOCARCINOMA = PANCREATIC ADENOCARCINOMA
  • Duct cells comprise only 4% of pancreatic tissue!
Incidence: 95% of malignant tumors of pancreas; 5th leading cause of cancer death in the United States (27,000 per year)
Etiology: alcohol abuse (4%), diabetes (2 × more frequent than in general population, particularly in females), hereditary pancreatitis (in 40%); cigarette smoking (risk factor 2 x)
Path: scirrhous infiltrative adenocarcinoma with a dense cellularity + sparse vascularity
Peak age: 7th (range, 4th–8th) decade; M:F = 2:1
Stage I = confined to pancreas
II = + regional lymph node metastases
III = + distant spread
  • At presentation:
    • 65% of patients have advanced local disease/distant metastases
    • 21% of patients have localized disease with spread to regional lymph nodes
    • 14% of patients have tumor confined to pancreas
Extension:
  • local extension beyond margins of organ (68%): posteriorly (96%), anteriorly (30%), into porta hepatis (15%), into splenic hilum (13%)
  • invasion of adjacent organs (42%):
    • duodenum > stomach > left adrenal gland > spleen > root of small bowel mesentery
  • local lymph node spread:
    • pancreaticosplenic nodes accompanying splenic a., pancreaticoduodenal nodes, superior mesenteric preaortic nodes
Metastases: liver (30–36%), regional lymph nodes >2 cm (15–28%), ascites from peritoneal carcinomatosis (7–10%), lungs (pulmonary nodules/lymphangitic), pleura, bone
  • • weight loss, anorexia, fatigue
  • • pain in hypochondrium radiating to back
  • • obstructive jaundice (75%):
    • Most frequent cause of malignant biliary obstruction
    • • painless jaundice (25%)
  • • acute onset diabetes (25–50%), steatorrhea
  • • hyperamylasemia
  • • spontaneous vein thrombosis (Trousseau syndrome)
Location: pancreatic head (60%); body (15%); tail (5%); diffuse involvement (20%)
Size: 2–10 cm (in 60% between 4–6 cm)
UGI:
  • “antral pad sign” = extrinsic indentation of the posteroinferior margin of antrum
  • “Frostberg inverted-3” sign = inverted 3 contour to the medial portion of the duodenal sweep
  • spiculated duodenal wall + traction + fixation (neoplastic infiltration of duodenal mucosa/desmoplastic response)
  • irregular/smooth nodular mass with ampullary carcinoma
BE:
  • diffuse tethering throughout peritoneal cavity (from intraperitoneal seeding)
  • P.735

  • localized haustral padding/flattening/narrowing with serrated contour at inferior aspect of transverse colon/splenic flexure
CT (75–96% detection rate for dynamic CT scan):
  • hypovascular lesion best depicted during parenchymal/portal venous phase (11% not visualized)
  • pancreatic mass (95%)/diffuse enlargement (4%)/normal scan (1%)
  • mass with central zone of diminished attenuation (75–83%)
  • indirect signs:
    • convex deformity of pancreatic contour
    • “double-duct sign” = pancreatic + bile duct obstruction without detectable mass (4%)
    • duct dilatation (58%): 3/4 biductal, 1/10 isolated to one duct; dilated pancreatic duct (67%); dilated bile ducts (38%)
    • atrophy of pancreatic body + tail (20%)
  • calcifications (2%)
  • postobstructive pseudocyst (11%)
  • obliteration of peripancreatic fat (50%) = pancreas lacks a capsule
  • vascular invasion:
    • thickening of celiac axis/SMA (invasion of perivascular lymphatics) in 60%
    • dilated collateral veins (12%)
    • high probability of unresectability if circumferential contiguity of tumor to vessel >50% (84% sensitive, 98% specific)
  • thickening of Gerota fascia (5%)
  • local tumor extension posteriorly, into splenic hilum, into porta hepatis (68%)
  • contiguous organ invasion (duodenum, stomach, mesenteric root) in 42%
  • hepatic metastases (75% sensitive)
US:
  • hypoechoic pancreatic mass
  • focal/diffuse (10%) enlargement of pancreas
  • contour deformity of gland; rounding of uncinate process
  • dilatation of pancreatic ± biliary duct
MR (no diagnostic improvement over CT; valuable in evaluation of an enlarged pancreatic head):
  • hypointense lesion on T1WI (accentuated on fat-suppressed images)
  • hypovascular lesion during capillary phase compared with surrounding pancreas (due to desmoplastic fibrotic component)
  • lesion enhancement >1 minute after contrast injection (due to desmoplasia with large interstitial spaces)
  • abnormally low signal intensity of pancreatic tail + body (due to atrophy/secondary chronic pancreatitis) on T1WI reducing the contrast relative to focal cancer
Angiography (70% accuracy):
  • hypovascular tumor/neovascularity (50%)
  • arterial encasement: SMA (33%), splenic artery (14%), celiac trunk (11%), hepatic artery (11%), gastroduodenal artery (3%), left renal artery (0.6%)
  • venous obstruction: splenic vein (34%), SMV (10%)
  • venous encasement: SMV (23%), splenic vein (15%), portal vein (4%)
Cholangiography:
  • “rat tail/nipplelike” occlusion of CBD
  • nodular mass/meniscuslike occlusion in ampullary tumors
  • double duct sign = abrupt obstruction of common bile + pancreatic duct
Pancreatography (abnormal in 97%):
  • irregular, nodular, rat-tailed, eccentric obstruction
  • localized encasement with prestenotic dilatation
  • acinar defect
Prognosis:
  • 10% 1-year survival, 2% 3-year survival, <1% 5-year survival; 14 months medial survival after curative resection, 8 months after palliative resection, 5 months without treatment; tumors resectable in only 8-15% at presentation, 5% 5-year survival rate after surgery
Survival rate & tumor size:
  • 100% 5-year survival rate for tumors <1 cm without parenchymal/vascular/lymphatic invasion; 30% for tumors <2 cm
DDx: focal pancreatitis, islet cell carcinoma, metastasis, lymphoma, normal variant
Pancreatic Islet Cell TUmors
Origin: embryonic neuroectoderm, derivatives of APUD (amine precursor uptake and decarboxylation) cell line arising from islet of Langerhans (APUDoma)
Prevalence: 1-5:1,000,000 population/year; isolated or part of MEN I syndrome (= Wermer syndrome)
Path: (a) small tumor: solid well-demarcated
(b) large tumor: cystic changes + necrosis + calcifications
In order of frequency: insulinoma > gastrinoma > glucagonoma > VIPoma > somatostatinoma
Histo: sheets of small round cells + numerous stromal vessels
Average time from onset of symptoms to diagnosis is 2.7 years
Classification:
  • functional (85%)
    • tumors small at presentation as a result of symptoms
  • nonfunctional (15%) below threshold of detectability/hypofunctional
    • tumors large at presentation
Metastases: in 60-90% to liver ± regional lymph nodes
  • Liver metastasis often hypervascular with enhancement during arterial phase
  • hyperechoic liver metastasis is suggestive of islet cell tumor rather than pancreatic adenocarcinoma!
  • marked enhancement on immediate images (hypervascularity)
  • marked enhancement on delayed images (large interstitial space with loose edematous stroma + abundant blood vessels)
  • No vascular encasement/duct obstruction
  • calcifications + large size highly suggestive of malignancy
US:
  • transabdominal US (70% sensitive)
  • endoscopic US (nearly 95% sensitive, 93% specific), less sensitive for distal pancreatic body + tail
  • intraoperative US (combined with palpation by surgeon)
  • homogeneous hypoechoic mass
CT (71-82% sensitive)
  • Tumors often small (<20 mm) and multiple + difficult to detect
  • P.736

  • isoattenuating tumor at NECT
  • avid enhancement in arterial phase
  • tumor may be cystic/hypoattenuating (rare)
MR:
  • low signal intensity on T1WI
  • high signal intensity on moderately T2WI
  • intense enhancement on arterial-phase postcontrast images
  • hypervascular liver metastases
NUC (70–90% sensitive, only 50% sensitive for gastrinomas + insulinomas)
  • Somatostatin Receptor Scintigraphy with Indium-111 octreotide
    • whole-body scintigraphy detects tumors >10 mm in size
    • predicts which patients will respond to radionuclide therapy
    • monitors response to therapy
Hepatic venous sampling (88% sensitive):
  • performed together with pancreatic angiography
  • rise in venous hormone concentration after selective injection of secretagogue (eg, calcium) into arteries supplying the pancreas
Prognosis: 50% 5-year survival rate
DDx: (1) Pancreatic ductal adenocarcinoma (hypovascular, smaller, encasement of SMA + celiac trunk)
(2) Microcystic adenoma (benign tumor, small cysts, older women)
(3) Metastatic tumor: renal cell carcinoma (clinical Hx)
(4) Solid and papillary epithelial neoplasm (young female, hemorrhagic areas)
(5) Paraganglioma (6) Sarcoma (rare)
ACTH-producing Tumor
  • = Corticotrophinoma
  • rare cause of Cushing syndrome
  • • increased level of serum cortisol
  • • impaired glucose tolerance > central obesity > hypertension, oligomenorrhea > osteoporosis > purpura > striae > muscle atrophy
Prognosis: almost all malignant with metastases at time of diagnosis
Gastrinoma
  • 2nd most common islet cell tumor
Age: 8% in patients <20 years; M > F
Histo: in αcells/δ cells
Path: (a) islet cell hyperplasia (10%)
(b) benign adenoma (30%): in 50% solitary, in 50% multiple (especially in MEN 1)
(c) malignant (50–60%) with metastases to liver, spleen, lymph nodes, bone
Associated with: MEN 1 (in 50–60%); the most common islet cell tumor in MEN 1
  • • Zollinger-Ellison syndrome: severe recurrent peptic ulcer disease (>90%), malabsorption, hypokalemia, gastric hypersecretion, hyperacidity/occasionally hypoacidity, diarrhea (from gastric hypersecretion)
    • Only 1:1,000 patients with peptic ulcer disease has a gastrinoma!
  • • epigastric pain (recurrent/intractable peptic ulcer disease)
  • • GI bleeding
  • • elevated serum levels of gastrin (DIAGNOSTIC)
    Location: usually multiple
    • 87% in pancreas (50% solitary in head/tail)
    • ectopic (7–33%):
      • duodenal wall (13% in medial wall of duodenum = gastrinoma triangle)
      • peripancreatic nodes/spleen
      • stomach, jejunum
      • omentum, retroperitoneum
      • ovary
    • frequently in “gastrinoma triangle” (= triangle defined by porta hepatis as apex of triangle + 2nd and 3rd parts of duodenum as the base)
  • ulcer in unusual location, eg, postbulbar
  • average tumor size 3.4 cm (up to 15 cm)
  • occasionally calcifications
  • homogeneous hypoechoic mass
Angio:
  • hypervascular lesion (70%)
  • hepatic venous sampling after intraarterial stimulation with secretin
CT:
  • transiently hyperdense on dynamic CT (majority)
  • thickening of gastric rugal folds
MR:
  • low-intensity mass on fat-suppressed T1WI
  • diminished central + peripheral ring enhancement
  • high-intensity mass on fat-suppressed T2WI
Sensitivity of preoperative localization:
  • 25% for US, 35% for CT, 20% for MRI, 42–63% for transhepatic portal venous sampling for gastrin, 68–70% for selective angiography, 77% for arteriography combined with intra-arterial injection of secretin
Rx: surgery curative in 30%
Cx: frequently malignant degeneration (liver metastases at time of diagnosis in 30%)
Glucagonoma
Incidence: uncommon tumor
Age: middle age; M < F
Histo: derived from α± cells
Associated with: MEN
  • • necrolytic erythema migrans (erythematous macules/papules on genitals, lower extremity, groin, buttocks, face) in >70% of patients
  • • 4D syndrome = dermatosis, diarrhea, depression, deep vein thrombosis
  • • painful glossitis/stomatitis, weight loss, anemia
  • • plasma glucagon level > 1,000 ng/L (DIAGNOSTIC);
  • ± diabetes mellitus due to elevated glucagon
  • • ± elevation of insulin, serotonin, gastrin
    Location: predominantly in pancreatic body/tail
  • tumor size 2.5–25 cm (mean 6.4 cm) with solid + necrotic components (in 70% >5 cm in size)
  • hypervascular in 90%; successful angiographic localization in 15%
Cx: deep vein thrombosis + pulmonary embolism
Prognosis: in 60–80% malignant transformation (liver metastases at time of diagnosis in 50–60%); 55% 5-year survival rate
P.737

Insulinoma
  • Most common syndromic islet cell tumor!
Age: 4th–6th decade; M:F = 2:3
Associated with: MEN type I (in 10%)
Path: (a) single benign adenoma (80–90%)
(b) multiple adenomas/microadenomatosis (5–10%)
(c) islet cell hyperplasia (5–10%)
(d) malignant adenoma (5–10%)
  • Whipple triad: starvation attack + hypoglycemia (fasting glucose <50 mg/dL) + relief by IV dextrose
  • • elevated levels of plasma insulin
  • • neuroglycopenic symptoms: headaches, confusion, coma
  • • hypoglycemia exacerbated by fasting results in frequent meals to avoid symptoms
  • • sweating, palpitations, tremor (secondary to catecholamine release in response to hypoglycemia)
  • • obesity
  • • firm rubbery palpable mass at surgery (in >90%)
    Location: no predilection for any part of pancreas,
    2–5% in ectopic location; 10% multiple
    memonic: 10% are associated with MEN 1;
    10% are multiple (especially in MEN 1)
    10% have islet cell hyperplasia;
    10% are malignant
  • average tumor size 1–2 cm; <1.5 cm in 70%
US (20–75% preoperative and 75–100% endoscopic + intraoperative sensitivity):
  • round/oval smoothly marginated solid homogeneously hypoechoic mass
Angio:
  • hypervascular tumor (66%): accurate angiographic localization in 50–90%
  • transhepatic portal venous sampling (correct localization in 95%)
  • hepatic venous sampling after intraarterial stimulation with calcium gluconate
CECT (30–75% sensitivity):
  • hypo-/iso-/hyperattenuating lesion
MR:
  • low signal intensity on fat-suppressed T1WI
  • hyperintense on T2WI + dynamic contrast-enhanced + suppressed inversion recovery images
  • tumors >2 cm show ring enhancement
Prognosis: malignant transformation in 5–10%
Rx: surgery curative
Nonfunctioning Islet Cell Tumor
  • = Nonsyndromic ICT
  • 3rd most common islet cell tumor!
Incidence: 15–25–50% of all islet cell tumors
Histo: derived from either α or βcells
Age: 24–74 (mean 57) years
  • mostly asymptomatic (= tumors may be hormonally active but without clinical evidence of hormone production)
  • abdominal pain, jaundice, gastric variceal bleeding
  • palpable mass, gastric outlet obstruction
Location: predominantly in pancreatic head
  • tumor size 6–20 cm (>5 cm in 72%) with solid + necrotic components
  • coarse nodular calcifications (20–25%)
  • CT contrast enhancement in 83%
  • hypoechoic mass
  • late dense capillary stain
  • large irregular pathologic vessels with early venous filling
Prognosis: in 80–100% malignant transformation with metastases to liver + regional nodes; 60% 3-year survival; 44% 5-year survival
Rx: may respond to systemic chemotherapy
Somatostatinoma
Origin: derived from δ cells
Incidence: fewer than 200 cases reported in literature
May be associated with: NF 1
  • • inhibitory syndrome = inhibitory action of somatostatin on other pancreatic + bowel peptides (growth hormone, TSH, insulin, glucagon, gastric acid, pepsin, secretin)
  • • diabetes, cholelithiasis, steatorrhea, hypochlorhydria
  • • elevated plasma level of somatostatin (DIAGNOSTIC)
    Location: predominantly in pancreatic head/duodenum at ampulla of Vater
  • tumor size 0.6–20 cm (average >4 cm)
  • hypervascular
  • obstruction of duodenum
Prognosis: 50–90% malignant transformation; metastatic disease to liver/lymph nodes in 50–70% at time of initial diagnosis
VIPoma
  • = solitary tumor liberating Vasoactive Intestinal Peptide acting directly on cyclic adenosine monophosphate (AMP) within epithelial cells of bowel relaxing vascular smooth muscle + causing electrolyte secretion; sporadic occurrence
Histo: adenoma/hyperplasia; M:F = 1:2
  • WDHA syndrome = watery diarrhea + hypokalemia + achlorhydria (VIP inhibits gastrin poroduction);
    • more recently + more accurately described as:
  • WDHH syndrome = watery diarrhea + hypokalemia + hypochlorhydria = “pancreatic cholera” = Verner-Morrison syndrome
  • • dehydration due to massive diarrhea (>1 L/day)
Location:
  • pancreas: from δ cells predominantly in pancreatic body/tail (75%)
  • extrapancreatic: retroperitoneal ganglioblastoma, pheochromocytoma, lung, neuroblastoma (in children)
  • average size 5–10 cm with solid + necrotic tissue
  • mostly hypervascular tumor
  • dilatation of gallbladder
Prognosis: in 50–80% malignant transformation
DDx: small cell carcinoma of lung/neuroblastoma may also cause WDHH syndrome
Pancreatic Lipomatosis
  • = FATTY REPLACEMENT = FATTY INFILTRATION
  • = deposition of fat cells in pancreatic parenchyma
Predisposing factors:
  • Atherosclerosis of elderly
  • Obesity
  • Steroid therapy
  • Diabetes mellitus
  • P.738

  • Cushing syndrome
  • Chronic pancreatitis
  • Main pancreatic duct obstruction
  • Cystic fibrosis (most common cause in childhood)
  • Malnutrition/dietary deficiency
  • Hepatic disease
  • Hemochromatosis
  • Viral infection
  • Schwachman-Diamond syndrome
  • Johanson-Blizzard syndrome
  • fatty replacement often uneven:
    • increase in AP diameter of pancreatic head with focal fatty replacement = lipomatous pseudohypertrophy
  • prominently lobulated external contour
US:
  • increased pancreatic echogenicity
CT:
  • “marbling” of pancreatic parenchyma/total fatty replacement/lipomatous pseudohypertrophy
Pancreatic Fatty Sparing
  • = sparing of fatty change in pancreatic head + uncinate process (ventral pancreatic anlage) as initial stage in pancreatic lipomatosis
Histo: ventral pancreatic anlage has smaller + more densely packed acini with scanty/absent interacinar fat
US:
  • rounded/triangular hypoechoic area within pancreatic head/uncinate process + diffusely increased echogenicity in remainder of gland
CT:
  • higher-density region of pancreatic head + uncinate process with diffusely decreased attenuation of pancreatic body + tail
Pancreatic Pseudocyst
  • = collection of pancreatic fluid encapsulated by fibrous tissue
Etiology: (1) Acute pancreatitis; requires >4 weeks to form; pseudocysts mature in 6–8 weeks
(2) Chronic pancreatitis
(3) Posttraumatic
(4) Pancreatic cancer
Incidence: 2–4% in acute pancreatitis;
10–15% in chronic pancreatitis
Location: 2/3 within pancreas
Atypical location (may dissect along tissue planes in 1/3):
  • intraperitoneal: mesentery of small bowel/transverse colon/sigmoid colon
  • retroperitoneal: along psoas muscle; may present as groin mass/in scrotum
  • intraparenchymal: liver, spleen, kidney
  • mediastinal (through esophageal hiatus > aortic hiatus > foramen of Morgagni > erosion through diaphragm): may present as neck mass
May communicate with: duodenum, stomach, spleen
Plain film/contrast radiograph:
  • smooth extrinsic indentation of posterior wall of stomach/inner duodenal sweep (80%)
  • indentation/displacement of splenic flexure/transverse colon (40%)
  • downward displacement of duodenojejunal junction
  • gastric outlet obstruction
  • splaying of renal collecting system/ureteral obstruction
US (pseudocyst detectable in 50-92%; 92-96% accuracy):
  • usually single + unilocular cyst
  • multilocular in 6%
  • fluid-debris level/internal echoes (may contain sequester, blood clot, cellular debris from autolysis)
  • septations (rare; sign of infection/hemorrhage)
  • may increase in size (secondary to hypertonicity of fluid, communication with pancreatic duct, hemorrhage, erosion of vessel)
  • obstruction of pancreatic duct/CBD
CT:
  • fluid in pseudocyst (0-30 HU)
  • cyst wall calcification (extremely rare)
Pancreatography:
  • communication with pancreatic duct in up to 50-70%
Indications for pseudocyst drainage:
  • pain, suspected infection, persistence of pseudocyst >5 cm, increasing size, biliary/gastrointestinal obstruction
Cx (in 40%):
  • Rupture into abdominal cavity, stomach, colon, duodenum
  • hemorrhage/formation of pseudoaneurysm
  • Infection = pancreatic abscess
    • • usually occurs >4 weeks after acute pancreatitis
    • • symptomatology of infection
    • gas bubbles (DDx: fistulous communication to GI tract)
    • increase in attenuation of fluid contents
    Dx: transcutaneous needle aspiration
  • Intestinal obstruction
Prognosis: spontaneous resolution (in 20–50%) secondary to rupture into GI tract/pancreatic/bile duct
DDx: pancreatic cystadenoma, cystadenocarcinoma, necrotic pancreatic carcinoma, fluid-filled bowel loop, fluid-filled stomach, duodenal diverticulum, aneurysm
Pancreatic Transplantation
Complications: sepsis, rejection, pancreatitis, pseudocyst, pancreatic abscess (22%), anastomotic leak
Prognosis: 40% survival rate >1 year
Graft-vessel thrombosis in pancreatic transplant (2-19%)
  • Early thrombosis (<1 month after transplantation)
    Cause: technical error in fashioning anastomosis, microvascular damage due to preservation injury
  • Late thrombosis (>1 month after transplantation)
    Cause: alloimmune arteritis with gradual occlusion of small blood vessels
Acute Rejection of Pancreatic Transplant
  • focal tenderness over transplant
  • measurement of urinary + serum amylase, blood glucose (nonspecific for diagnosis of rejection)
US:
  • poor margination of transplant
  • acoustic inhomogeneity
  • dilated pancreatic duct
P.739

image
Pancreatic Transplantation
Pancreatitis
Cause:
  • IDIOPATHIC (20%)
  • ALCOHOLISM (25%): acute pancreatitis (15%); chronic pancreatitis (70%)
  • CHOLELITHIASIS (50–70%): acute pancreatitis (75%); chronic pancreatitis (20%)
  • METABOLIC DISORDERS
    • Hypercalcemia in hyperparathyroidism (10%), multiple myeloma, amyloidosis, sarcoidosis
    • Hereditary pancreatitis: autosomal dominant, only Caucasians affected, most common cause of large spherical pancreatic calcifications in childhood (in 50%), recurrent episodes of pancreatitis, development into pancreatic carcinoma in 20–40%; pronounced dilatation of pancreatic duct; pseudocyst formation (50%); associated with type I hypercholesterolemia
    • Hyperlipidemia types I and V
    • Cystic fibrosis
  • INFECTION/INFESTATION
    • Viral infection (mumps, hepatitis, Coxsackie virus, mononucleosis)
    • Parasites (ascariasis, clonorchis)
  • TRAUMA
    • One of the most common causes of pancreatitis in childhood!
    • Penetrating ulcer
    • Blunt/penetrating trauma; nonaccidental trauma
    • Surgery (in 0.8% of Billroth-II resections, 0.8% of splenectomies, 0.7% of choledochal surgery, 0.4% of aortic graft surgery)
  • STRUCTURAL ABNORMALITIES
    • Pancreas divisum
      • In 12–50% of cases with no other underlying abnormalities
    • Choledochocele
  • DRUGS
    • Azathioprine, thiazide, furosemide, ethacrynic acid, sulfonamides, tetracycline, phenformin, steroids (eg, renal transplant), l-asparaginase, acetaminophen, procainamide
  • MALIGNANCY
    • Pancreatic carcinoma (in 1%), metastases, lymphoma
  • MULTISYSTEM CONDITIONS
    • Sepsis and shock
    • Hemolytic-uremic syndrome
    • Reye syndrome
    • Systemic lupus erythematosus
Theories of pathogenesis:
  • reflux of bile/pancreatic enzymes/duodenal succus
  • (a) terminal duct segment shared by common bile duct + pancreatic duct
  • (b) obstruction at papilla of Vater from inflammatory stenosis, edema/spasm of sphincter of Oddi, tumor, periduodenal diverticulum
  • (c) incompetent sphincter of Oddi
Acute Pancreatitis
  • = inflammatory disease of pancreas producing temporary changes with potential for restoration of normal anatomy + function following resolution
Path:
  • INTERSTITIAL EDEMATOUS PANCREATITIS (75–95%): edema, congestion, leukocytic infiltrates; mortality rate of 4%
  • NECROTIZING PANCREATITIS (5–25%):
    • proteolytic destruction of pancreatic parenchyma; mortality rate of 80–90%
    • (a) HEMORRHAGIC PANCREATITIS:
      • + fat necrosis and hemorrhage (due to erosion of small vessels)
      • • falling hematocrit
    • (b) SUPPURATIVE PANCREATITIS:+ bacterial infection
Clinical stages:
  • I = EDEMATOUS PANCREATITIS (75%)
    • rapid improvement following conservative Rx
    • gradual decrease of elevated enzymes
    Mortality: 1–5%
  • II = PARTIALLY NECROTIZING PANCREATITIS
    • delayed/no response to conservative Rx
    • delayed/no normalization of enzymes:
      • hyperglycemia of <200 mg/100 mL
      • hypocalcemia of >4 mval/L
      • base deficit of <4 mval/L
    • leukocytosis of <16,000
    Mortality: 30–75%
  • P.740

  • III = TOTALLY NECROTIZING PANCREATITIS
    • deterioration under conservative therapy:
      • hyperglycemia of >200 mg/100 mL
      • hypocalcemia of <4 mval/L
      • base deficit of >4 mval/L
      • leukocytosis of >16,000
Mortality: 100% (40% by 2nd day, 75% by 5th day, 100% by 10th day)
  • acute epigastric pain radiating to back/chest (peaking after a few hours, resolving in 2–3 days)
  • nausea, vomiting
  • raised pancreatic amylase + lipase in blood + urine
  • increased amylase-creatinine clearance ratio
  • signs of hemorrhagic pancreatitis:
    • Cullen sign = periumbilical ecchymosis
    • Grey-Turner sign = flank ecchymosis
    • Fox sign = infrainguinal ecchymosis
  • subcutaneous nodules + fat necrosis + polyarthritis
Distribution:
  • Diffuse pancreatitis (52%)
  • Focal pancreatitis (48%):
    • location of head:tail = 3:2
  • NO findings on US/CT in 29%
Abdominal film:
  • “colon cutoff” sign (2–52%) = dilated transverse colon with abrupt change to a gasless descending colon (inflammation via phrenicocolic ligament causes spasm + obstruction at the splenic flexure impinging on a paralytic transverse colon)
  • “sentinel loop” (10–55%) = localized segment of gas-containing bowel in duodenum (in 20–45%)/terminal ileum/cecum
  • “renal halo” sign = water-density of inflammation in anterior pararenal space contrasts with perirenal fat; more common on left side
  • mottled appearance of peripancreatic area (secondary to fat necrosis in pancreatic bed, mesentery, omentum)
  • intrapancreatic gas bubbles (from acute gangrene/suppurative pancreatitis)
  • “gasless abdomen” = fluid-filled bowel associated with vomiting
  • ascites
CXR (findings in 14–71%):
  • pleural effusion (in 10–20%), usually left-sided, with elevated amylase levels (in 85%)
  • left-sided diaphragmatic elevation
  • left-sided subsegmental atelectasis (20%)
  • parenchymal infiltrates, pulmonary infarction
  • pulmonary edema, ARDS
  • pleural empyema, pericardial effusion
  • mediastinal abscess, mediastinal pseudocyst
  • pancreatico-bronchial/-pleural/-pulmonary fistula
UGI:
  • esophagogastric varices (from splenic vein obstruction)
  • enlarged tortuous edematous rugal folds along antrum + greater curvature (20%)
  • widening of retrogastric space (from pancreatic enlargement/inflammation in lesser sac)
  • diminished duodenal peristalsis + edematous folds
  • widening of duodenal sweep + downward displacement of ligament of Treitz
  • Poppel sign = edematous swelling of papilla
  • Frostberg inverted-3 sign = segmental narrowing with fold thickening of duodenum
  • jejunal + ileal fold thickening (proteolytic spread along mesentery)
BE:
  • narrowing, nodularity, fold distortion along inferior haustral row of transverse colon ± descending colon
Cholangiography:
  • long gently tapered narrowing of CBD
  • prestenotic biliary dilatation
  • smooth/irregular mucosal surface
Bone films (findings in 6%):
Cause: metastatic intramedullary lipolysis + fat necrosis + trabecular bone destruction
Time of onset: usually 3–6 weeks after peak of clinical pancreatitis
  • punched out/permeative mottled destruction of cancellous bone + endosteal erosion
  • aseptic necrosis of femoral/humeral heads
  • metaphyseal infarcts, predominantly in distal femur + proximal tibia
US (pancreatic visualization in 62–78%):
  • hypoechoic diffuse/focal enlargement of pancreas
  • dilatation of pancreatic duct (if head focally involved)
  • perivascular cloaking = spread of inflammatory exudate along perivascular spaces
  • extrapancreatic hypoechoic mass with good acoustic transmission (= phlegmonous pancreatitis)
  • fluid collection: lesser sac (60%), L > R anterior pararenal space (54%), posterior pararenal space (18%), around left lobe of liver (16%), in spleen (9%), mediastinum (3%), iliac fossa, along transverse mesocolon/mesenteric leaves of small intestine
    • Fate of fluid collection:
      • complete resolution
      • pseudocyst formation
      • bacterial infection = abscess
  • pseudocyst formation (52%): extension into lesser sac, transverse mesocolon, around kidney, mediastinum, lower quadrants of abdomen
CT (pancreatic visualization in 98%):
  • no detectable change in size/appearance (29%)
  • enlargement of pancreas with convex margins + indistinctness of gland + parenchymal heterogeneity:
    • hypodense (5–20 HU) mass in phlegmonous pancreatitis; may persist long after complete recovery
    • hyperdense areas (50–70 HU) in hemorrhagic pancreatitis for 24–48 hours
  • thickening of anterior pararenal fascia
  • “halo sign” = sparing of perirenal space
  • non–contrast-enhancing parenchyma during bolus injection (= pancreatic necrosis)
  • fluid collection
Angiography:
  • may be normal
  • hypovascular areas (15–56%)
  • hypervascularity + increased parenchymal stain (12–45%)
  • P.741

  • venous compression secondary to edema
  • formation of pseudoaneurysms (in 10% with chronic pancreatitis): splenic artery (50%), pancreatic arcades, gastroduodenal artery
Cx:
  • Phlegmon (18%)
  • Pseudocyst formation (10%)
  • Hemorrhagic pancreatitis (2–5%)
  • Abscess (2–10%)
  • Pancreatic ascites
  • Biliary duct obstruction
  • Thrombosis of splenic vein/SMV
  • Pseudoaneurysm
    • rupture into preexisting pseudocyst
    • digestion of arterial wall by enzymes
    Incidence: in up to 10% of severe pancreatitis
    Location: splenic artery (most common), gastroduodenal, pancreatico-duodenal, hepatic, left gastric artery
    Mortality: 37% for rupture, 16–50% for surgery
  • Thoracopancreatic fistula
    • pancreaticopleural fistula
    • pancreaticopericardial fistula
    • pancreaticoesophageal fistula
    • pancreaticobronchial fistula
    • mediastinal pseudocyst
Rx:
  • Conservative (NPO, gastric tube, atropine, analge-sics, sedation, prophylactic antibiotics) for stage I
  • Early surgery in stages II and III
Mild Acute Pancreatitis (75%)
  • minimal organ dysfunction
Path: interstitial edema
Prognosis: improvement within 48–72 hours following conservative therapy with gradual decrease of elevated enzymes
Mortality: 1–5%
Severe Acute Pancreatitis
  • Develops shortly after onset of untreated mild acute pancreatitis
  • • increased abdominal tenderness, rebound distension, hypoactive bowel sounds
Associated with: organ failure/local complications
Path: pancreatic cell breakdown + necrosis
Cx: acute fluid collection, pancreatic necrosis, pseudocyst, abscess
Acute Fluid Collections (30–50%)
  • = early form of acute pseudocyst/pancreatic abscess
Path: lack of a defined wall of fibrous/granulation tissue; pancreatic phlegmon [misnomer, no infection] = solid boggy inflammatory mass characterized by edema, infiltration of inflammatory cells + necrosis of retroperitoneal fat
Location: extension into lesser sac, anterior pararenal space, transverse mesocolon, small bowel mesentery, retroperitoneum, pelvis
  • near 0 HU on CT
Prognosis: spontaneous regression (in 40–50%)
Pancreatic Necrosis
  • = focal/diffuse area of nonviable pancreatic parenchyma
Path: clumps of devitalized pancreatic parenchyma + hemorrhage in pancreatic and peripancreatic tissues
Histo: extensive interstitial fat necrosis with vessel damage + necrosis of acinar cells, islet cells, ductal system
Associated with: peripancreatic fat necrosis
  • focal/diffuse well-marginated zones of unenhanced pancreatic parenchyma > 3 cm/involving >30% of the pancreatic gland
Acute Pseudocyst
  • = collection of pancreatic fluid enclosed by a wall of fibrous/granulation tissue
Path: absence of epithelium-lined wall
Cause: acute pancreatitis, pancreatic trauma, chronic pancreatitis
Time of onset: >4 weeks after acute pancreatitis
  • amylase-rich fluid
Prognosis: persistent pseudocyst usually communicates with pancreatic duct; spontaneous resolution in 44%; <4 cm: resolution anticipated; >7 cm: treatment recommended
Cx: hemorrhage, infection; spontaneous rupture into hollow viscera
PANCREATIC ABSCESS
  • = well-demarcated fluid collection of pus usually close to the pancreas
Time of onset: 2-4 weeks after severe acute pancreatitis
Organism: most commonly due to E. coli
  • • liquefied tissue with little/no necrosis
  • may contain gas within pancreatic bed in 30-50% (DDx of gas: cutaneous/enteric fistula, ruptured duodenum, iatrogenic gas collection)
DDx: infected necrosis
Chronic Pancreatitis
  • = continued inflammatory disease of pancreas characterized by scarring with irreversible permanent damage to anatomy
    • + function primarily of the exocrine pancreas
Incidence: 4:100,000 (in Western countries)
Etiology:
  • UNKNOWN CAUSE (20%)
  • CHRONIC CALCIFYING PANCREATITIS
    • Alcoholism (70%)
    • Juvenile tropical pancreatitis = Kwashiorkor: in equatorial third-world countries, associated with pure protein malnutrition, patients present with diabetes + chronic abdominal pain
    • hereditary pancreatitis
    • Inborn errors of metabolism
    • hyperlipidemia
    • hypercalcemia
  • CHRONIC OBSTRUCTIVE PANCREATITIS
    P.742

    • acute exacerbation of epigastric pain (93%): decreasing with time due to progressive destruction of gland, usually painless after 7 years
    • jaundice (42%) from common bile duct obstruction
    • steatorrhea (80%)
    • diabetes mellitus (58%)
    • secretin test with decreased amylase + bicarbonate in duodenal fluid
Plain film:
  • numerous irregular calcifications (in 20–50% of alcoholic pancreatitis) PAThoGNoMoNIC
UGI:
  • displacement of stomach/duodenum by pseudocyst
  • shrinkage/fold induration of stomach (DDx: linitis plastica)
  • stricture of duodenum
Cholangiopancreatography (most sensitive imaging modality):
  • side-branch ectasia = slight ductal ectasia/clubbing of side branches (minimal disease)
  • “nipping” = narrowing of the origins of side branches
  • dilatation >2 mm, tortuosity, wall rigidity, main ductal stenosis (moderate disease)
  • “beading, chain of lakes, string of pearls” = multifocal dilatation, stenosis, obstruction of main pancreatic duct + side branches (severe disease)
  • intraductal filling defects due to mucinous protein plugs/calculi/debris
  • prolonged emptying of contrast material
  • may have stenosis/obstruction + prestenotic dilatation of CBD
  • filling of pseudocysts (<50%)
US/CT:
  • irregular (73%)/smooth (15%)/beaded (12%) pancreatic ductal dilatation (in 41-68%)
  • small atrophic pancreas (in 10-54%)
  • pancreatic calcifications (4–50–68%)
  • inhomogeneous gland with increased echogenicity (62%)
  • irregular pancreatic contour (45–60%)
  • focal (12–32%)/diffuse (27–45%) pancreatic enlargement during flare up (DDx: pancreatic carcinoma)
  • mostly mild biliary ductal dilatation (29%)
  • intra-/peripancreatic pseudocysts (20–34%)
  • segmental portal hypertension (= splenic vein thrombosis + splenomegaly) in 11%
  • arterial pseudoaneurysm formation
  • peripancreatic fascial thickening + blurring of organ margins (16%)
  • ascites/pleural effusion (9%)
  • no abnormalities (7%)
MR:
  • loss of signal intensity on fat-suppressed T1WI (from loss of aqueous protein in pancreatic acini secondary to fibrosis)
  • diminished heterogeneous contrast enhancement (from loss of normal capillary network replaced by fibrous tissue)
Angiography:
  • increased tortuosity + angulation of pancreatic arcades + intrahepatic arteries (88%)
  • luminal irregularities/focal fibrotic arterial stenoses (25–75%)/smooth beaded appearance
  • irregular parenchymal stain
  • venous compression/occlusion (20–50%)
  • portoportal shunting + gastric varices without esophageal varices
Cx: pancreatic carcinoma (2–4%), jaundice, pseudocyst formation, pancreatic ascites, thrombosis of splenic/mesenteric/portal vein
Rx: surgery for infected pseudocyst, GI bleeding from portal hypertension, common bile duct obstruction, gastrointestinal obstruction
DDx: pancreatic carcinoma (extrapancreatic spread)
Chronic Alcoholic Pancreatitis
  • = characterized by heterogeneous lobular distribution; typically >8 years of heavy ethanol abuse
  • Pathophysiology:
    • thick pancreatic secretions with increased protein concentration precipitate in pancreatic ductules causing obstruction; protein plugs may calcify
  • protein plugs/calculi within ductal system
  • ductal abnormalities more severe in smaller branches
Chronic Obstructive Pancreatitis
Etiology:
  • Congenital/acquired lesions of pancreatic duct
  • Trauma/surgical duct ligation
  • Sphincter of Oddi dysfunction, ampullary stenosis
  • Primary sclerosing cholangitis
  • Idiopathic fibrosing pancreatitis
  • Renal failure
  • Slow growing ampullary tumor
  • dilatation of main pancreatic duct
  • normal sized/focally or diffusely enlarged/small atrophic gland
  • calcifications uncommon
Nonalcoholic Duct-Destructive Chronic Pancreatitis
  • = characterized by periductal inflammation + duct destruction
Location: body + tail of pancreas
  • focal/diffuse enlargement with decreased attenuation
  • narrow main pancreatic duct without irregularities
  • no calcifications
MR:
  • homogeneously decreased signal intensity on T1WI isointense relative to spleen
  • variable intensity on T2WI
Pancreatoblastoma
  • = rare childhood tumor often misdiagnosed as neuroblastoma/hepatoblastoma
Age: <7 years
  • • palpable mass, anorexia, vomiting
  • up to 10 cm large well-defined lobulated solid/multiloculated mass in region of lesser sac
Papillary Adenoma Of Bile Ducts
  • = very rare benign tumor of biliary tract
Path: usually solitary tumor/papillomatosis with papillary fronds extending into lumen
P.743

Histo: columnar epithelium supported by connective tissue from lamina propria
  • biliary obstruction
Location: common bile duct > right/left hepatic duct
  • usually small intraductal mass
  • visualized at cross-sectional imaging only if large enough
Prognosis: high rate of recurrence after surgical resection
Cx: malignant transformation (rare)
Passive Hepatic Congestion
Cause: CHF, constrictive pericarditis
Pathophysiology: chronic central venous hypertension transmitted to hepatic sinusoids results in centrilobular congestion + eventually hepatic atrophy, necrosis, fibrosis
  • abnormal liver function tests
CT:
  • globally delayed enhancement (36%)
  • enhancement of portal veins + hepatic arteries + immediately adjacent parenchyma (56%)
  • “reticulated mosaic” pattern = lobular patchy areas of enhancement separated by coarse linear regions of diminished attenuation (100%)
  • diminished periportal attenuation (24%)
  • diminished attenuation around intrahepatic IVC (8%)
  • prominent IVC + hepatic vein enhancement (due to contrast reflux from right atrium into dilated IVC)
DDx: Budd-Chiari syndrome (regional/lobular distribution of reticulated mosaic pattern, caudate lobe hypertrophy)
Peliosis
[pelios, Greek = purple]
  • = rare benign disorder characterized by multiple blood-filled cavities within organs of the RES
Cause: (a)? acquired: chronic infection (disseminated TB), hepatotoxic drugs (androgen-anabolic steroids, corticosteroids, tamoxifen citrate, chemotherapeutic agents, azathioprine, oral contraceptives, thorium dioxide injection), diabetes mellitus, chronic renal failure, advanced malignancy (Hodgkin disease, myeloma, disseminated cancer)
(b) bacillary peliosis hepatis in AIDS (lesions contain bacilli of Rochalimaea species) responsive to antibiotics
(c)? congenital: angiomatous malformation
Histo: (1) Phlebectatic peliosis hepatis (early stage)
= endothelial-lined cysts (=? dilatation of central veins) communicating with dilated hepatic sinusoids + compression of surrounding liver
(2) Parenchymal peliosis hepatis (late stage)
= irregularly shaped cysts without lining communicating with dilated hepatic sinusoids + areas of liver cell necrosis
Associated with: hormonally induced benign/malignant tumors
Location: liver (most common), spleen, bone marrow, lymph nodes, lungs)
Age: fetal life (rare) to adult life
  • • incidental discovery
  • hepatomegaly, splenomegaly
US:
  • multiple indistinct areas of hypo-/hyperechogenicity
CECT:
  • initially hypoattenuating, with passage of time isoattenuating/enhancing round lesions
MR:
  • mixed signal intensity due to repeated hemorrhage (deoxyhemoglobin + methemoglobin + siderotic nodules)
Angio:
  • multiple small (several mm to 1.5 cm) round collections of contrast medium scattered throughout liver in late arterial phase of hepatic arteriogram
  • ± simultaneous opacification of hepatic veins
Prognosis: reversible after drug withdrawal/progression to hepatic failure/intraperitoneal hemorrhage leading to death
Porcelain Gallbladder
  • =calcium carbonate incrustation of gallbladder wall
Incidence: 0.6–0.8% of cholecystectomy patients; M:F = 1:5
Histo: (a) flakes of dystrophic calcium within chronically inflamed + fibrotic muscular wall
(b) microliths scattered diffusely throughout mucosa, submucosa, glandular spaces, Rokitansky-Aschoff sinuses
Associated with: gallstones in 90%
  • • minimal symptoms
  • curvilinear (muscularis)/granular (mucosal) calcifications in segment of wall/entire wall
  • nonfunctioning GB on oral cholecystogram
  • highly echogenic shadowing curvilinear structure in GB fossa (DDx: stone-filled contracted GB)
  • echogenic GB wall with little acoustic shadowing (DDx: emphysematous cholecystitis)
  • scattered irregular clumps of echoes with posterior acoustic shadowing
Cx: 10–20% develop carcinoma of gallbladder
Portal Hypertension
  • = portal venous pressure >10 mm Hg
  • • normal hepatic blood flow of 550–900 mL/min (= 25% of cardiac output) passes through portal system (2/3) + through hepatic artery (1/3)
Classification:
  • DYNAMIC/HYPERKINETIC PORTAL HYPERTENSION
    • congenital/traumatic/neoplastic arterioportal fistula
  • INCREASED PORTAL RESISTANCE
    • @ Prehepatic
      • portal vein thrombosis (portal phlebitis, oral contraceptives, coagulopathy, neoplastic invasion, pancreatitis, neonatal omphalitis)
      • portal vein compression (tumor, trauma, lymphadenopathy, portal phlebosclerosis, pancreatic pseudocyst)
    • @ Intrahepatic (= obstruction of portal venules)
      • presinusoidal
        • Congenital hepatic fibrosis
        • Idiopathic noncirrhotic fibrosis
        • P.744

        • Primary biliary cirrhosis
        • alpha-1 antitrypsin deficiency
        • Wilson disease
        • Sarcoid liver disease
        • Toxic fibrosis (arsenic, copper, PVC)
        • Reticuloendotheliosis
        • Myelofibrosis
        • Felty syndrome
        • Schistosomiasis
        • Cystic fibrosis
        • Chronic malaria
      • sinusoidal
        • Hepatitis
        • Sickle cell disease
      • postsinusoidal
        • Cirrhosis (most frequent): Laennec cirrhosis, postnecrotic cirrhosis from hepatitis
        • Venoocclusive disease of liver
    • @ Posthepatic
      • Budd-Chiari syndrome
      • Constrictive pericarditis
      • CHF (tricuspid incompetence)
Pathophysiology:
  • continued elevated pressure despite formation of portal venous collateral vessels may be explained by
    • backward flow theory = hypodynamic flow theory
      • = increase in sinusoidal pressure due to deposition of collagen in the spaces of Disse + hepatocyte swelling
      • • low/stagnant portal venous flow rates
    • forward flow theory = hyperdynamic flow theory
      • = splanchnic flow increases secondary to mesenteric vasodilators + increase in cardiac output to preserve hepatic perfusion + intrahepatic endogenous vasoconstrictors
      • • increased portal venous flow rates >15 mL/min/kg
Flow direction:
  • hepatopetal (petere, Latin = to seek)
  • hepatofugal (fugere, Latin = to flee) = flow reversal
    Cause: intrahepatic arterioportal communications (inside portal triads vasa vasorum of portal veins + hepatic arteries connect via bile duct capillaries to portal vein)
Spontaneous Portosystemic Shunts
Type of Varices Frequency (%)
Coronary venous 80–86
Esophageal 45–65
Paraumbilical 10–43
Abdominal wall 30
Perisplenic 30
Retrogastric/gastric 2–27
Paraesophageal 22
Omental 20
Retroperitoneal paravertebral 18
Mesenteric 10
Splenorenal 10
Gastrorenal 7
  • • elevated hepatic wedge pressure (HWP) = portal venous pressure; normal values seen in presinusoidal portal hypertension
  • caput medusae = drainage from paraumbilical + omental veins through superficial veins of chest (lateral thoracic vein to axillary vein; superficial epigastric vein to internal mammary vein and subclavian vein) + abdominal wall (circumflex iliac vein and superficial epigastric vein to femoral vein; inferior epigastric vein to external iliac vein)
  • • hemorrhaging esophageal varices (50%)
  • @ Splanchnic system:
    • portal vein >13 mm (57% sensitivity, 100% specificity)
    • SMV + splenic vein >10 mm; coronary vein >4 mm; recanalized umbilical vein >3 mm (size of vessels not related to degree of portal hypertension or presence of collaterals)
    • loss of respiratory increase of splanchnic vein diameters of <20% (81% sensitive, 100% specific)
    • portal vein aneurysm
    • portal vein thrombosis
    • cavernous transformation of portal vein
    • increased echogenicity + thickening of portal vein walls
    • Doppler US:
      • continuous monophasic portal venous flow pattern without respiratory fluctuations
      • reduction of mean portal vein velocities to 7–12 cm/sec (normally 12–30 cm/sec)
      • loss of flow increase in portal venous system during expiration
      • congestive index >0.13 cm/sec (= ratio of area of portal vein divided by flow velocity; 67% sensitive)
      • may have bidirectional/hepatofugal (<10%) flow within spontaneous splenorenal shunts (indicates high incidence of hepatic encephalopathy)
      • dilated hepatic artery may demonstrate elevated resistive index >0.78
  • @ Spontaneous portosystemic shunts:
    • • high frequency of hepatic encephalopathy
    • varices = serpentine tubular rounded structures
    • coronary (left gastric) vein >5–6 mm (in 26%)
    • gallbladder wall varices in thickened gallbladder wall (in 80% associated with portal vein thrombosis)
    • connection to SVC
      • Esophageal varices (= subepithelial + submucosal veins) supplied by anterior branch of left gastric vein
      • Paraesophageal varices (endoscopically not visible) supplied by posterior branch of coronary (= left gastric) vein draining into azygos + hemiazygos vv. + vertebral plexus
        • NOT connected to esophageal varices!
        • mediastinal/lung mass on CXR in 5–8%
    • connection to pulmonary circulation
      • Gastropulmonary shunt (between gastric/esophageal vv. and left pericardiophrenic/inferior pulmonary vv.)
        • nodularity along left cardiac border on CXR
    • P.745

    • retrograde mesenteric flow
      • Veins of Retzius (= anastomoses between portal vein and IVC)
        • ileocolic veins — right gonadal vein — IVC
        • pancreaticoduodenal vein — IVC
        • proximal small left branches of SMV — left gonadal vein — left renal vein
        • ileocolic veins — directly into IVC
    • retroperitoneal collaterals
      • Splenorenal/splenoadrenorenal shunt
      • Gastrorenal shunt
      • Mesenterorenal shunt (between SMV + right renal v.)
      • Mesenterogonadal shunt (between ileocolic v. + right testicular v.)
      • Splenocaval shunt (between splenic v. + left hypogastric v.)
    • intrahepatic shunt (portal v. to hepatic v.)
  • @ Cruveilhier-von Baumgarten syndrome (20–35%)
    • = recanalized paraumbilical veins (NoT recanalized umbilical veins)
    • hypoechoic channel in ligamentum teres
      • size <2 mm (in 97% of normal subjects; in 14% of patients with portal hypertension)
      • size ≥ mm (86% sensitivity for portal hypertension)
    • arterial signal on Doppler US in 38%
    • hepatofugal venous flow (82% sensitivity, 100% specificity for portal hypertension)
  • @ Spleen
    • splenomegaly (absence does not rule out portal hypertension)
    • siderotic Gamna-Gandy nodules in 13% (= small foci of perifollicular + trabecular hemorrhage):
      • multiple 3–8-mm low-intensity spots on FLASh/GRASS images
      • multiple hyperechoic spots on US
    • multiple faint calcifications on CT
  • ascites
Cx: Acute gastrointestinal bleeding (mortality of 30–50% during 1st bleeding)
Segmental Portal Hypertension
  • = splenic vein occlusion/superior mesenteric vein occlusion
Portosystemic Surgical Connections
  • NONSELECTIVE SHUNT
    • = decompression of the entire portal system with increased risk of hepatic encephalopathy
    • Portocaval shunt
      • = portal vein to IVC end-to-side/side-to-side
    • Mesocaval shunt
      • = synthetic graft between SMV and IVC
      • short “H-graft” to posterior wall of SMV
      • long “C-graft” to anterior wall of SMV
      • direct mesocaval shunt dividing IVC (rare)
    • Mesorenal shunt
    • Mesoatrial shunt
      • = polytetrafluoroethylene (PTFE) graft between anterior wall of SMV superior to pancreas and right atrium coursing through abdomen + diaphragm into right thoracic cavity
  • SELECTIVE SHUNT
    • = decompression of parts of the portal system with preservation of blood flow to the liver
    • Contraindicated in patients with ascites
    • Distal splenorenal shunt = Warren shunt (popular)
      • = splenic vein to left renal vein
Doppler criteria for shunt patency:
  • increased local velocities
  • turbulence + severe spectral broadening
  • dilatation of recipient vein at shunt site
  • phasic flow pattern in portal tributaries
  • hepatofugal flow in intrahepatic portal vein branches
  • reduction in size + number of portosystemic collaterals
  • reduction/absence of ascites or splenomegaly
Transjugular Intrahepatic Portosystemic Shunt (TIPS)
  • = portal decompression through percutaneously established shunt with expandable metallic stent between hepatic + portal veins within the liver
Indication: patients with esophageal + gastric variceal hemorrhage/refractory ascites due to advanced liver disease with portal hypertension, hepatorenal syndrome
Type of stent: 10-mm Wall stent (curved), Palmaz stent (straight), Strecker stent, spiral Z stent
Shunt surveillance: at regular 3–6-month intervals for
Assessment:
  • MORPHOLOGY
    • Ascites
    • Portosystemic collaterals
    • Size of spleen
    • Diameter of stent (usually 8–10 mm)
    • Configuration of stent: areas of narrowing
    • Extension of stent into portal + hepatic veins
  • HEMODYNAMICS
    • Direction of flow in: extrahepatic portal vein, R + L portal vein, SMV, splenic vein, all 3 hepatic veins, intrahepatic IVC, paraumbilical vein, coronary vein
    • Peak blood flow velocity within main portal vein
    • Peak blood flow velocity within proximal + mid + distal aspects of stent
    • Hepatic artery: PSV, EDV, RI
  • high-velocity turbulent flow (50–270 cm/s) at least double that of pre-TIPS values
  • superimposed cardiac + respiratory variations
  • increase in hepatic artery velocities from 77 cm/s (pre-TIPS) to 119 cm/s (post-TIPS)
  • reversed flow direction within portal vein branches
Cx:
  1. Obstruction to flow
    1. Shunt obstruction (38%)
    2. Hepatic vein stenosis
  2. Trauma
    1. Vascular injury
      1. Hepatic artery pseudoaneurysm
      2. Arterioportal fistula
      3. Intrahepatic/subcapsular hematoma
      4. Hemoperitoneum (due to penetration of liver capsule)
    2. Biliary injury
      1. Transient bile duct dilatation (due to hemobilia)
      2. Bile collection
  3. Stent dislodgment with embolization to right atrium, pulmonary artery, internal jugular vein
Mortality: <2% (intraperitoneal hemorrhage)
P.746

TIPS failure
Cause: acute thrombosis, improper stent placement, intimal hyperplasia, hepatic vein stenosis, change in stent configuration, bulging of liver parenchyma into shunt
Prevalence: 31% at 1 year, 42% at 2 years
  • recurrent bleeding = shunt abnormality in 100%
  • >50% stenosis (in 30–80% within 12 months)
    • irregular filling defects along wall of shunt on color Doppler
      • Pseudointimal hyperplasia is isoechoic to blood!
    • generalized decrease in shunt velocity:
      • maximal shunt velocity of <60 cm/sec (>95% sensitive + specific)
      • gradual decrease in shunt velocity over 1–6 months (due to intimal hyperplasia)
      • decrease in peak flow velocity in similar location within stent >50 cm/sec relative to initial baseline study
      • decrease in maximal portal vein velocity >33% from baseline
    • local increase in shunt velocity:
      • velocity transition zone within stent with flow acceleration by a factor of 2
      • increase in peak flow velocity in similar location within stent >50 cm/sec relative to initial baseline study
    • change in flow direction:
      • reversal of portal venous flow direction (100% sensitive, 92% specific, 71% PPV, 100% NPV)
      • change in flow direction in collateral veins from baseline
      • retrograde flow in RHV (developing stenosis of right hepatic venous outflow tract)
    • loss of pulsatility of portal/shunt flow:
      • venous pulsatility index (Vmax–Vmin)/Vmax <0.16 (94% sensitive, 87% specific)
    • developing/worsening ascites/splenomegaly
  • Occlusion
    • absent flow within shunt
    • echogenic material within stent
    • –acute cause: prolonged procedural catheterization, leakage of bile into/around stent
    • –delayed cause: pseudointimal hyperplasia, stent shortening with delayed stent expansion
Pre- and Post-TIPS Baseline Study
(under stable fasting conditions)
  Pre-TIPS Post-TIPS
Portal vein velocity (cm/s) 10–30 40–60
Mean portal vein velocity (cm/s) 18 ± 6 55 ± 7
Portal pressure (mm hg) 37 ± 8 22 ± 6
Shunt peak velocity (cm/s) 0 95 ± 58
Portal Vein Thrombosis
Etiology:
  • IDIOPATHIC (mostly):? neonatal sepsis
  • SECONDARY:
    • Cirrhosis + portal hypertension (5%)
    • Malignancy: tumor invasion by HCC, cholangiocarcinoma, pancreatic carcinoma, gastric carcinoma, metastasis/extrinsic compression by tumor
    • Trauma: umbilical venous catheterization; surgery; Cx of splenectomy (7%, higher in patients with myeloproliferative disorders)
    • Hypercoagulable state: blood dyscrasia; clotting disorder; estrogen therapy; severe dehydration
    • Intraperitoneal inflammatory process (portal vein phlebitis): perinatal omphalitis; pancreatitis; appendicitis; ascending cholangitis
Age: predominantly children, young persons
  • abdominal pain
  • portal systemic encephalopathy
  • hematemesis (esophageal varices)
Acute Portal Vein Thrombosis
Plain film:
  • hepatosplenomegaly
  • enlarged azygos vein
  • paraspinal varices
UGI:
  • esophageal varices
  • thickening of bowel wall
US:
  • echogenic material within vessel lumen (67%)
  • increase in portal vein diameter (57%)
  • portosystemic collateral circulation (48%)
  • enlargement of thrombosed segment >15 mm (38%)
  • thickening of lesser omentum
Doppler-US:
  • no flow on postprandial Doppler color scans:
    • Malignant thrombus tends to distend vein + exhibit pulsatile flow, a bland thrombus does not!
  • decrease in hepatic artery resistive index:
    • RI <0.50 (in acute occlusive portal vein thrombosis)
    • minimal decrease/normal RI (in chronic portal vein thrombosis/nonocclusive thrombosis)
NECT:
  • decreased attenuation of affected hepatic parenchyma (due to edema, depletion of hepatocytes, fibrosis)
CECT:
  • transient high attenuation during hepatic arterial phase (due to increased arterial flow)
  • low-density center of portal vein thrombus surrounded by peripheral enhancement:
    • portal vein density 20–30 HU less than aortic density
MR:
  • absent flow void in portal area + abnormal signal intensity in main portal vein
  • hyperintense thrombus on T1WI + T2WI (if <5 weeks old)
  • filling defect on MRA
P.747

Angio:
  • “thread and streaks” sign of tumor thrombus (streaky contrast opacification of tumor vessels)
Cx: (1) Cavernous transformation (19%)
(2) Hepatic infarction
(3) Bowel infarction
Chronic Portal Vein Thrombosis
Pathophysiology:
  • central part (caudate lobe + lateral segment) is well supplied by collateral venous vessels; the peripheral zone (mainly right lobe) receives less portal venous blood resulting in increased arterial flow
  • nonvisualization of extrahepatic portal vein (= fibrotic portal vein)
  • calcification within clot/wall of portal vein
  • cavernous transformation (= cavernoma) of portal vein:
    • presence of a racemose conglomerate of collateral veins with portal venous flow linking pancreas + duodenum + gallbladder fossa
  • splenomegaly
  • ascites
CECT:
  • peripheral scattered areas of high attenuation in liver during hepatic arterial phase
US:
  • echogenic/nonvisualized portal vein
MR:
  • hypointense portal vein on T1WI + hyperintense on T2WI (2–18 months old)
  • numerous abnormal flow voids in porta hepatis
Postcholecystectomy Syndrome
  • = symptoms recurring/persisting after cholecystectomy
Incidence:
  • mild recurrent symptoms in 9–25%; severe symptoms in 2.6–32% (result of 1,930 cholecystectomies):
  • — completely cured (61%)
  • — satisfactory improvement with
    • persistent mild dyspepsia (11%)
    • mild attacks of pain (24%)
  • — failure with
    • occasional attacks of severe pain (3%)
    • continuous severe distress (1.7%)
    • recurrent cholangitis (0.7%)
Cause:
  • BILIARY CAUSES
    • Incomplete surgery
      • Gallbladder/cystic duct remnant
      • Retained stone in cystic duct remnant (1%)
      • Overlooked CBD stone (5%)
    • Operative trauma
      • Bile duct stricture
      • Bile peritonitis
      • Suture granuloma of cystic duct remnant
    • Bile duct pathology
      • Fibrosis of sphincter of Oddi
      • Biliary dyskinesia
      • Biliary fistula
      • Cystic duct mucocele
    • Residual disease in neighboring structures
      • Pancreatitis
      • Hepatitis
      • Cholangitis
    • Overlooked bile duct neoplasia
  • EXTRABILIARY CAUSES (erroneous preoperative diagnosis)
    • Other GI tract disease:
      • Inadequate dentition
      • Hiatus hernia
      • Peptic ulcer
      • Spastic colon
    • Anxiety state, air swallowing
    • Abdominal angina
    • Carcinoma outside gallbladder
    • Coronary artery disease
Richter Syndrome
  • = development of large cell/diffuse histiocytic lymphoma in patients with CLL
Etiology: transformation/dedifferentiation of CLL lymphocytes
Incidence in CLL patients: 3–10%
Median age: 59 years
Medium time interval after diagnosis of CLL: 24 months
  • fever (65%) without evidence of infection
  • increasing lymphadenopathy + hepatosplenomegaly (46%)
  • weight loss (26%), abdominal pain (26%)
Location: bone marrow, lymph nodes, liver, spleen, bowel, lung, pleura, kidney, dura
Prognosis: median survival time: 4 months from diagnosis of lymphoma; 14% rate of remission rate
Schistosomiasis
  • Major cause of portal hypertension worldwide: 200 million people affected
Types:
  • SCHISTOSOMA MANSONI
    • occurs in >70 million inhabitants of parts of Africa, Caribbean, Arabic peninsula, West Indies, northern part of South America
  • SCHISTOSOMA JAPONICUM
    • coastal areas of China, Japan, Formosa, Philippines, Celebes
  • SCHISTOSOMA HAEMATOBIUM
    • in Africa, Mediterranean, Southwest Asia → typically affects urinary tract
Cycle:
  • cercariae enter lymphatics + blood system via thoracic duct; larvae are transported into mesenteric capillaries; mature in portal system + liver into worms; worms live in pairs in copula within portal vein + tributaries for 10–15 years; female swims against blood flow to reach venules of urinary bladder (S. haematobium) or intestine + rectum (S. mansoni, S. japonicum); deposits eggs in wall of urinary bladder or intestines, eggs pass with urine + feces; hatch within water to release miracidia which infect snail hosts; cercariae emerge after maturation from snails
Infection: cercariae penetrate human skin/buccal mucosa from contaminated water (slow-moving streams, irrigation canals, paddy fields, lakes)
Histo: granulomatous reaction + fibrosis along portal vein branches
  • • clinically mild infection with chronic course
  • @ Liver & spleen (10%)
    • hepatosplenomegaly
    • portal vein dilatation in 73% (= presinusoidal portal hypertension)
    • marked diffuse thickening of echogenic walls of portal venules = periportal fibrosis
      • Schistosoma infection is the most frequent cause of liver fibrosis worldwide!
    • normal parenchymal echogenicity + small peripheral hyperechoic foci in 50%
    • hyperechoic gallbladder bed
    • thickened gallbladder wall
    • capsular “turtleback/tortoise shell” calcifications extending perpendicularly from the surface toward the center (Schistosomiasis japonicum)
  • @ GI tract
    • gastric + esophageal varices
    • polypoid bowel wall masses (esp. in sigmoid)
    • granulomatous colitis
    • strictures with extensive pericolic inflammation
Cx: ileus
P.748

Schwachman-Diamond Syndrome
  • = rare probably autosomal recessive condition characterized by congenital absence of pancreatic exocrine tissue
  • 2nd most frequent cause of exocrine pancreatic insufficiency in childhood after cystic fibrosis!
  • • pancreatic insufficiency, steatorrhea
  • • recurrent respiratory and skin infections (secondary to bone marrow hypoplasia)
  • • normal electrolytes in sweat
  • • failure to thrive
  • • tends to improve with time
  • total fatty replacement of pancreas
  • metaphyseal chondrodysplasia resulting in dwarfism
DDx: cystic fibrosis (pancreatic calcifications, cyst formation, abnormal sweat test)
Serous Cystadenoma Of Pancreas
  • = MICROCYSTIC CYSTADENOMA = GLYCOGEN-RICH CYSTADENOMA
  • = benign lobulated neoplasm composed of innumerable small cysts (1–20 mm) containing proteinaceous fluid separated by thin connective tissue septa
Incidence: approximately 50% of all cystic pancreatic neoplasms
Histo: cyst walls lined by cuboidal/flat glycogen-rich epithelial cells derived from centroacinar cells of pancreas (DDx: lymphangioma), thin fibrous pseudocapsule
Age: 34–88 years; mean age 65 years; 82% over 60 years of age; M:F = 1:2–4
Associated with: von Hippel-Lindau syndrome
  • pain, weight loss, malaise, anorexia, fatigue, jaundice
  • palpable mass
Location: any part of pancreas affected, slight predominance for head + neck
  • well-demarcated lobulated mass 1–25 (mean 5) cm in diameter with smooth/nodular contour
  • innumerable small <2 cm cysts of honeycomb/bunch of grapes appearance; uncommonly few large cysts (in <5%)/cyst up to 8 cm in diameter
  • prominent central stellate scar (ChARACTERISTIC)
  • amorphous central calcifications (in 18%) in dystrophic area of stellate central scar (“sunburst”)
  • pancreatic duct + CBD may be displaced, encased, or obstructed
  • US:
    • solid predominantly echogenic mass with mixed hypoechoic + echogenic areas
  • CT:
    • attenuation values close to water
    • contrast enhancement
  • Angio:
    • hypervascular mass with dilated feeding arteries, dense tumor blush, prominent draining veins, neovascularity, occasional AV shunting, No vascular encasement
  • MR:
    • delayed enhancement of scar on contrast-enhanced FLASh images
Prognosis: no malignant potential
Rx: surgical excision/follow-up examinations
DDx: malignant mucinous cystic neoplasm (younger age, body + tail of pancreas, >10 cm large at presentation)
Solid And Papillary Neoplasm Of Pancreas
  • = SOLID AND CYSTIC TUMOR = PAPILLARY-CYSTIC NEOPLASM = SOLID AND PAPILLARY EPITHELIAL NEOPLASM = HAMOUDI TUMOR
  • = rare, low-grade malignant tumor; often misclassified as nonfunctioning islet cell tumor, cystadenoma, or cystadenocarcinoma of pancreas
Prevalence: 0.17–2.7% of all nonendocrine pancreatic tumors
Mean age: 25 (range 10–74) years; M:F = 1:9; especially in black and East Asian patients
Path: large well-encapsulated mass with considerable hemorrhagic necrosis + cystic degeneration
Histo: sheets + cords of cells arranged around a fibrovascular stroma
  • vague upper abdominal discomfort and pain
  • gradually enlarging abdominal mass
Location: tail of pancreas (most frequently)
  • well-encapsulated inhomogeneous round/lobulated pancreatic mass with solid + cystic portions
  • may be completely cystic (when complicated by extensive necrosis + internal hemorrhage)
  • fluid-debris level (20%)
  • mean diameter of 9 cm (range 3–15 cm)
  • ± stippled/punctate/amorphous dystrophic calcification (33%)
  • hypovascular with no contrast enhancement/enhancement of solid tissue projecting toward center of mass
  • P.749

  • US:
    • echogenic mass with necrotic center
  • MR:
    • high signal intensity on T1WI (consistent with hemorrhagic necrosis)
Prognosis: (1) excellent after excision
(2) metastases (in 4%): omentum, lymph nodes, liver
DDx: (1) Microcystic adenoma (innumerable tiny cysts, older age group)
(2) Mucinous cystic neoplasm (large uni-/multilocular cysts, older age group)
(3) Nonfunctioning islet cell tumor (hypervascular)
(4) Pleomorphic carcinoma of pancreas (smaller tumor in older patient)
(5) Pancreatoblastoma (childhood tumor)
(6) Calcified hemorrhagic pseudocyst
Splenic Angiosarcoma
Incidence: rare, <100 cases in literature
Cause: usually not due to thorotrast or toxic exposure to vinyl chloride/arsenic as in liver angiosarcoma
Age: 50–60 years
  • • splenomegaly, abdominal pain
  • multiple nodules of varying size usually enlarging the spleen
  • solitary complex mass with variable contrast enhancement
  • metastasizes to liver (70%)
  • spontaneous rupture (33%)
MR:
  • focal/diffuse hypointense foci on T1WI + T2WI (iron deposition from hemorrhage)
Prognosis: 20% survival rate after 6 months
Splenic Hamartoma
  • SPLENOMA
  • rare typically single nonneoplastic lesion composed of a mixture of normal splenic elements
Etiology: congenital
May be associated with: hamartomas elsewhere as in tuberous sclerosis
Histo:
  1. mixture of white + red pulp (most common)
  2. white pulp subtype = aberrant lymphoid tissue
  3. red pulp subtype = aberrant complex of sinusoids
  • • asymptomatic
  • CT:
    • attenuation equal to/hypodense to splenic tissue
    • prolonged heterogeneous enhancement
  • MR:
    • heterogeneously hyperintense on T2WI
    • diffuse heterogeneous enhancement, more homogeneous on delayed images
Splenic Hemangioma
Cause: congenital, arising from sinusoidal epithelium
Prevalence: 0.03–14% (autopsy); M > F
♢Most common primary splenic tumor!
Age: 20–50 years
Histo: proliferation of vascular channels lined by single layer of endothelium; mostly of cavernous type; may contain areas of infarction, hemorrhage, thrombosis, fibrosis
Associated with: generalized angiomatosis Klippel-Trénaunay-Weber syndrome, Beckwith-Wiedemann syndrome, Turner syndrome
  • • asymptomatic/pain + fullness in LUQ
  • usually small single lesion <4 cm, up to 17 cm in size
  • foci of speckled/snowflakelike calcifications
  • US:
    • well-marginated predominantly hyperechoic lesion
  • CT:
    • predominantly cystic lesion is avascular
    • solid areas hypo-/isodense to normal spleen and enhancing
  • MR:
    • hypo-/isointense on T1WI + hyperintense on T2WI
    • hypointense areas due to hemosiderin deposits
    • progressive centripetal enhancement with persistent uniform enhancement on delayed images
  • NUC:
    • no uptake of Tc-99m sulfur colloid
Prognosis: slow growth, thus becoming symptomatic in adulthood
Cx: (1) Spontaneous splenic rupture (in up to 25%)
(2) Kasabach-Merritt syndrome (= anemia, thrombocytopenia, coagulopathy) with large hemangioma
(3) Portal hypertension
(4) Malignant degeneration
Splenic Infarction
  • Most common cause of focal defects!
  • Cause:
    • Embolic: bacterial endocarditis (responsible in 50%), atherosclerosis with plaque emboli, cardiac thrombus (atrial fibrillation, left ventricular thrombus), metastatic carcinoma
    • Local thrombosis: sickle cell disease (leading to functional asplenia), myelo-/lymphoproliferative disorders (CML most common), polycythemia vera, myelofibrosis with myeloid metaplasia + splenomegaly, Gaucher disease, collagen vascular disease, portal hypertension
    • Vasculitis: periarteritis nodosa
    • Vascular compromise of splenic artery: focal inflammatory process (eg, pancreatitis), thrombus from splenic artery aneurysm, splenic torsion
    • Therapeutic complication: transcatheter hepatic arterial embolization
mnemonic: PSALMS
  • Pancreatic carcinoma, Pancreatitis
  • Sickle cell disease/trait
  • Adenocarcinoma of stomach
  • Leukemia
  • Mitral stenosis with emboli
  • Subacute bacterial endocarditis
Anatomy: branches of the splenic artery are noncommunicating end arteries
  • • LUQ pain, fever
  • • elevated erythrocyte sedimentation rate, leukocytosis
  • • abnormal lactate dehydrogenase levels
  • single/multiple focal wedge-shaped peripheral defects
  • global infarction
  • P.750

  • US:
    • initially ill-defined hypoechoic lesion (due to inflammation, edema, necrosis)
    • later increasingly well-defined echogenic lesion (due to organization of infarct with fibrosis)
  • CT phases:
    • hyperacute phase (day 1)
      • mottled area of increased attenuation on NECT (hemorrhage)
      • large focal hyperattenuating lesion on CECT
      • mottled pattern of contrast enhancement
    • acute (days 2–4) + subacute phase (days 4–8)
      • focal progressively more well-demarcated areas of decreased attenuation without enhancement
    • chronic phase (2–4 weeks)
      • size decreases + attenuation returns to normal
      • complete resolution/residual contour defect
      • areas of calcification
Cx: acute febrile illness, abscess formation, pseudocyst formation, splenic rupture, hemorrhage
Splenosis
= posttraumatic autotransplantation of splenic tissue to other sites (heterotopic splenic tissue)
Age: young men with history of trauma/splenectomy
Time of detection: mean of 10 years (range of 6 months to 32 years) after trauma
Location: diaphragmatic surface, liver, greater omentum, small bowel serosa, parietal peritoneum, pleura after diaphragmatic rupture (attaches to peritoneal/pleural surface)
  • multiple small encapsulated sessile implants
Size: few mm to 3 cm (due to limited blood supply from local neovascularization)
  • CT:
    • isodense to normal spleen with homogeneous enhancement
  • MR:
    • hypointense on T1WI
    • heterogeneous enhancement (red + white pulp differences)
    • hyperintense/rarely hypointense (due to iron deposition) on T2WI
  • NUC:
    • uptake by Tc-99m sulfur colloid; In-111 labeled platelets; Tc-99m heat-damaged RBC (best detection rate without uptake by liver)
  • Significance:
    • protects against infection in pediatric patients
    • may be confused with metastases/lymphoma
    • responsible for disease recurrence after splenectomy (eg, idiopathic thrombocytopenic purpura)
DDx: accessory spleen
Spontaneous Perforation Of Common Bile Duct
Pathogenesis: unknown (? CBD obstruction, localized mural malformation, ischemia, trauma)
Age: 5 weeks to 3 years of age
  • • vague abdominal distension
  • • mild persistent hyperbilirubinemia
  • • varying acholic stools
  • US:
    • biliary ascites/loculated subhepatic fluid
    • localized pseudocholedochal cyst in porta hepatis
  • Hepatobiliary scintigraphy:
    • radioisotope diffusely throughout peritoneal cavity
Thorotrastosis
  • Thorotrast = 25% colloidal suspension of thorium dioxide; used as contrast agent between late 1920s and mid 1950s, in particular for cerebral angiography and liver spleen imaging; chemically inert with high atomic number of 90; >100,000 people injected
  • Thorium dioxide = consists of 11 radioactive isotopes (thorium-232 is major isotope); decay by means of alpha, beta, and gamma emission; biologic half-life of 1.34 × 1010 years; hepatic dose of 1,000–3,000 rads in 20 years
Distribution: phagocytized by RES + deposited in liver (70%), spleen (30%), bone marrow, abdominal lymph nodes (20%)
  • linear network of metallic density contrast material in spleen, lymph nodes, liver
  • spleen may be shrunken/nonfunctional
Cx: hepatic fibrosis, angiosarcoma (50%), cholangiocarcinoma, hepatocellular carcinoma (latency period of 3–40 years; mean 26 years)
Tyrosinemia
= rare autosomal recessive metabolic disorder
Country: increased prevalence in Canadian province of Quebec and parts of Scandinavia
Biochemistry: deficiency of enzyme fumarylacetoacetase (last step in catabolic pathway of tyrosine, serum methionine, urinary succinylacetone); elevated levels of serum tyrosine as a precursor of dopamine, norepinephrine, epinephrine, melanin, thyroxin
  • ACUTE FORM
    • fulminant liver failure, often by 1 year of age
  • CHRONIC FORM
    • = Fanconi syndrome with renal tubular dysfunction
    • •vitamin D-resistant rickets
    • •intermittent porphyria-like symptoms
  • • progressive liver failure in early childhood
  • • anemia, abnormal liver function tests
  • • elevated levels of α±-fetoprotein
  • hepatosplenomegaly
  • micro- and macronodular cirrhosis (early childhood):
    • regenerating nodules of 2–20 mm: hyper- (mostly) /iso-/hypoattenuating; hypo-/occasionally hyperechoic
    • portal hypertension
    • increased echogenicity (fibrosis + fatty infiltration)
  • nephromegaly with uniformly thickened renal cortices
  • nephrocalcinosis
Prenatal Dx: enzyme deficiency demonstrable in hepatocytes, skin fibroblasts, lymphocytes, amniocytes
Cx: hepatocellular carcinoma (in 37% beyond 2 years of age)
Rx: (1) Diet restricted in phenylalanine + tyrosine (alleviates kidney damage but does not prevent fatal outcome)
(2) 2-2-nitro-4-trifluoro-methylbenzoyl-1,3-cyclohexanedione (NTBC) inhibits 4-hydroxyphenylpyruvate dioxygenase + prevents formation of maleylacetoacetate and fumarylacetoacetate
(3) Liver transplantation (before HCC develops)
P.751

Undifferentiated Sarcoma Of Liver
  • = EMBRYONAL SARCOMA
Incidence: 4th/5th most common liver tumor in pediatric population
Age: <2 months (in 5%); 6–10 years (in 52%); by 15 years (in 90%); up to 49 years; M:F = 1:1
Histo: primitive undifferentiated stellate/spindle-shaped sarcomatous cells closely packed in whorls + sheets/scattered loosely in a myxoid ground substance with foci of hematopoiesis (50%)
  • painful RUQ mass and fever
  • mild anemia + leukocytosis (50%)
  • elevated liver enzymes (33%)
  • fever (5%)
Location: right lobe (75%); left lobe (10%);both lobes (15%)
  • 7–14–21 cm in size
  • well-defined margins (fibrous pseudocapsule)
  • NUC:
    • photodefect on sulfur colloid scan
  • US/CT:
    • large intrahepatic mass with cystic areas up to 4 cm in diameter (myxoid stroma + necrosis + hemorrhage)
    • discordant finding between US (solid) + CT (cystlike)
  • Angio:
    • hypo-/hypervascular with stretching of vessels
    • scattered foci of neovascularity
Prognosis: mostly results in death within 12 months
DDx: mesenchymal hamartoma
(a) solid lesion + cystic degeneration:
hepatocellular carcinoma, fibrolamellar carcinoma, intrahepatic cholangiocarcinoma, angiosarcoma, epithelioid hemangio-endothelioma, other sarcomas, lymphoma, metastatic disease, hepatocellular adenoma
(b) solitary cystic lesion:
biliary cystadenoma/biliary carcinoma, cystic degeneration of hepatocellular carcinoma, bacterial/parasitic abscess, metastatic disease, posttraumatic resolving hematoma
Wandering Spleen
  • = ABERRANT/FLOATING/PTOTIC/DRIFTING/DYSTOPIC/DISPLACED/PROLAPSED SPLEEN
  • = excessively mobile spleen on an elongated pedicle displaced from its usual position in LUQ
Cause: embryologically absent/malformed gastrosplenic + splenorenal ligaments; deficient/lax abdominal musculature (prune-belly syndrome, pregnancy)
Age: any (higher frequency in women of childbearing age)
  • • asymptomatic mobile abdominal/pelvic mass
  • • chronic vague lower abdominal/back pain
  • • nausea, vomiting, eructation, flatulence
  • •acute abdomen (with splenic infarction from torsion)
  • empty splenic fossa + associated soft-tissue mass in center of abdomen/pelvis
  • inverted malpositioned stomach
  • splenic hilum often located anteriorly
  • displaced large spleen (congestion during torsion)
  • Cx:
    • Torsion with prolonged venous occlusion: perisplenitis, localized peritonitis, adhesions, venous thrombosis, hypersplenism
      • no flow within spleen on Doppler US
      • elevated resistive index in proximal splenic artery
      • low attenuation with heterogeneous enhancement on CT
      • whorled appearance of twisted splenic pedicle
    • Torsion with arterial occlusion: hemorrhagic infarction, subcapsular/intrasplenic hemorrhage, gangrene, degenerative cysts, functional asplenism
    • GI complications:
      • @ Stomach: compression, distension, volvulus, traction diverticulum, varices
      • @ Small bowel: dilatation, obstruction
      • @ Colon: compression, volvulus, laxity, ptosis
Rx: 1. Splenectomy (4% postsplenectomy sepsis)
2. Splenopexy
3. Conservative treatment (if asymptomatic)